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ABSTRACT 
THE OCCURRENCE, FATE, ENVIRONMENTAL IMPACT, AND 
MANAGEMENT IMPLICATIONS OF PHARMACEUTICAL AND PERSONAL 
CARE PRODUCTS IN WASTEWATER AND THE ENVIRONMENT 
 
By 
Benjamin D. Blair 
The University of Wisconsin-Milwaukee, 2014 
Under the Supervision of Professor Rebecca Klaper 
 
Pharmaceuticals and personal care products (PPCPs) are a critical part of modern life. 
However, there is growing evidence that the levels of PPCPs detected in wastewater 
effluent and in the environment have the potential to cause damage to aquatic 
organisms. These pollutants enter the aquatic environment primarily through human 
use, disposal in the drain or toilet, land application of biosolids, and veterinary 
sources. Numerous questions remain regarding the occurrence, fate, and impacts of 
PPCPs in wastewater, along with limited feasible management recommendations that 
would adequately mitigate the risk from these pollutants. This dissertation will 
present three advances in the field of PPCPs in the aquatic environment: 1) An 
experiment that describes the occurrence of PPCPs in a large scale urban wastewater 
treatment plant and the assessment of a model that predicts the removal of these 
PPCPs across the different wastewater treatment processes; 2) A study that monitors 
the occurrence of PPCPs in Lake Michigan and an assessment of the ecological risks 
at the detected levels; and 3) A case study that provides an analysis of current 
wastewater treatment regulations (e.g. requiring phosphorus removal from 
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wastewater) and whether the regulations can be modified to remove unregulated 
PPCPs. Overall, this research provides an assessment of the fate, occurrence, and 
corresponding ecological damage from PPCPs in wastewater and the environment, 
along with an evaluation of a potential management technique. The major 
contribution of this work is to further the understanding of the distribution and fate of 
PPCPs in the aquatic environment, which can ultimately be used to assist in 
constructing relevant policy and management recommendations.  
  
 
 
iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©Copyright by Benjamin D. Blair, 2014 
All Rights Reserved 
  
 
 
v 
 
TABLE OF CONTENTS 
Chapter   Title        Page 
 
1    Introduction       1 
2 Evaluation of a model for the removal   16 
of pharmaceuticals, personal care products, 
and hormones from wastewater 
3 Pharmaceuticals and personal care products   46 
found in the Great Lakes above concentrations  
of environmental concern 
4 Assessing current wastewater regulations  73 
to minimize the risk quotient of  
pharmaceuticals and personal care products  
(PPCPs): A case study in Wisconsin, USA 
5   Discussion and Conclusions    112 
Appendix A   Supporting Data for Chapter 2   125 
Appendix B  BIOWIN4 Calculations    139  
Appendix C Detection Frequency and Classification   142 
of Compounds 
Appendix D  Supporting Data for Chapter 3   145 
Appendix E  Supporting Data for Chapter 4   158 
   Curriculum Vitae     207 
 
 
  
 
 
vi 
 
LIST OF FIGURES  
Chapter Figure  Number Caption Page 
2 1 Concentration of Caffeine across 
the Stages of SSWRF on Six Dates 
 
42 
2 2 Concentration of Codeine across 
the Stages of SSWRF on Six Dates 
 
43 
2 3 Median Removal Efficiency across 
the Secondary Treatment Process at 
SSWRF Compared to BIOWIN4 
(Pearson Correlation = 0.773, p < 
0.001, coefficient of determination 
and correlation includes only log 
Kow values < 4.5) 
 
44 
2 4 Predicted Removal Efficiency using 
Pseudo First-order Removal with 
the BIOWIN4 Converted 
Biodegradation Rate Constant 
Compared to Observed Data from 
South Shore (Pearson Correlation = 
0.792, p < .001) 
 
45 
3 5 Lake Michigan and the Sampling 
locations in Lake Michigan near 
Milwaukee, Wisconsin, USA. 
Boxes represent the two WWTPs 
discussed: JIWRF and SSWRF. 
 
70 
3 6 Concentration of metformin (a) and 
carbamazepine (b) in wastewater 
effluent and in Lake Michigan on 
six dates 
 
71 
3 7 Risk Quotient for 14 PPCPs in 
Wastewater Effluent and in Lake 
Michigan (RQ > 1 is high risk, RQ 
from 0.1 to 1 is medium risk, and 
RQ < 0.1 is low risk 
 
72 
 
 
vii 
 
Chapter Figure  Number Caption Page 
4 8 Influent concentration results of 11 
PPCPs from meta-analysis. Box 
plot represents minimum, 25th 
percentile, 75th percentile, and 
maximum. 
 
108 
4 9 Effluent concentration (a) and 
effluent risk quotient (b) for 
ibuprofen after treatment from a 
CAS then tertiary treatment with 
MBR, UF, NF, and MF systems. 
“+” is the maximum value from the 
simulation, central mark is the 
median, the edges of the box are the 
25th and 75th percentiles, the 
whiskers extend to the most 
extreme data points not considered 
outliers. 
 
109 
4 10 Effluent concentration (a) and 
effluent risk quotient (b) for 
carbamazepine after treatment from 
a CAS then tertiary treatment with 
MBR, UF, NF, and MF systems. 
“+” is the maximum value from the 
simulation, central mark is the 
median, the edges of the box are the 
25th and 75th percentiles, the 
whiskers extend to the most 
extreme data points not considered 
outliers. 
 
110 
4 11 Maximum RQ and (b) Median RQ 
for 11 PPCPs 
 
111 
 
  
 
 
viii 
 
LIST OF TABLES 
 
Chapter Table  Number Caption Page 
2 1 Classification, Minimum Detection 
Limit (MDL), Minimum 
Quantification Limit (MQL), range 
and median values for compounds 
assessed at SSWRF. Below 
Detection Limit (BDL) values are 
below the MDL. 
 
38 
2 2 PPCPs found in suspended solids 
on April 9th, 2010 
 
41 
3 3 Concentration of PPCPs at the final 
effluent and at seven locations in 
Lake Michigan (Below Detection 
Limit (BDL) 
 
65 
3 4 PPCPs Levels in Sediment from 
Lake Michigan (Compounds listed 
in Table 3 that were not detected 
above the MDL in the sediment 
samples are omitted from this table) 
 
68 
4 5 Summary from meta-analysis of 
influent concentration and removal 
efficiencies for 11 PPCPs and 4 
tertiary technologies. 
 
106 
4 6 Estimated 20 year present value 
(PV) for selected technologies with 
a design flow of 100 MGD. 
107 
 
 
 
 
 
 
ix 
 
LIST OF ABBREVIATIONS 
 
Abbreviation  Extended Nomenclature 
CAS    conventional activated sludge  
BDL    below detection limit 
HQ    hazard quotient 
JIWRF   Jones Island Water Reclamation Facility 
MDL    minimum detection limit  
MBR    membrane bioreactor 
MEC    maximum environmental concentration 
MF    microfiltration 
MGD    million gallons per day  
MQL    minimum quantification limit  
NF    nanofiltration 
PNEC   predicted no-effect concentration 
PPCPs   pharmaceutical and personal care products  
RQ    risk quotient 
SSWRF   South Shore Water Reclamation Facility  
UF    ultrafiltration 
WWTP   wastewater treatment plant 
  
 
 
x 
 
ACKNOWLEDGMENTS  
First, I thank my advisor, Rebecca Klaper, for her encouragement and support. 
Without her guidance and persistent help, this dissertation would not have been possible. 
I would like to extend the deepest appreciation to Timothy Grundl for his mentoring 
throughout my time at UW Milwaukee. In addition, I thank Jenny Kehl for helping me 
learn to bridge the gap between science and policy research. I also thank Laura Grant and 
Zhen He for their critical feedback, guidance, and support.  
I thank the numerous agencies and groups that provided funding for this work: 
Milwaukee Metropolitan Sewerage District, Veolia North America, Great Lakes 
Consortium for Oceans and Human Health Graduate Training Program through the 
National Oceanic and Atmospheric Administration (NOAA), and the University of 
Wisconsin at Milwaukee.  
My wife, Megan, has been a constant support throughout this experience and 
words cannot express my appreciation for her encouragement and patience over the past 
four years. Lastly, I am grateful to have wonderful parents and I thank them for the 
unequivocal support while pursuing this degree.  
  
1 
 
 
 
 
Chapter 1:  INTRODUCTION 
Since the mid-19
th
 century, pharmaceutical use has become a mainstay of the 
health care system. To illustrate this trend, over the last 10 years, the percentage of 
Americans who took at least one prescription drug in the past month increased from 44% 
to 48%, the percentage who use  two or more drugs increased from 25% to 31%, and the 
percentage who use five or more drugs increased from 6% to 11% (Gu et al., 2010). More 
recent studies have found 68% of the population used at least one prescription drug per 
year (Zhong et al., 2013). The advances in the development and widespread use of 
pharmaceutical medicines has played a partial role in the American life span increasing 
from an average of 47 years in 1850 to 79 years in 2010 (Daimmrich and Bowden 2005; 
Murphy et al., 2013). Overall, it is reasonable to expect that the worldwide usage of 
pharmaceuticals and personal care products (PPCPs) will continue to increase as 
populations and affluence rises. 
  Thirty years ago, concerns were raised regarding the probable presence of 
pharmaceuticals and personal care products (PPCPs) in the aquatic environment (e.g., 
Aherne et al., 1985). In spite of these concerns, pharmaceuticals in the aquatic 
environment received relatively little attention until Ternes et al. (1998) detected 
pharmaceuticals in wastewater effluent and Jobling et al. (1998) and Desbrow et al. 
(1998) found that pharmaceuticals were impacting aquatic organisms (Sumpter 2010). 
Together, these findings led the way for a surge in research and thousands of papers have 
since been published regarding PPCPs in, and the potential impact on, the aquatic 
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environment (Daughton and Scuderi, 2013). Despite the significant research efforts 
regarding PPCPs in the aquatic environment, numerous questions remain unanswered.  
Background and Significance 
The term PPCPs is used to describe a set of compounds consisting primarily of 
human and veterinary pharmaceutical medicines, over-the-counter drugs, stimulants, 
hormones, cosmetics, soaps, and fragrances. These pollutants enter the aquatic 
environment through human use, disposal in the drain or toilet, land application of 
biosolids, and veterinary sources such as waste overflow and land application (Kolpin et 
al., 2002; Lapen et al., 2008). Many PPCPs enter the waste stream through the 
recommended use: orally consumed PPCPs are excreted unchanged or partly metabolized 
through urine or feces while topically applied PPCPs are washed off (Kasprzyk-Hordern 
et al., 2009).  
When PPCPs enter the waste stream through excretion or disposal, these complex 
pollutants are partially removed from wastewater and a fraction of the influent 
concentration is discharged into the environment. Municipal wastewater treatment plants 
(WWTPs) were not designed to remove PCPPs, as they have been implemented with the 
aim of removing easily or moderately biodegradable carbon, nitrogen and phosphorus 
compounds and microbiological organisms (Verlicchi et al., 2012). The removal of 
PPCPs through the most common WWTP configuration, primary treatment followed by a 
conventional active sludge process and disinfection, can be explained through three 
primary mechanisms: sorption to sludge, biological degradation, and volatilization, but 
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other additional factors can impact the removal (Khan and Ongerth, 2004; Verlicchi et al. 
2012).  
Antibiotics, pharmaceuticals, stimulants, recreational drugs, hormones, non-
prescription drugs, and personal care products have all been found in surface and ground 
waters across the world (Cahill et al., 2004; Fatta-Kassinos et al., 2011; Fent et al., 2006; 
Focazio et al., 2008; Halling-Sorensen et al., 1998; Kolpin et al., 2002; Ternes, 1998). 
The concentration of PPCPs detected in the environment can depend on the wastewater 
treatment processes used, the PPCPs’ chemical characteristics, the flow of the waste 
stream, and the different PPCPs usage patterns that vary by region and over time 
(Dickenson et al., 2011; Le-Minh et al., 2010; Oulton et al., 2010; USEPA, 2010; 
Verlicchi et al., 2012). Large water bodies have been generally disregarded due to the 
expected low levels of PPCPs from dilution and the complex hydrodynamics in a lake as 
large as one of the Great Lakes; however, insignificant levels of PPCPs cannot be 
assumed.  Therefore, few studies have been conducted on PPCPs in the Great Lakes and 
they have focused on locations close to shore, in harbors, or where rivers enter the lakes 
(Csiszar et al., 2010; Ferguson et al., 2013; Li et al., 2010; Metcalf et al., 2003).  
PPCPs have been shown to cause a wide range of impacts on aquatic organisms. 
One of the most well-known studies assessing the environmental harm of PPCPs was an 
experiment conducted in a formerly pristine lake at the Experimental Lakes Area in 
Ontario, Canada where it was found that the addition of synthetic estrogen (17α-
ethynylestradiol [EE2]) to the lake led to feminization of males and caused the collapse 
of a fish population (Kidd et al., 2007). As another example of the environmental impacts 
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of PPCPs, the non-steroidal anti-inflammatory drug (NSAID) diclofenac used by 
veterinarians for the treatment of inflammation and fever in domestic livestock, caused 
the near extinction of three types of Old World vultures in southeast Asia because the 
vultures fed on the livestock carcasses (Oaks et al., 2004).  
Overall, a complete understanding of the impacts of PPCPs on aquatic organisms 
and the ecosystem is lacking. Studies have assessed the acute toxicity of PPCPs on 
aquatic organisms with a limited number of endpoints; however, more research is needed 
on the potential effects and risks of these pollutants, in particular at the concentrations 
PPCPs have been detected in the environment (Boxall et al., 2011). In the absence of a 
complete understanding of the toxicity of PPCPs, risk assessment studies have evaluated 
the potential impacts that PPCPs may have on ecosystem health using existing data (e.g. 
Verlicchi et al., 2012). For example, the risk quotient (RQ, also known as the hazard 
quotient or risk index) is defined as the ratio of the maximum observed concentration to 
the predicted no-effect concentration and has been used to determine the potential 
ecological impact of PPCPs (Al Aukidy et al., 2012; Gros et al., 2010; Hernando et al., 
2006; Tewari et al., 2013; Verlicchi et al., 2012). To determine the predicted no-effect 
concentration, a wide range of toxicity endpoints have been used and these include 
endocrine disruption, changes in growth, and changes in behaviors important to feeding, 
reproduction, and predator avoidance, along with modeled toxicity endpoints (Brausch 
and Rand, 2011; Brodin et al., 2013; Kidd et al., 2007; Nassef et al., 2010; USEPA 2012; 
Weinberger and Klaper 2013). In addition, research suggests that the effects of a mixture 
of PPCPs can cause a greater impact than the individual effect from a specific PPCP, 
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particularly if they share a similar mechanism of action (Crago and Klaper, 2012; 
DeLorenzo and Flemming, 2008). 
Although research has been completed on the potential impacts and biological 
degradation of PPCPs in the aquatic environment, experimental data that assesses these 
characteristics are sparse (Dickenson et al., 2010).  The paucity of these data causes great 
difficulty in determining the degradation of PPCPs in wastewater and the environment, 
along with an inability to determine the predicted no-effect concentration. A common 
thread throughout this work will be the use of quantitative structure–activity relationship 
(QSAR) models, which have been used to fill in many of the gaps in assessing the 
degradation and ecological impacts of PPCPs. For example, BIOWIN from the EPA’s 
EPI Suite is a model used to predict the biological degradation of pollutants in the 
environment, and it has been proposed for use in WWTP aerobic basins (Khan and 
Ongerth, 2004). Also, the model ECOSAR from the EPA is used to predict the ecosystem 
toxicity of pollutants in response to Pre-Manufacture Notices mandated under the Toxic 
Substances Control Act (TSCA). In addition, ECOSAR has been used in assessing the 
risk quotient for PPCPs (USEPA 2012; Verlicchi et al., 2012).  Using a combination of 
experimental data and modeled characteristics allows PPCPs to be assessed using the best 
data available.  
With over 5,000 different pharmaceuticals and thousands more personal care 
products currently available for use (Williams and Brooks, 2012), significant 
complications surround the management of these pollutants. At this time, no regulations 
exist for PPCPs in drinking or natural waters in the United States (Ryu et al., 2014). The 
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efforts to reduce PPCPs in the aquatic environment often lack the support of critical 
stakeholders in the regulatory process. For example, previous research has found that 
investment in advanced waste or drinking water treatment to reduce pharmaceuticals is 
opposed by both wastewater treatment companies and drinking water suppliers (Titz and 
Döll 2008). The management and policy solutions currently proposed in the academic 
literature consist of the following strategies: take-back and landfill disposal of unused 
PPCPs, tertiary wastewater treatment, urine separation, dilution through watershed 
management, producing pharmaceuticals that would cause less harm to the environment, 
selecting PPCPs possessing environment-friendly excretion profiles, improving drug 
delivery, and prescribing patients the minimum therapeutic dosage (Borsuk et al. 2008; 
Cook et al., 2012; Daughton and Ruhoy 2013; Eckstein and Sherk 2012; Glassmeyer et 
al., 2009; Khetan and Collins, 2007; Schimmelpfennig et al., 2012). Overall, given the 
increasing concerns over PPCPs in wastewater and the environment, it has been 
speculated that PPCPs will be eventually regulated in the United States (Eckstein, 2012; 
Eckstein and Sherk, 2011). Therefore, research is needed at this time that addresses the 
fate, occurrence, and environmental damage of PPCPs, along with assessing the 
regulatory framework and management implications to prevent the release of PPCPs into 
the aquatic environment.  
Objectives 
This research seeks to provide data that can help to fill the gaps in the current 
literature surrounding PPCPs in wastewater and the environment. Therefore, the goal of 
this work is to advance the understanding of PPCPs in the aquatic environment and to 
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then use this knowledge to engage in the management and policy discussions regarding 
these complex pollutants. In doing so, this research aims to answer three primary 
questions:  
1) Is it possible to predict the removal of PPCPs from a WWTP that utilizes a 
conventional active sludge (CAS) system?  
2) What is the fate, occurrence, and corresponding environmental risk quotient 
for PPCPs in Lake Michigan and the Milwaukee Harbor?   
3) Is it feasible to modify wastewater treatment regulations to remove 
unregulated PPCPs to levels that will minimize environmental harm?  
To answer these questions, two experiments and a case study are presented. The 
objective of Chapter 2, published in Science of the Total Environment, was to assess the 
fate and occurrence of PPCPs across the different stages of a wastewater treatment plant. 
This chapter presented two advances in the field of PPCPs in wastewater: a dataset that 
assessed 54 PPCPs on six dates for a conventional actived sludge WWTP and the 
assessment of a model that determined the fate across an activated sludge treatment 
process. The results showed that of the 54 PPCPs assessed, 48 were detected above the 
level of detection at some time in wastewater. The in situ data were then used to show 
that PPCPs with a log octanol-water partitioning coefficient (Kow) that is greater than 4.5 
are removed through a combination of sorption to solids and biodegradation. This study 
demonstrated that BIOWIN4 from the USEPA’s EPI Suite can be used to establish a 
basic understanding of the biological degradation of PPCPs across an aerobic biological 
treatment process. Overall, this chapter advanced the understanding of PPCPs in 
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wastewater through the use of the log Kow along with BIOWIN4 integrated into pseudo-
first order kinetics to predict the removal of easily degradable and recalcitrant PPCPs 
from a WWTP. 
The objective of Chapter 3, published in Chemosphere, was to assess the 
occurrence of PPCPs in the water and sediments of Lake Michigan, including sites 3.2 
km (2 miles) from shore. The sampling sites included the area surrounding the South 
Shore Water Reclamation Facility outfall and within the Milwaukee Harbor. Using the 
risk quotient, this chapter presented that PPCPs were detected at concentrations that are 
estimated to cause environmental concern and these results are of great importance 
because these area are near locations for fish spawning and aquatic organisms. Of the 54 
PPCPs assessed, 32 PPCPs were detected in Lake Michigan water and 30 PPCPs were 
detected in the sediment above the level of detection. Using the risk quotient, it was 
found that medium or high risk was associated with twenty-four compounds in the final 
effluent, and fourteen were found to be of medium or high risk in Lake Michigan.   
  Further research is needed to understand how emerging wastewater treatment 
processes impact the fate of PPCPs so that we can minimize the discharge and associated 
risks of PPCPs in the environment. The objective of Chapter 4 was to assess whether 
current wastewater regulations could be modified to significantly reduce the emission of 
PPCPs. More specifically, this chapter will assess whether the regulations and 
technologies to address phosphorus emissions from WWTPs could also remove PPCPs. 
To accomplish this objective, this chapter applied a meta-analysis of PPCPs removal 
from tertiary treatment technologies to a case study using the potential WWTPs upgrades 
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under a statewide phosphorus reduction policy. Two of the technologies proposed to meet 
the improved phosphorus effluent regulations also significantly reduced the risk quotient 
from PPCPs, the tertiary membrane bioreactor and nanofiltration, and the median risk 
quotient from PPCPs was estimated to be reduced by 71 and 81 percent, respectively. In 
addition, ultrafiltration was estimated to reduce the median risk quotient by 28 percent, 
with no additional cost under the current phosphorus regulations.  Therefore, the 
conclusion was reached that evaluating nutrient reduction policies to minimize emissions 
of PPCPs should be considered by managers and policy makers.  
Implications of the Present Studies  
 Collectively, the results of these projects will help us further understand the fate, 
occurrence, and ecological damage from PPCPs in wastewater and the aquatic 
environment, along with advancing the debate on how to accomplish meaningful 
reductions in these pollutants.  The overarching goal of this work is to contribute to the 
scientific and political debate on how to achieve a significant reduction in the amount of 
PPCPs being emitting into the aquatic environment.   
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Abstract 
Current wastewater treatment processes are insufficient at removing many 
pharmaceutical and personal care products (PPCPs) from wastewater and it is necessary 
to identify the chemical characteristics that determine their fate. Models that predict the 
fate of various chemicals lack verification using in situ data, particularly for PPCPs. 
BIOWIN4 is a quantitative structure–activity relationship (QSAR) model that has been 
proposed to estimate the removal of PPCPs from wastewater, but data verifying the 
accuracy of its predictions is limited. In this study, the in situ soluble and suspended solid 
concentrations were assessed from raw influent, primary effluent, secondary effluent, and 
final effluent for 54 PPCPs and hormones over six dates. When assessing the removal 
efficiency across the different stages of the WWTP, the majority of the removal occurred 
across the secondary treatment process for the majority of the compounds. The primary 
treatment and disinfection process had limited impacts on the removal of most PPCPs. 
Sorption to solids was found to influence the removal for compounds with a log octanol–
water partitioning coefficient greater than 4.5 across the secondary treatment process. For 
other compounds, the removal of PPCPs across the secondary treatment process was 
significantly correlated with the biodegradation predicted by BIOWIN4. Removal 
efficiencies across the aerobic secondary treatment process were predicted by integrating 
BIOWIN4 into pseudo-first order kinetics of PPCPs and these predicted values were 
compared to the in situ data. This study determines that under a certain set of operating 
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conditions, two chemical characteristics — the expected hydrophobic interaction and the 
modeled biological degradation from BIOWIN4 — were found to predict the removal of 
highly degradable and recalcitrant PPCPs from a wastewater secondary treatment 
process.    
 
Introduction  
  Pharmaceuticals and personal care products (PPCPs) have been detected in 
surface waters worldwide and risk analysis studies have led to the concern that these 
PPCPs may have a negative impact on ecosystem and human health (Al Aukidy et al., 
2012; Cahill et al., 2004; Fatta-Kassinos et al., 2011; Fent et al., 2006; Focazio et al., 
2008; Gros et al., 2010; Halling-Sorensen et al., 1998; Kolpin et al., 2002; Ternes, 1998). 
In general, the removal of PPCPs through wastewater treatment plants (WWTPs) has 
been shown to depend on the PPCPs' chemical characteristics, the treatment processes 
used, and the concentration found in the influent, but other variables can influence the 
removal efficiencies (Le-Minh et al., 2010; Oulton et al., 2010; USEPA, 2010; Verlicchi 
et al., 2012).  
The understanding of the fate of PPCPs in wastewater is limited, in particular, the 
removal efficiency across the varying configurations of WWTPs. WWTPs that utilize 
conventional activated sludge (CAS) systems have been found to present a wide range of 
removal efficiencies for different PPCPs (Miege et al., 2009; Oulton et al., 2010; 
Verlicchi et al., 2012). The removal of PPCPs through primary and secondary treatment 
can be explained through three mechanisms: sorption to sludge, biological degradation, 
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and volatilization (Khan and Ongerth, 2002). The incomplete removal of many PPCPs is 
primarily due to the resistance of these compounds to biological degradation (Joss et al., 
2006). The hydrophobic interaction, which explains sorption to solids, is expected to be 
significant for PPCPs with a log octanol– water partitioning coefficient (Kow) greater than 
4.0 (Thompson et al., 2011) and removal by sorption was concluded to be a minor 
pathway for most PPCPs (Radjenovic et al., 2009). Additionally, Khan and Ongerth 
(2004) estimated that removal by sorption accounted for 10% or less of the overall 
removal of 47 of the top 50 PPCPs in use in Australia. Volatilization can be considered 
negligible for the majority of PPCPs (Joss et al., 2006).  
The biological degradation rate constant (Kbiol) has been suggested to be a strong 
indicator of the removal efficiency of PPCPs due to biological transformation being the 
major elimination mechanism (Abegglen et al., 2009; Salgado et al., 2012; Thompson et 
al., 2011). However, the Kbiol values for many PPCPs are not available (Dickenson et al., 
2010). Since the biological degradation is the key mechanism for the removal of many 
PPCPs, finding these values is critical to understanding the removal efficiency. The Kbiol 
values have been found for a limited number of compounds using pseudo-first-order 
kinetics (Joss et al., 2006; Schwarzenbach et al., 2003). At this time, the majority of Kbiol 
values used in modeling the removal of PPCPs are estimated using their chemical 
composition and characteristics (Dickenson et al., 2010). However, with over 3000 
pharmaceuticals currently in use (Monteiro and Boxall, 2010), being able to predict the 
removal of these PPCPs without in situ testing is necessary.  
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BIOWIN, a quantitative structure–activity relationship (QSAR) based model that 
is included in the Environmental Protection Agency's EPI Suite, estimates the probability 
of biodegradation based on mathematical models for predicting aerobic biodegradability 
from chemical structure (Boethling et al., 1994). BIOWIN models have been used to 
predict the biological half-life of pollutants with varying success (Aronson et al., 2006). 
One of the BIOWIN models, BIOWIN4, was designed as an expert survey model for 
primary biodegradation estimation and it calculates the time required to achieve primary 
biodegradation in a typical aquatic environment (Boethling et al., 1994). It has been 
predicted that BIOWIN4 can be used to determine the aerobic biodegradation in WWTP 
systems (Clark et al., 1995; Khan and Ongerth, 2002).  
While many studies have investigated the fate of PPCPs during secondary 
treatment, these studies are seldom combined with an in situ evaluation of a model. This 
is often due to the difficulties in predicting the fate of PPCPs in WWTPs and the number 
of variables that influence the removal efficiency. The purpose of this study was to detect 
the concentration of 54 PPCPs with varying chemical characteristics across the stages of 
a WWTP and to use these data to verify a model assessing the fate of PPCPs in 
wastewater. This paper presents a substantial PPCP monitoring data set by collecting 
these PPCPs at the raw influent, primary effluent, secondary effluent, and final effluent 
stages. With the use of these data, the observed PPCPs removal efficiencies are compared 
to the predicted removal efficiencies from a simple model that integrates BIOWIN4 into 
pseudo-first order kinetics.  
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Materials and methods  
PPCPs were measured at South Shore Water Reclamation Facility (SSWRF) in 
Oak Creek, WI, which is a facility that services the greater Milwaukee, WI area. Samples 
of raw influent, primary effluent, secondary effluent and final effluent were collected on 
six dates over a two-year period (Spring 2009–Fall 2010). SSWRF uses preliminary 
treatment (7 bar screens/grit channels), primary treatment (16 primary clarifiers), 
activated sludge treatment (28 aeration basins and 24 secondary clarifiers) and chlorine 
disinfection (2 5-pass contact channels). SSWRF has a treatment capacity of 1,135,000 
m
3
 day
−1
 (300 MGD (million gallons day
−1
)) with an average flow of approximately 
379,000 m
3
 day
−1
 (100 MGD). The base flow is 246,000 to 284,000 m
3
 day
−1
 (65 to 75 
MGD) in dry conditions. The disinfection process used variable levels of sodium 
hypochlorite and sodium bisulfite and the dosage was adjusted to obtain the required 
disinfecting performance and to obtain zero residual chlorine. The pH on the sampling 
dates ranged from 6.73 to 7.06, with the average being 6.91. All samples were taken over 
a 24-hour period. The sampling for the raw influent and final effluent were flow 
proportional and the primary effluent and secondary effluent were time proportional. The 
influent was sampled using a Hach/Sigma SD 900 instrument that was set to collect a 
composite sample in flow pace with a target of 6–8 L. The system would cycle every 
2000 to 5000 gal depending on influent flow to the plant and collected 50 mL of sample 
each cycle. The primary effluent was sampled using a Sanford instrument where 20 mL 
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was collected every 4 min for a final volume of 6–8 L. The secondary effluent was 
sampled using a grab method of 250 mL every 3 h. The final effluent was sampled using 
an ISCO 6712FR instrument with the same flow dependent setup as the influent sample. 
All samples were then well mixed and 1 L was sampled and extracted.  
 
PPCP analysis  
Methods are based upon US EPA Method 1694 (USEPA, 2007a), which 
determines PPCPs in environmental samples and US EPA Method 1698 (USEPA, 
2007b), which determines steroids and hormones in environmental samples by high 
performance liquid chromatography combined with tandem mass spectrometry 
(HPLC/MS/MS). One liter liquid samples were filtered through Whatman GF-A glass 
fiber filter media to retain particulate material. The filtrate pH was adjusted to 2 with 
concentrated sulfuric acid and 0.5 g of EDTA was added to chelate minerals for acid 
analytes (or pH adjusted to 10 with concentrated ammonium hydroxide for basic 
extraction analytes).  
Liquid samples were then spiked with a suite of mass labeled internal standard 
compounds and extracted with 20 mL, 1 g Waters Oasis HLB cartridges and eluted 
sequentially with 12 mL methanol, 6 mL methanol:acetone (50:50), and 6 mL 
MTBE:methanol (90:10) for acid analytes or 6 mL of methanol followed by 9 mL 
methanol with 2% formic acid for basic analytes. The elution solvents were concentrated 
under nitrogen to approximately 0.2 mL and quantitatively transferred to 1.0 mL final 
volume with methanol pending analysis.  
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Liquid samples for hormones were spiked with a suite of mass labeled internal 
standard compounds and extracted with 6 mL, 200 mg Biotage Isolute ENV+ cartridges 
and eluted sequentially with 6 mL methanol and 6 mL methanol:ethyl acetate (50:50). 
The elution solvents were concentrated under nitrogen to approximately 0.2 mL and 
quantitatively transferred to 0.5 mL final volume with methanol pending analysis. 
Particulates were captured on glass fiber filters from the April 9, 2010 sampling 
date and these data are presented separate from the liquid concentration in the results. 
This study did not assess the concentration of PPCPs in the waste activated sludge. An 
extraction of the particulates that were filtered was conducted and then an additional 
solids extraction was completed for those particulates. Aliquots (1 g) of filtered solids 
were placed in 50 mL polypropylene centrifuge tubes with pH 2 phosphate buffer: 
acetonitrile, spiked with a suite of mass labeled internal standard compounds, and 
extracted three times by sonication. The pooled acetonitrile was removed from the extract 
using a rotary evaporator and the aqueous extract was brought to 200 mL volume with 18 
MΩ/cm water before further processing by the liquids method described above. From the 
extract, 15 μL was injected onto a Phenomenex Synergi MAX-RP 250×4.6 mm, 4 μm 
column and separated by a binary gradient employing an Agilent 1100 HPLC system. 
Detection was achieved with an Applied Biosystems/ MDS SCIEX API 4000 MS/MS 
system operating with Turbo Ion Spray ionization and multiple reaction monitoring 
(MRM) detection. The data are presented in Appendix A.  
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BIOWIN assessment  
The USEPA's Estimation Program Interface (EPI) Suite v4.10 was used to find 
the BIOWIN4 values and log Kow (USEPA, 2011). The QSAR model used was 
BIOWIN4 and it was designed as an expert survey model to determine the time needed 
for primary biodegradation (Boethling et al., 1994). BIOWIN4 was used in this paper due 
to it providing the best estimate of biodegradation when compared with measured first-
order rate constants (Dickenson et al., 2010). The BIOWIN4 values are interpreted as the 
environmental biological degradation timeframe, where 2=months, 3=weeks, and 4=days. 
Along with predicting the environmental biological degradation timeframe, BIOWIN4 
has been predicted to determine the aerobic biodegradation timeframe in WWTP systems 
using the relationship developed by Khan and Ongerth (2002). Also, ultimate degradation 
was not studied in the present paper, which reinforced the decision to use the primary 
biodegradation estimation model, BIOWIN4.  
The median suspended solid concentration (Xss) on the five sampling dates was 
used for the pseudo first-order calculation. On the sampling dates, the median hydraulic 
retention time in the aeration basin was 9.8 h and the median hydraulic retention time in 
the secondary clarifier was 7.3 h. Using the settling velocity and activated sludge blanket 
depth, it was estimated that the soluble compounds were in contact with the activated 
sludge for approximately 30% of hydraulic retention time in the secondary clarifier. 
When the compounds were not in contact with the activated sludge, it was assumed that 
the biodegradation was negligible. When optimizing the biological degradation equation 
to correspond with the experimental data only the compounds with a Kow of less than 4.5 
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were used. For this assessment, the compounds with negative removal efficiency were 
considered to have no removal. If the secondary effluent concentration was below the 
minimum detection limit, the compound was considered to be 100% removed. The 
removal efficiencies were found for each date and the median of these values was used 
for this analysis. Calculations are shown in Appendix B.  
 
Detection limits and statistics  
The minimum detection limit (MDL) and minimum quantification limit (MQL) 
were found using the USEPA CFR 40, part 136 (USEPA, 2003). PASW Statistics v18 
was used to find the statistical correlation and significance when finding the relationships 
between BIOWIN4 and removal efficiency and between the modeled and observed 
removal efficiency.  
 
Results and discussion  
SSWRF PPCP Levels  
The concentrations of 54 PPCPs, at the raw influent, primary effluent, secondary 
effluent, and final effluent sites, are shown in Table 1. The minimum detection limit and 
minimum quantification limit are also shown. The suspended solids were filtered from 
the April 9, 2010 samples and these were assessed for sorption of PPCPs to the solids and 
the results are shown in Table 2. All compounds not shown in Table 2 had levels below 
MDL for all 4 stages across the WWTP. The compounds with log Kow values greater than 
4.5, triclosan and triclocarban, had the highest concentrations found in the suspended 
26 
 
 
 
solids. Of the 54 compounds listed in Table 1, 48 of them were detected at a level above 
the MDL at some time in SSWRF. However, substantial variations were seen for the 
majority of the compounds across dates and the stages of SSWRF.  
When assessing the removal efficiency across the different stages of the WWTP, 
the majority of the removal occurred across the secondary treatment process for the 
majority of the compounds. For example, caffeine which is shown in Fig. 1, had a high 
removal efficiency, but caffeine also had notable values in the final effluent. In contrast 
to caffeine, many compounds, such as codeine, had poor removal efficiencies as shown in 
Fig. 2.  
The removal efficiency was low for the majority of PPCPs across the primary 
clarifier, but some PPCPs had notable removal efficiencies. One compound, ibuprofen, 
had a high removal efficiency (88% median removal efficiency) in the primary treatment 
process. Some PPCPs that had moderate removal across the primary treatment process 
were acetaminophen (22% median removal efficiency), estrone (59% median removal 
efficiency), fluoxetine (45% median removal efficiency), metformin (24% median 
removal efficiency), paraxanthine (22% median removal efficiency), and triclosan (32% 
median removal efficiency).  
Minimal PPCPs were removed across the disinfection process, which used 
sodium hypochlorite for disinfection and sodium bisulfite for de-chlorination. The 
compounds that had notable removal across the disinfection stage were caffeine (69% 
median removal efficiency), gemfibrizol (60% median removal efficiency), naproxen 
(73% median removal efficiency), paraxanthine (78% median removal efficiency), and 
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sulfanilamide (41% median removal efficiency). Caffeine has been shown to have no 
interaction with chlorine and gemfibrizol was implied to be chlorinated (Glassmeyer and 
Shoemaker, 2005). The removal of caffeine across the disinfection process could be due 
to the biological degradation prior to complete disinfection. Some compounds, such as 
naproxen, have been shown to have a high removal efficiency (>80%) from chlorine 
disinfection (Benotti et al., 2009).  
A few compounds had negative removal efficiencies across the entire treatment 
plant where lower concentrations were seen in the raw influent than the final effluent. 
Also, many compounds had a negative removal efficiency across one of the stages 
assessed at SSWRF. Numerous explanations are available for the observed negative 
removal efficiency and five possible explanations apply specifically to this study. First, 
shifting the primary effluent, secondary effluent, and final effluent sampling periods by 
the hydraulic retention time or sampling using the residence time distribution may lower 
the potential for errors (Majewsky et al., 2011a). Second, 24-hour composite samples 
may be insufficient to determine PPCP removal in WWTPs (Ort et al., 2010). Third, 
some compounds have also been proposed to have conjugate compounds that are not 
detected at the influent but retransformed into the original compound due to biological 
processes (Monteiro and Boxall, 2010; Salgado et al., 2012). Fourth, desorption from the 
return activated sludge may occur during the secondary treatment process (Salgado et al., 
2012). Finally, PPCPs may be released from fecal particles as the feces are being broken 
down by microbes (Göbel et al., 2007).  
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BIOWIN4 results  
The median removal efficiency from each date was used when assessing 
BIOWIN4. When using very low concentrations to establish a relationship with removal 
efficiencies, the low concentrations will cause unavoidable instrumental errors that may 
affect their observed removal values (Verlicchi et al., 2012). To minimize this error in the 
removal efficiency calculations, the compounds selected for assessment using BIOWIN 
had at least three of the five samples with a primary effluent concentration greater than 
the MQL. Also, since using 24-hour composite samples may not adequately determine 
the removal of PPCPs (Ort et al., 2010), using the median value from the three to five 
sampling dates will create a stronger representative removal efficiency value. Only the 
data from the dates where the detection was greater than the MQL at the primary effluent 
site were used. If the secondary effluent concentration was less than the MQL, the 
removal efficiency assigned to this compound was 100%. The following eighteen met 
these criteria and were further analyzed: acetaminophen, caffeine, carbamazepine, 
codeine, cotinine, diltiazem, diphenhydramine, fluoxetine, ibuprofen, metformin, 
naproxen, paraxanthine, ofloxacin, ranitidine, sulfamethoxazole, triclocarban, triclosan, 
and trimethoprim.  
As shown in Fig. 3, a statistically significant correlation (Pearson 
correlation=0.773, p<0.001) between the observed removal efficiency across the 
secondary treatment process and the BIOWIN4 estimated biological degradation in the 
environment was found. This relationship does not include the compounds with a log Kow 
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greater than 4.5, therefore, the relationship is based on the remaining 16 PPCPs with 
primary effluent concentrations consistently above their respective MDLs. Triclosan and 
triclocarban were two compounds assessed that had a log Kow greater than 4.5. These two 
compounds' high removal efficiency and lowBIOWIN4 value, implies removal by 
sorption to solids as well as limited biological degradation.  
 
BIOWIN and half-life  
It has been approximated that the BIOWIN4 values can be converted to biological 
degradation half-lives (t½) in an aeration tank with using the following relationship 
(Khan and Ongerth, 2004):  
        (1) 
Using the expected biological degradation half-life from Eq. (1), the intrinsic 
biological rate constant (Kbiol) can be found using Eq. (2): 
        (2) 
The pseudo first-order kinetic equation (Joss et al., 2006) was used to convert the 
biological half-life to removal efficiency across the secondary treatment process:  
        (3) 
where, Ct is the soluble compound concentration at time t (ng L
−1
), t is hydraulic 
retention time (day), Kbiol is the biological rate constant (L gss 
−1
 day
−1
), Xss is the 
concentration of suspended solids (gss L
−1
), and C0 is the initial soluble compound 
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concentration (ng L
−1
). This median concentration of mixed liquor suspended solids at 
SSWRF was 1.74 g L
−1
. By integrating Eq. (3) and combining it with Eq. (2), the results 
are shown in Eq. (4):  
       (4) 
Using Eq. (4), the predicted results relate significantly to the actual removal 
observed at SSWRF (Pearson correlation=0.792, p<.001). The PPCPs with a log Kow 
greater than 4.5 were omitted from this analysis. These results are shown in Fig. 4. This 
relationship demonstrates that BIOWIN4 paired with pseudo-first order kinetics may be 
used to predict the removal of PPCPs across a secondary treatment process for 
compounds that are expected to biological degrade quickly (i.e. acetaminophen, 
naproxen) and the recalcitrant compounds (i.e. codeine, ofloxacin).  
The compounds with a BIOWIN4 value between 3.3 and 3.7 are more difficult to 
predict. For example, caffeine and carbamazepine have similar BIOWIN4 values, 3.57 
and 3.51 respectively, but caffeine had a high removal efficiency and carbamazepine was 
not removed. Other studies have reported incomplete removal efficiencies for 
carbamazepine while caffeine has been shown to be degraded in aWWTP (>50% removal 
efficiency) (Santos et al., 2007; Radjenovic et al., 2009; Rosal et al., 2010; Vieno et al., 
2007). This demonstrates the difficulty in assessing the removal of PPCPs from 
wastewater and the variability seen in the removal efficiencies for many compounds.  
The results from the use of BIOWIN4 with the removal of PPCPs across the 
aeration basin were more accurate than reported by Dickenson et al. (2010). These results 
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suggest that using a combination of BIOWIN models may not be necessary to accurately 
predict removal of PPCPs across an aeration basin as proposed by Posthumus et al. 
(2005); BIOWIN4 was found to have a statistically significant relationship with the 
removal of PPCPs across the aeration basin.  
Other variables have been shown to impact removal, such as the fraction of active 
biomass, solids retention time (SRT), recirculation rate, water pH, temperature, reactor 
configuration, molecular charge, and hydraulic retention time (Abegglen et al., 2009; 
Fatta-Kassinos et al., 2011; Majewsky et al., 2011b; Suarez et al., 2012; Tadkaew et al., 
2010; Verlicchi et al., 2012). For example, the SRT at SSWRF was between 8.0 and 15.5 
days. WWTPs with a SRT of 8 days or higher used for nitrification will have higher 
removal efficiencies for PPCPs in comparison with WWTPs without nitrification 
(Abegglen et al., 2009). Furthermore, the solubility should also be considered in relation 
to the pH of the matrix in which it is present (Fatta-Kassinos et al., 2011); however, the 
average pH at SSWRF on the sampling dates was 6.9. Therefore, these variables must all 
be considered when assessing the removal of PPCPs from a WWTP.  
Since this analysis focuses on primary biological degradation and sorption to 
solids, it may be neglecting other degradation or removal processes. For example, 
triclosan has been shown to create polychlorodibenzo-p-dioxin (PCDD) photoproducts 
when exposed to UV light combined with the chlorination process that is commonly used 
in the wastewater processes and this is important because these PCDD photoproducts 
have been found in the environment (Buth et al., 2009). An additional limitation of this 
study is that BIOWIN4 assesses primary degradation and future research should also 
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place an emphasis on metabolites and transformation products since it is necessary to 
evaluate the fate of these transformation products (Farre et al., 2012).  
 
Conclusion  
  This paper presented two advances in the field of PPCPs in wastewater: a dataset 
that assesses the occurrence and fate of 54 PPCPs on six dates for a CAS WWTP and the 
assessment of a model that determines the fate across an activated sludge treatment 
process. Of the 54 PPCPs assessed, 48 were detected in SSWRF and the concentrations at 
each treatment stage were determined. The large number of variables that could influence 
the removal efficiency causes great difficulty in determining an intrinsic biological 
degradation rate constant. These in situ data showed that PPCPs with a log Kow that is 
greater than 4.5 are removed through a combination of sorption to solids and 
biodegradation. This study also demonstrates that BIOWIN4 can be used to establish a 
basic understanding of the removal of PPCPs across an aerobic biological treatment 
process. Overall, using log Kow along with BIOWIN4 integrated into pseudo-first order 
kinetics, it was possible to predict the removal of easily degradable and recalcitrant 
PPCPs from the aerobic treatment process at SSWRF.  
 
  
33 
 
 
 
REFERENCES 
Abegglen, C., Joss, A., McArdell C.S., Fink, G., Schlusener, M.P., Ternes, T.A., et al. 
(2009). The fate of selected micropollutants in a single-house MBR. Water 
Research, 43, 2036–46.  
 
Al Aukidy, M., Verlicchi, P., Jelic, A., Petrovic, M., Barcelò, D. (2012). Monitoring 
release of pharmaceutical compounds: occurrence and environmental risk 
assessment of two WWTP effluents and their receiving bodies in the Po Valley, 
Italy. Science of the Total Environment,  438, 15–25. 
 
Aronson, D., Boethling, R., Howard, P., Stiteler, W. (2006). Estimating biodegradation 
half-lives for use in chemical screening. Chemosphere, 63, 1953–60. 
 
Benotti, M.J., Trenholm, R.A., Vanderford, B.J., Holady, J.C., Stanford, B.D., Snyder, 
S.A. (2009). Pharmaceuticals and endocrine disrupting compounds in US drinking 
water. Environmental Science and Technology, 43, 597–603. 
 
Boethling, R.S., Howard, P.H., Meylan, W., Stiteler, W., Beauman, J., Tirado, N. (1994). 
Group contribution method for predicting probability and rate of aerobic 
biodegradation. Environmental Science and Technology, 28, 459–65. 
 
Buth, J.M., Grandbois, M., Vikesland, P.J., McNeill, K., Arnold, W.A. (2009). 
Photochemistry of chlorinated triclosan derivatives: potential source of 
polychlorinateddibenzo-p-dioxins. Environmental Toxicology and Chemistry, 28, 
2555–63. 
 
Cahill, J.D., Furlong, E.T., Burkhardt, M.R., Kolpin, D., Anderson, L.G. (2004). 
Determination of pharmaceutical compounds in surface- and ground-water 
samples by solid-phase extraction and high-performance liquid chromatography–
electrospray ionization mass spectrometry. Journal of Chromatography A, 1041, 
171–80.  
 
Clark, B., Henry, J.G., Mackay, D. (1995). Fugacity analysis and model of organic 
chemical fate in a sewage treatment plant. Environmental Science and 
Technology, 29, 1488–94. 
 
 Dickenson, E.R.V., Drewes, J.E., Stevens-Garmon, J., Khan, S., McDonald, J. (2010). 
Evaluation of GSPR techniques for wastewater treatment processes. Water 
Environment Research Foundation, IWA Publishing.  
 
Farre, M., Kantiani, L., Petrovic, M., Perez, S., Barcelo, D. (2012). Achievements and 
future trends in the analysis of emerging organic contaminants in environmental 
samples by mass spectrometry and bioanalytical techniques. Journal of 
34 
 
 
 
Chromatography A, 1259, 86–99.  
 
Fatta-Kassinos, D., Meric, S., Nikolaou, A. (2011). Pharmaceutical residues in 
environmental waters and wastewater: current state of knowledge and future 
research. Analytical and Bioanalytical Chemistry, 399, 251–75. 
 
 Fent, K., Weston, A.A., Caminada, D. (2006). Ecotoxicology of human pharmaceuticals. 
Aquatic Toxicology, 76, 122–59.  
 
Focazio, M.J., Kolpin, D.W., Barnes, K.K., Furlong, E.T., Meyer, M.T., Zaugg, S.D., et 
al. (2008). A national reconnaissance for pharmaceuticals and other organic 
wastewater contaminants in the United States — II, untreated drinking water 
sources. Science of the Total Environment, 402, 201–16.  
 
Glassmeyer, S.T., Shoemaker, J.A. (2005). Effects of chlorination on the persistence of 
pharmaceuticals in the environment. Bulletin of Environmental Contamination 
and Toxicology, 74, 24–31.  
 
Göbel, A., McArdell, C.S., Joss, A., Siegrist, H., Giger, W. (2007). Fate of sulfonamides, 
macrolides, and trimethoprim in different wastewater treatment technologies. 
Science of the Total Environment, 372, 361–71.  
 
Gros, M., Petrovic, M., Ginebreda, A., Barcelo, D. (2010). Removal of pharmaceuticals 
during wastewater treatment and environmental risk assessment using hazard 
indexes. Environment International, 36, 15–26.  
 
Halling-Sorensen, B., Nielsen, S.N., Lanzky, P.F., Ingerslev, F., Lutzhoft, H.C.H., 
Jorgensen, S.E. (1998). Occurrence, fate and effects of pharmaceutical substances 
in the environment — a review. Chemosphere, 36, 357–94.  
 
Joss, A., Zabczynski, S., Gobel, A., Hoffmann, B., Loffler, D., McArdell, C.S., et al. 
(2006). Biological degradation of pharmaceuticals in municipal wastewater 
treatment: proposing a classification scheme. Water Research, 40, 1686–96.  
 
Khan, S.J., Ongerth, J.E. (2002). Estimation of pharmaceutical residues in primary and 
secondary sewage sludge based on quantities of use and fugacity modelling. 
Water Science and Technology, 46, 105–13.  
 
Khan, S.J., Ongerth, J.E. (2004). Modelling of pharmaceutical residues in Australian 
sewage by quantities of use and fugacity calculations. Chemosphere, 54, 355–67.  
 
Kolpin, D.W., Furlong, E.T., Meyer, M.T., Thurman, E.M., Zaugg, S.D., Barber, L.B., et 
al. (2002). Pharmaceuticals, hormones, and other organic wastewater 
contaminants in US streams, 1999–2000: a national reconnaissance. 
35 
 
 
 
Environmental Science and Technology, 36, 1202–11.  
 
Le-Minh, N., Khan, S.J., Drewes, J.E., Stuetz, R.M. (2010). Fate of antibiotics during 
municipal water recycling treatment processes. Water Research, 44, 4295–323.  
 
Majewsky, M., Galle, T., Bayerle, M., Goel, R., Fischer, K., Vanrolleghem, P.A. (2011a). 
Xenobiotic removal efficiencies in wastewater treatment plants: residence time 
distributions as a guiding principle for sampling strategies. Water Research, 45, 
6152–62.  
 
Majewsky, M., Galle, T., Yargeua, V., Fisher, K. (2011b). Active heterotrophic biomass 
and sludge retention time (SRT) as determining factors for biodegradation 
kinetics of pharmaceuticals in activated sludge. Bioresource Technology, 102, 
7415–21.  
 
Miege, C., Choubert, J.M., Ribeiro, L., Eusebe, M., Coquery, M. (2009). Fate of 
pharmaceuticals and personal care products in wastewater treatment plants — 
conception of a database and first results. Environmental Pollutution, 157, 1721–
6.  
 
Monteiro, S.C., Boxall, A.B.A. (2011). Occurrence and fate of human pharmaceuticals in 
the environment. In: Whitacre DM, editor. Reviews of Environmental 
Contamination and Toxicology, 202, 53-154.  
 
Ort, C., Lawrence, M.G., Reungoat, J., Mueller, J.F. (2010). Sampling for PPCPs in 
wastewater systems: comparison of different sampling modes and optimization 
strategies. Environmental Science and Technology, 44, 6289–96.  
 
Oulton, R.L., Kohn, T., Cwiertny, D.M. (2010). Pharmaceuticals and personal care 
products in effluent matrices: a survey of transformation and removal during 
wastewater treatment and implications for wastewater management. Journal of 
Environmental Monitoring, 12, 1956–78.  
 
Posthumus, R., Traas, T.P., Peijnenburg, W., Hulzebos, E.M. (2005). External validation 
of EPIWIN biodegradation models. SAR and QSAR Environmental Research, 16, 
135–48.  
 
Radjenovic, J., Petrovic, M., Barcelo, D. (2009). Fate and distribution of pharmaceuticals 
in wastewater and sewage sludge of the conventional activated sludge (CAS) and 
advanced membrane bioreactor (MBR) treatment. Water Research, 43, 831–41.  
 
Rosal, R., Rodriguez, A., Perdigon-Melon, J.A., Petre, A., Garcia-Calvo, E., Gomez, 
M.J., et al. (2010). Occurrence of emerging pollutants in urban wastewater and 
their removal through biological treatment followed by ozonation. Water 
36 
 
 
 
Research, 44, 578–88.  
 
Salgado, R., Marques, R., Noronha, J.P., Carvalho, G., Oehmen, A., Reis, M.A.M. 
(2012). Assessing the removal of pharmaceuticals and personal care products in a 
full-scale activated sludge plant. Environmental Science and Pollution Research, 
19, 1818–27.  
 
Santos, J.L., Aparicio, I., Alonso, E. (2007). Occurrence and risk assessment of 
pharmaceutically active compounds in wastewater treatment plants. a case study: 
Seville city (Spain). Environment International, 33, 596–601.  
 
Schwarzenbach, R.P., Gschwend, P.M., Imboden, D.M. (2003). Environmental organic 
chemistry. Hoboken, NJ: Wiley-Interscience. 
 
Suarez, S., Reif, R., Lema, J.M., Omil, F. (2012). Mass balance of pharmaceutical and 
personal care products in a pilot-scale single-sludge system: influence of T, SRT 
and recirculation ratio. Chemosphere, 89, 164–71.  
 
Tadkaew, N., Sivakumar, M., Khan, S.J., McDonald, J.A., Nghiem, L.D. (2010). Effect 
of mixed liquor pH on the removal of trace organic contaminants in a membrane 
bioreactor. Bioresource Technology, 101, 1494–500.  
 
Ternes, T.A. (1998). Occurrence of drugs in German sewage treatment plants and rivers. 
Water Research, 32, 3245–60.  
 
Thompson, K., Zhang, J.Y., Zhang, C.L. (2011). Use of fugacity model to analyze 
temperaturedependent removal ofmicro-contaminants in sewage treatment plants. 
Chemosphere, 84, 1066–71.  
 
USEPA. (2003). CFR 40, part 136 — guidelines establishing test procedures for the 
analysis of pollutants. Washington DC: United Stated Environmental Protection 
Agency.  
 
USEPA. (2007a). Method 1694: pharmaceuticals and personal care products in water, 
soil, sediment, and biosolids by HPLC/MS/MS. Washington DC: United Stated 
Environmental Protection Agency.  
 
USEPA. (2007b). Method 1698: steroids and hormones in water, soil, sediment, and 
biosolids by HRGC/HRMS. Washington DC: United Stated Environmental 
Protection Agency.  
 
USEPA. (2010). Treating contaminants of emerging concern: a literature review 
database. Washington DC: United Stated Environmental Protection Agency.  
` 
37 
 
 
 
USEPA. (2011). Estimation Program Interface (EPI) Suite. Washington DC: United 
Stated Environmental Protection Agency.  
 
Verlicchi, P., Al Aukidy, M., Zambello, E. (2012). Occurrence of pharmaceutical 
compounds in urban wastewater: removal, mass load and environmental risk after 
a secondary treatment — a review. Science of the Total Environment, 429, 123–
55.  
 
Vieno, N., Tuhkanen, T., Kronberg, L. (2007). Elimination of pharmaceuticals in sewage 
treatment plants in Finland. Water Research, 41, 1001–12.  
  
 
 
 
 
 
3
8
 
Table 1: Classification, Minimum Detection Limit (MDL), Minimum Quantification Limit (MQL), range and median values 
for compounds assessed at SSWRF. Below Detection Limit (BDL) values are below the MDL.  
 Classification MDL MQL Raw Influent Primary Effluent Secondary Effluent Final Effluent 
    Min - Max, Median Min - Max, Median Min - Max, Median Min - Max, Median 
   ng L-1 ng L-1 ng L-1 ng L-1 ng L-1 ng L-1 
17,20-dihydroxyprogesterone Sex Hormone 1.4 4.2 BDL - 3.8*, BDL BDL - 2.9*, BDL BDL - BDL, BDL BDL - BDL, BDL 
17-alpha-estradiol Sex Hormone 1.2 3.5 BDL - 10000, BDL BDL - 760000, BDL BDL - 2900, BDL BDL - 4700, BDL 
17-beta-estradiol Sex Hormone 1.3 3.8 BDL - 9.4, BDL BDL - 11, BDL BDL - BDL, BDL BDL - 2.8*, BDL 
4-androstene-3,17-dione Sex Hormone 0.5 1.4 BDL - 150, 12 BDL - 73, 0.8* BDL - 1.9, BDL BDL - 2.3, BDL 
5-alpha-androstane-3,17-dione Anabolic Agent 2.3 6.9 BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL BDL - 24, BDL 
Acetaminophen   Antipyretic, Analgesic 2.5 7.5 5900 - 150000, 18000 8000 - 150000, 14000 BDL - 22000, 29 BDL - 650, 39 
Albuterol Antiasthmatic 1.4 4.2 BDL - 23, 6.3 BDL - 69, 7.2 BDL - 12, BDL BDL - 2.6*, BDL 
Azithromycin  Macrolide Antibiotic 3.7 11.0 BDL - 280, BDL BDL - 340, 6.9* BDL - 47, 6.5* BDL - 350, 110 
Boldenone Anabolic Steroid 1.3 4.0 BDL - 170, 13 BDL - 16, BDL BDL - BDL, BDL BDL - BDL, BDL 
Caffeine  Stimulant 3.1 9.3 3300 - 130000, 9200 4200 - 110000, 9400 34 - 7800, 1000 BDL - 1400, 310 
Carbadox  Quinoxaline Antibiotic 3.4 10.1 BDL - 44, BDL BDL - 68, BDL BDL - BDL, BDL BDL - 15, BDL 
Carbamazepine   Anticonvulsant 2.7 8.2 21 - 310, 72 24 - 310, 73 33 - 170, 88 27 - 340, 180 
Cimetidine Anti-acid reflux 1.3 3.8 BDL - 39, BDL BDL - 120, BDL BDL - 18, BDL BDL - BDL, BDL 
Ciprofloxacin   Quinoline antibiotic 3.3 9.9 BDL - 87, BDL BDL - 19, BDL BDL - 16, BDL BDL - BDL, BDL 
Clarithromycin   Macrolide antibiotic 3.2 9.6 BDL - 5.6*, BDL BDL - BDL, BDL BDL - BDL, BDL BDL - 19, BDL 
Codeine   Opiate 3.6 10.7 15 - 540, 45 15 - 460, 43 9.6* - 170, 62 BDL - 230, 100 
Cotinine   Nicotine metabolite 3.5 10.6 BDL - 130, 18 BDL - 810, 28 BDL - 810, BDL BDL - BDL, BDL 
Digoxigenin   Cardanolide Steroid 4.4 13.2 BDL - 850, 26 BDL - 710, 34 BDL - 68, BDL BDL - BDL, BDL 
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Diltiazem   Antihypertensive 3.5 10.4 20 - 640, 52 17 - 720, 41 BDL - 160, 38 BDL - 510, 45 
Diphenhydramine Antihistamine 3.6 10.9 11 - 420, 35 7* - 420, 24 5.8* - 140, 22 BDL - 360, 54 
Estriol Sex Hormone 2.0 6.1 BDL - 22, BDL BDL - 44, 3* BDL - 6.1, BDL BDL - BDL, BDL 
Estrone Sex Hormone 2.2 6.7 BDL - 350, 64 BDL - 290, 26 BDL - BDL, BDL BDL - BDL, BDL 
Fluoxetine   SSRI Antidepressant 3.5 10.5 6.1* - 95, 20 4* - 120, 11 5* - 25, 8.3* BDL - 96, 28 
Gemfibrozil Antilipemic 1.6 4.8 29 - 1200, 180 62 - 1100, 500 85 - 1100, 420 30 - 1100, 170 
Ibuprofen Analgesic 4.7 14.0 670 - 11000, 2100 BDL - 14000, 260 BDL - 4000, BDL BDL - BDL, BDL 
Lincomycin   Lincosamide antibiotic 3.1 9.3 BDL - 25, BDL BDL - 29, BDL BDL - BDL, BDL BDL - 15, BDL 
Lomefloxacin   Quinoline antibiotic 4.7 14.2 BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL 
Melengestrol Steroid Hormone 1.3 4.0 BDL - 43, BDL BDL - 49, BDL BDL - BDL, BDL BDL - BDL, BDL 
Melengestrol Acetate Steroid Hormone 0.6 1.7 BDL - 1300, BDL BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL 
Metformin Anti-diabetic drug 0.5 1.5 3200 - 100000, 55000 9800 - 92000, 42000 800 - 33000, 27000 640 - 47000, 26000 
Miconazole   Tetracycline antibiotic 2.7 8.1 BDL - 81, BDL BDL - 69, BDL BDL - 6.4*, BDL BDL - 25, 3* 
Naproxen NSAIDs 1.0 2.9 780 - 9400, 3000 260 - 11000, 3000 19 - 4000, 520 8.3 - 580, 140 
Norfloxacin   Quinoline antibiotic 5.1 15.3 BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL 
Ofloxacin   Quinoline antibiotic 3.9 11.7 BDL - 980, 16 BDL - 530, BDL BDL - 220, 11* BDL - 670, 44 
Oxacillin   β-lactam antibiotics 2.5 7.4 BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL 
Paraxanthine   Caffeine Metabolite 6.1 18.2 740 - 15000, 3800 1500 - 13000, 3000 25 - 2700, 540 BDL - 770, 120 
Progesterone Sex Hormone 0.7 2.0 BDL - 23, 3.7 BDL - 8.7, BDL BDL - 0.8*, BDL BDL - 2.9, BDL 
Ranitidine Anti-acid reflux 0.9 2.6 BDL - 130, 16 BDL - 330, 53 BDL - 29, BDL BDL - 13, BDL 
Roxithromycin   Macrolide antibiotic 4.3 13.0 BDL - 1500, BDL BDL - 88, BDL BDL - BDL, BDL BDL - 110, 9.2* 
Sarafloxacin   Fluoroquinolone antibiotic 5.4 16.3 BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL 
Sulfachloropyridazine   Sulfonamide antibiotic 4.1 12.3 BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL 
Sulfadiazine   Sulfonamide antibiotic 2.8 8.5 BDL - 2.8*, BDL BDL - BDL, BDL BDL – 3*, BDL BDL - 5.7*, BDL 
Sulfadimethoxine   Sulfonamide antibiotic 2.4 7.1 BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL BDL - 13, BDL 
Sulfamerazine   Sulfonamide antibiotic 2.1 6.2 BDL - BDL, BDL BDL - BDL, BDL BDL - 3.2*, BDL BDL - BDL, BDL 
Sulfamethazine   Sulfonamide antibiotic 4.0 12.1 BDL - BDL, BDL BDL - 48, BDL BDL - BDL, BDL BDL - BDL, BDL 
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Sulfamethizole   Sulfonamide antibiotic 4.2 12.7 BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL BDL - BDL, BDL 
Sulfamethoxazole   Sulfonamide antibiotic 4.1 12.4 54 - 1200, 140 21 - 1300, 93 34 - 300, 67 17 - 810, 180 
Sulfanilamide   Sulfonamide antibiotic 2.9 8.6 BDL - 900, 57 BDL - 2500, 21 BDL - 68, 42 BDL - 900, 25 
Sulfathiazole   Sulfonamide antibiotic 2.6 7.8 BDL - 3.8*, BDL BDL – 5.0*, BDL BDL - BDL, BDL BDL - BDL, BDL 
Testosterone Sex Hormone 1.1 3.2 BDL - 25, 1.7* BDL - 13, BDL BDL - BDL, BDL BDL - BDL, BDL 
Thiabendazole   Fungicide 1.8 5.3 BDL - 26, BDL BDL - 19, BDL BDL - 9.5, BDL BDL - 16, 6.8 
Triclocarban Antimicrobial 0.5 1.4 3.3 - 5900, 120 17 - 2800, 260 61 - 120, 74 27 - 980, 120 
Triclosan Antimicrobial 0.5 1.6 89 - 9100, 650 250 - 5700, 440 24 - 350, 120 BDL - 850, 97 
Trimethoprim   Pyrimidine antibiotic 3.4 10.1 18 - 590, 49 19 - 510, 44 21 - 260, 41 BDL - 660, 120 
* Value above MDL, but below MQL 
 Compound where values above the MDL were found in the method blanks, see Appendix A for values
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Table 2:  PPCPs found in suspended solids on April 9
th
, 2010 
Compound 
Raw Influent 
(ng g
-1
) 
Primary Effluent 
(ng g
-1
) 
Secondary Effluent 
(ng g
-1
) 
Final Effluent 
(ng g
-1
) 
Acetaminophen 12 BDL BDL BDL 
Caffeine 142 33 BDL BDL 
Diltiazem 7* BDL BDL BDL 
Diphenhydramine 23 BDL BDL BDL 
Fluoxetine 18 BDL BDL BDL 
Naproxen BDL 8 BDL BDL 
Ofloxacin 45 BDL 8* BDL 
Triclocarban 3280 108 BDL 155 
Triclosan 5601 182 BDL 31 
* Value above MDL, but below MQL.  
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Figure 1. Concentration of Caffeine across the Stages of SSWRF on Six Dates 
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Figure 2. Concentration of Codeine across the Stages of SSWRF on Six Dates 
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Figure 3. Median Removal Efficiency across the Secondary Treatment Process at 
SSWRF Compared to BIOWIN4 (Pearson Correlation = 0.773, p < 0.001, coefficient of 
determination and correlation includes only log Kow values < 4.5) 
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Figure 4. Predicted Removal Efficiency using Pseudo First-order Removal with the 
BIOWIN4 Converted Biodegradation Rate Constant Compared to Observed Data from 
South Shore (Pearson Correlation = 0.792, p < .001) 
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Abstract 
The monitoring of pharmaceuticals and personal care products (PPCPs) has focused on 
the distribution in rivers and small lakes, but data regarding their occurrence and effects 
in large lake systems, such as the Great Lakes, are sparse. Wastewater treatment 
processes have not been optimized to remove influent PPCPs and are a major source of 
PPCPs in the environment. Furthermore, PPCPs are not currently regulated in wastewater 
effluent. In this experiment we evaluated the concentration, and corresponding risk, of 
PPCPs from a wastewater effluent source at varying distances in Lake Michigan. Fifty-
four PPCPs and hormones were assessed on six different dates over a two-year period 
from surface water and sediment samples up to 3.2 km from a wastewater treatment plant 
and at two sites within a harbor. Thirty-two PPCPs were detected in Lake Michigan and 
30 were detected in the sediment, with numerous PPCPs being detected up to 3.2 km 
away from the shoreline. The most frequently detected PPCPs in Lake Michigan were 
metformin, caffeine, sulfamethoxazole, and triclosan. To determine the ecological risk, 
the maximum measured environmental concentrations were compared to the predicted 
no-effect concentration and 14 PPCPs were found to be of medium or high ecological 
risk. The environmental risk of PPCPs in large lake systems, such as the Great Lakes, has 
been questioned due to high dilution; however, the concentrations found in this study, 
and their corresponding risk quotient, indicate a significant threat by PPCPs to the health 
of the Great Lakes, particularly the near shore organisms.  
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Introduction 
Pharmaceutical and personal care products (PPCPs) have been found in 
wastewater worldwide (Aydin and Talinli, 2013; Gomez et al., 2007; Miege et al., 2009; 
Suarez et al., 2012; Ternes, 1998; Tewari et al., 2013; Vieno et al.,  2007). The level of 
removal has been found to vary widely depending on the chemical, the operating 
conditions, and the treatment technologies (Blair et al., 2013; Miege et al., 2009; Oulton 
et al.,  2010; Verlicchi et al., 2012). Variable removal of PPCPs through WWTPs has led 
to detection of these compounds in the aquatic environment, albeit mostly in microgram 
to nanogram per liter concentrations (Cahill et al., 2004; Focazio et al., 2008; Glassmeyer 
et al., 2005; Halling-Sorensen et al., 1998; Kolpin et al., 2002; Kümmerer, 2009; Li et al., 
2010; Scheurer et al., 2009; Snyder 2008; Yu and Chu 2009). Higher pharmaceutical 
concentrations in WWTP effluent have been measured under certain circumstances, such 
as WWTPs that receive a substantial amount of their flow rate from pharmaceutical 
manufacturing (Phillips et al., 2010, Larsson et al., 2007). Research has shown that 
certain PPCPs may have an impact on the environment at the microgram to nanogram per 
liter concentrations with a range of potential impacts (Al Aukidy et al., 2012; Brodin et 
al., 2013; Brooks et al., 2002; Christensen et al., 2009; Fent et al., 2006; Gros et al., 2010; 
Han et al., 2006; Hernando et al., 2006; Tewari et al., 2013).  
The emission of PPCPs into the environment from wastewater can depend on the 
wastewater treatment processes, the flow of the waste stream, and different PPCPs usage 
patterns that vary by region and season (Dickenson et al., 2011, Yu et al., 2013). In an 
aquatic environment the fate and concentration of PPCPs be can reliant on the receiving 
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water body flow rate, partitioning to sediments or biological entities, uptake up by biota, 
volatilization, biological degradation, photodegradation, or transformed through other 
abiotic transformations such as hydrolysis (Yamamoto et al., 2009). In the Great Lakes, 
which contains 84% of North America’s freshwater (USEPA 2012a), dilution from the 
source may also be a major factor in the occurrence and detection of PPCPs in surface 
water and sediments.  
Limited studies are available that assess PPCPs offshore in large water bodies due 
to the expected low levels of PPCPs from dilution and the complex hydrodynamics in a 
lake as large as one of the Great Lakes. Site selection for PPCPs research has focused on 
bodies of water that are potentially contaminated from human, industrial, and agricultural 
wastewater (Kolpin et al., 2002). Four previous studies have looked at PPCPs levels in 
the Great Lakes (Csiszar et al. 2011; Li et al., 2010; Metcalf et al., 2003; Wu et al., 2009) 
with a wide range of results and they have focused near shore, in harbors, and in rivers 
that are tributaries to the Great Lakes. No previous studies have assessed PPCPs offshore 
in Lake Michigan. Lake Michigan is the sixth largest lake in the world by volume and 
fifth by area (Beeton, 2002) and understanding the concentration of these pollutants in 
Lake Michigan is critical. Additionally, no previous studies have assessed the extent of 
the temporal and spatial distribution of PPCPs from a large, urban WWTP into the Great 
Lakes.  
Using a risk quotient (RQ), which is defined as the ratio of the maximum 
measured environmental concentration (MEC) to the predicted no-effect concentration 
(PNEC), the ecosystem risk from pollutants can be gauged (Hernando, 2006). However, 
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calculating this ratio can be challenging due to a lack of information regarding the effects 
of PPCPs in the environment and difficulty in establishing the PNEC. Researchers have 
used the RQ to assess the low levels of PPCPs on the ecosystem health with varying 
results. Recent studies have found limited ecological risk is expected for many PPCPs, 
which may be due to the risk being partially mitigated by high dilution (Al Aukidy et al., 
2012; Gros et al., 2010; Yu et al., 2013). Conversely, other studies have found PPCPs of 
high or medium risk in secondary effluent, rivers, and small lakes (Christensen et al., 
2009; Tewari et al., 2013; Valcárcel et al., 2011; Verlicchi et al. 2012). Additionally, 
levels of concern have been found in sewage sludge (Yu et al., 2013).  
Studies have not been conducted evaluating the occurrence and risk of PPCPs in 
Lake Michigan and other studies on the Great Lakes have assessed a small number of 
PPCPs. A better understanding of the occurrence of PPCPs in large water systems, 
particularly in areas with substantial urban development, needs further investigation. The 
purpose of our study was to assess the risk of 54 PPCPs in Lake Michigan from varying 
proximities to a major effluent discharge site and to assess the risk potential to the 
environment. PPCPs were measured in both surface water and sediment samples over six 
dates. The sampling pattern was selected due to the prevailing southern current in this 
portion of the Lake Michigan basin (Rao and Schwab, 2007).  When possible, a RQ was 
estimated to determine which compounds are at a level of concern based on existing 
effects data or models.  
Materials and Methods 
  South Shore Water Reclamation Facility (SSWRF) and Jones Island Water 
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Reclamation Facility (JIWRF) services the greater Milwaukee, Wisconsin area. Fifty-four 
PPCPs were measured in Lake Michigan and compared to the related data on wastewater 
effluent from Blair et al. (2013). Both SSWRF and JIWRF uses preliminary treatment 
(bar screens/grit channels), primary clarifiers, activated sludge treatment and chlorine 
disinfection. SSWRF has a treatment capacity of 1,135,000 m
3
 day
−1
 (300 MGD (million 
gallons per day)) with an average flow of approximately 379,000 m
3
 day
−1
 (100 MGD). 
JIWRF has a treatment capacity of 1,457,000 m
3
 day
−1
 (385 MGD) with an average flow 
of approximately 473,000 m
3
 day
−1
 (125 MGD). 
Surface water and sediment samples were collected in Lake Michigan the day 
following the sampling at SSWRF. Sampling was conducted using a Niskin bottle at a 
depth of 5 m over sites up to 3.6 km away from the effluent discharge site (Figure 5). 
SSWRF discharges directly into Lake Michigan whereas JIWRF discharges into the 
Milwaukee Harbor. Field blanks were collected on each date using distilled water. Grab 
sediment samples were collected on 5/15/2009 and 4/9/2010. Water and sediment 
samples were also collected in the Milwaukee Harbor near JIWRF as a comparison site 
that has lower dilution and potentially higher PPCPs concentration than the open lake. 
The final effluent was sampled using a 24-hour composite sample as described by Blair et 
al. (2013).  
PPCPs Analysis 
  PPCPs were extracted and analyzed based upon US EPA Method 1694 (USEPA, 
2007a) for pharmaceuticals and US EPA Method 1698 (USEPA, 2007b) for steroids and 
hormones by using high performance liquid chromatography combined with tandem mass 
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spectrometry (HPLC/MS/MS) with modifications as published by Blair et al. (2013). The 
PPCPs were selected for this study based on the EPA methods. Forty-one PPCPs were 
assessed under EPA 1694 and thirteen hormones were assessed under EPA 1698. 
Sediment samples were collected for a subset of the sampling dates and these data are 
presented separate from the liquid concentration. The same 54 PPCPs were assessed in 
both the water and sediment samples.  
Risk Quotient 
 To determine the risk quotient (RQ) for each compound, the PNECs were found 
using the review paper from Verlicchi et al. (2012) and ECOSAR v1.11 from the US 
EPA (USEPA 2012b). When the values found by Verlicchi et al. (2012) were from an 
older version of ECOSAR, or if the data were not available, the lowest freshwater 
toxicity value from ECOSAR v1.11 was used. The PNEC selected from these values also 
included the chronic values from ECOSAR.  An assessment factor (1000) was introduced 
to take into account the effect on other, potentially more sensitive, aquatic species 
(Hernando et al., 2006; Al Aukidy et al., 2012). An accepted definition was used for the 
RQ, where low risk is below 0.1, medium risk is from 0.1 to 1, and high risk is greater 
than 1 (Hernando et al., 2006; Verlicchi et al., 2011).  When a PPCP had a concentration 
in the blank above the MQL, this value was subtracted from the maximum concentration 
before the RQ was calculated. 
Results and Discussion 
Surface Water Concentration 
  Over six sampling dates, 38 of the 54 compounds were detected from effluent or 
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Lake Michigan samples. Four compounds were detected with greater than 50% frequency 
at all of the sampling sites in Lake Michigan and the Milwaukee Harbor: metformin 
(100%), caffeine (97.6%), sulfamethoxazole (83.3%), and triclosan (71.4%).  Table 3 has 
the mean and maximum levels from the six samples dates along with the MDL, MQL, 
and maximum value found in the method blanks. The frequency of detection and general 
classifications for the compounds assessed are available in Appendix C. The complete 
data are available in Appendix C.  
The most widely detected pharmaceutical in our study was the antidiabetic 
metformin, which was detected above the minimum detection limit with 100% frequency 
in Lake Michigan (Figure 6a). Metformin was detected at sites up to 3.2 km away from 
the shore, which was unanticipated given the volume of such a large lake system and the 
predominant southern current in this portion of Lake Michigan. Although metformin is 
less frequently measured than other compounds in PPCP studies, we have found, along 
with others, that metformin is prevalent in WWTP influent at concentrations as high as 
129,000 ng L
-1
 but the removal efficiency ranges from 41% to over 98% (Blair et al., 
2013; Oosterhuis et al., 2011; Scheurer et al., 2009; Scheurer et al., 2012; Trautwein and 
Kümmerer, 2011). The median value for metformin in Lake Michigan was greater than 
100 ng L
-1
, comparable to stream and small lake studies where metformin has been 
observed in 4.8% of samples with estimated levels of 110 ng L
-1
 in the U.S. (Kolpin et 
al., 2002) and was detected at all of the sites assessed at concentration up to 2,000 ng L
-1
 
in German rivers (Scheurer et al., 2009; Scheurer et al., 2012). Given the prevailing 
southern water current, the concentration of metformin was expected to vary at the 
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different sampling sites depending on the direction from source. Yet average metformin 
concentrations were similar to levels found in smaller water bodies and the prevailing 
currents did not seem to lead to differences in concentration with location. Other 
compounds that followed the same general trend as metformin were caffeine, 
paraxanthine, sulfamethoxazole, and triclosan.  
 As a contrast to metformin, the anticonvulsant compound carbamazepine, shown 
in Figure 6b, was detected on all of the sampling dates in the final effluent at SSWRF but 
rarely in Lake Michigan water or sediment. Carbamazepine has been found to be highly 
persistent in wastewater since it is expected to resist biological degradation (Blair et al., 
2013; Gomez et al., 2007; Radjenovic et al.,  2009; Rosal et al., 2010; Santos et al., 
2007). However, carbamazepine was not detected in the water or sediment samples 
surrounding SSWRF. Dilution of the wastewater effluent may have been adequate to 
reduce the concentration to below the MDL. However, carbamazepine was detected with 
66.7% frequency at both locations in the Milwaukee harbor at levels above the MDL. 
Given the lack of detection of carbamazepine around SSWRF, the fate of carbamazepine 
in Lake Michigan is unknown.  
  Twenty-seven PPCPs were detected at notable levels at the JI outfall and South 
gap in the Milwaukee harbor. JI Water Reclamation Facility discharges into the 
Milwaukee harbor and this is a potential source of these PPCPs, although effluent levels 
were not assessed at this WWTP. Additionally, the Milwaukee River also flows into the 
harbor and is an additional potential source of the PPCPs that were detected. As shown in 
Table 3, the PPCPs concentrations in the Milwaukee Harbor were overall higher than the 
55 
 
 
 
area surrounding SSWRF. This was used as a reference site as previous research has 
shown chronic fecal pollution in the harbor (Newton et al., 2011).  These results agree 
with other studies assessing harbors on the Great Lakes (Csiszar et al., 2011; Metcalf et 
al., 2003).  
  Hormones were not consistently detected above the minimum detection limit in 
Lake Michigan. The concentrations of hormones were low and inconsistent in the final 
effluent at SWWRF which may be due to the high expected removal from a WWTP 
through adsorption, biodegradation, and exposure to chlorine (Benotti  et al., 2009; 
Esperanza  et al., 2007; Huerta-Fontela  et al., 2011; Joss et al., 2006).  Given the 
inconsistent and low levels detected in the effluent and the high dilution from entering 
Lake Michigan, the levels of hormones in the lake from the WWTP would be expected to 
be below the detection limit.  
Sediment Levels 
Thirty compounds were detected in the sediment at levels above the MDL in Lake 
Michigan and these compounds are listed in Table 4. The most commonly detected 
compounds were: azithromycin, clarithromycin, diphenhydramine, metformin, triclosan 
and triclocarban.  Of these compounds, all of them were regularly detected in the final 
effluent, with the exception of the macrolide antibiotic clarithromycin, which was 
detected only once. Given the low occurrence in the final effluent and across the stages of 
SSWRF (Blair et al, 2013), the regular and widespread occurrence of clarithromycin in 
sediment needs further investigation. Azithromycin and clarithromycin were found to 
have limited sorption to sludge in WWTPs (Verlicchi et al., 2012) therefore their 
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detection in sediment needs further investigation. Triclosan and triclocarban were 
detected in Lake Michigan sediment due to their regular occurrence in effluent and their 
known hydrophobic characteristics (Loranzo et al., 2013). Additionally, the detection of 
metformin and diphenhydramine in Lake Michigan sediment needs further research.  
Other PPCPs detected in the sediment cannot be clearly contributed to the effluent 
from SSWRF. For example, thiabendazole, a fungicide, was detected at low levels in the 
final effluent, but was only located in the sediment at the 1.6 km east and 3.2 km east 
sampling locations and was not detected in the surface water. The detection at these 
locations implies the potential source is from land runoff, not discharged from SSWRF. 
With detection only at the eastern locations, not the southern locations, the source may be 
from area north of the WWTP. Significant agricultural developments are not present in 
the area north of SSWRF, but a residential area that includes many parks and golf courses 
are a possible source of this fungicide.   
Ecological Risk Quotient 
  Overall, a total of twenty-four compounds were detected in the final effluent or 
Lake Michigan at a level of medium or high risk.  As shown in Figure 7, fourteen 
compounds were detected in Lake Michigan itself with high or medium risk. Metformin, 
the most widespread compound, did not correspond with high or medium risk at the 
concentrations detected; however, this may be due to the lack of predictive toxicity data 
on the chronic effects of this compound. When comparing the final effluent RQs to the 
values in Lake Michigan, many compounds drop below the threshold to medium or low 
risk after the compound is discharged from the WWTP, such as gemfibrozil, diltiazem. 
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However, dilution is not sufficient to reduce the risk of all compounds to below the high 
and medium threshold, even at a distance of 3.2 km from shore, such as for 
sulfamethoxazole and codeine.  
Conclusion 
  The detection of such a large number of PPCPs with high or medium risk in the 
Great Lakes is novel and of concern. The area surrounding the SS outfall and the sites 
within the Milwaukee Harbor are important as they are near locations for fish spawning 
and aquatic organisms, such as perch, can be found congregating around the effluent 
pipes of SSWRF and are exposed to effluent concentration with little dilution. Knowing 
that PPCPs can impact the behavior of aquatic organisms (Brodin et al.,2013, Brooks et 
al., 2003) leads to the conclusion that the endpoints used to assess the PNEC values for 
PPCPs may not properly address the ecological impacts and further testing is needed to 
identify the PPCPs of greatest concern. Additionally, the RQ may also underestimate risk 
due to potential mixture effects of PPCPs with similar mechanisms of action that may be 
additive in their impact. Reliance on a model such as ECOSAR is useful for identification 
of PPCPs that warrant further research, but these models are not a replacement for 
experimental tests to determine the full ecological impacts from PPCPs.  
PPCPs were frequently detected in the water and sediments at the ng L
-1 
level, 
including sites 3.2 km from shore in Lake Michigan at concentrations that are estimated 
to cause environmental concern. At the concentrations detected, medium or high risk was 
associated with twenty four compounds in the final effluent, and fourteen were found to 
be of medium or high risk in Lake Michigan. The most frequently detected PPCPs were 
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metformin, caffeine, sulfamethoxazole, and triclosan. Given the widespread detection of 
PPCPs, these pollutants are not ephemeral and pose an environmental risk to the sixth 
largest lake in the world. Therefore, high dilution is not adequate to mitigate the risk from 
this cocktail of PPCPs and the potential ecological risk for large lake systems is much 
higher than previously understood.  
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Table 3: Concentration of PPCPs at the final effluent and at seven locations in Lake Michigan (Below Detection Limit 
(BDL) 
  
Field 
Blank 
    Outfall 
1.6 km East 
(1 mi. East) 
1.6 km South 
(1 mi. South) 
3.2 km East 
(2 mi. East) 
3.2 km South 
(2 mi. South) 
JI Outfall South Gap 
 
Max MDL MQL Mean, Max Mean, Max Mean, Max Mean, Max Mean, Max Mean, Max 
Mean, 
Max 
  ng L-1 ng L-1 ng L-1 ng L-1 ng L-1 ng L-1 ng L-1 ng L-1 ng L-1 ng L-1 
17,20-dihydroxyprogesterone BDL 1.4 4.2 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
17-alpha-estradiol BDL 1.2 3.5 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
17-beta-estradiol BDL 1.3 3.8 BDL, 1.7* BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, 1.3* 
4-androstene-3,17-dione 4.5 0.5 1.4 97, 580 BDL, 2.0 0.9*, 5.3 3.1, 17 0.8*, 3.5 0.3*, 1.4 BDL, 0.9* 
5-alpha-androstane-3,17-dione BDL 2.3 6.9 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Acetaminophen BDL 2.5 7.5 4.2*, 21 BDL, BDL BDL, BDL BDL, BDL BDL, 2.5* 17, 73 13, 45 
Albuterol BDL 1.4 4.2 BDL, BDL BDL, BDL BDL, 5.9 BDL, BDL BDL, BDL BDL 4.3 BDL, BDL 
Azithromycin 15.9 3.7 11 BDL, BDL BDL, 12 BDL, 12 BDL, 7.5* BDL, 11 BDL, 22 BDL, 12 
Boldenone BDL 1.3 4.0 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Caffeine 62.1 3.1 9.3 44, 110 18, 42 37, 86 21, 35 24, 39 67, 230 71, 190 
Carbadox  44.9 3.4 10 7.2*, 20 BDL, 17 12, 49 BDL, 6 6.7*, 33 6.1*, 22 4.2*, 19 
Carbamazepine  BDL 2.7 8.2 BDL, 6.2* BDL, BDL BDL, BDL BDL, BDL BDL, BDL 15, 38 6.4*, 17 
Cimetidine BDL 1.3 3.8 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Ciprofloxacin   BDL 3.3 9.9 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Clarithromycin  BDL 3.2 9.6 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Codeine  BDL 3.6 11 BDL, 11 BDL, 8.7* BDL, 9.2* BDL, 5.4* BDL, 7.2* 4.4*, 11 5.3*, 15 
Cotinine  BDL 3.5 11 BDL, 7.4* BDL, 6.5* BDL, 5* BDL, 6.1* BDL, 11 BDL, 20 3.5*, 21 
Digoxigenin  BDL 4.4 13.2 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Diltiazem 5.4 3.5 10 BDL, 7.9* BDL, 5.5* BDL, 7.8* BDL, BDL BDL, BDL 6.3, 21 BDL, 10 
Diphenhydramine  4.2 3.6 11 4.1*, 14 BDL, 6.6* BDL, 9.2* BDL, 4.9* BDL, 6.7* 10*, 43 3.6*, 12 
Estriol BDL 2 6.1 BDL, BDL BDL, 3.9* BDL, BDL BDL, 5.0* BDL, BDL BDL, BDL BDL, 4.9* 
Estrone BDL 2.2 6.7 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, 3.4* BDL, BDL BDL, BDL 
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Fluoxetine  BDL 3.5 11 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 8.2*, 49 10*, 62 
Gemfibrozil BDL 1.6 4.8 9.1, 42 BDL, BDL 1.6*, 4.5* BDL, BDL 3.1*, 19 14, 36 13, 43 
Ibuprofen BDL 4.7 14 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Lincomycin  BDL 3.1 9.3 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Lomefloxacin BDL 4.7 14.2 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Melengestrol BDL 1.3 4 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Melengestrol Acetate BDL 0.6 1.7 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Metformin 35.5 0.5 1.5 1200, 3800 240, 820 270, 840 120, 160 110, 160 4100, 9200 1200, 2400 
Miconazole  BDL 2.7 8.1 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Naproxen BDL 1 2.9 4.9, 19 BDL, BDL 2.5*, 15 BDL, BDL BDL, BDL 8.4, 31 4.8, 18 
Norfloxacin  BDL 5.1 15.3 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Ofloxacin  BDL 3.9 12 10*, 61 BDL, 21 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Oxacillin  BDL 2.5 7.4 BDL, BDL BDL, BDL BDL, BDL 2.9*, 17 BDL, BDL BDL, BDL BDL, BDL 
Paraxanthine 11.6 6.1 18 6.3*, 23 BDL, 9.7* 11*, 39 BDL, BDL BDL, 8.7* 15*, 57 15*, 45 
Progesterone 17.8 0.7 2 2.0, 11 1.0*, 4.9 1.5*, 8.7 15, 88 2.6, 13 BDL, BDL BDL, BDL 
Ranitidine BDL 0.9 2.6 BDL, BDL BDL, 3.7 BDL, BDL BDL, BDL BDL, BDL 5.4, 27 BDL, BDL 
Roxithromycin 5.5 4.3 13 BDL, 8.7* BDL, BDL BDL, 7.5* 4.5*, 15 6.5*, 39 BDL, 9.2* BDL, BDL 
Sarafloxacin  BDL 5.4 16 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Sulfachloropyridazine  BDL 4.1 12 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Sulfadiazine  BDL 2.8 8.5 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, 3.8* BDL, BDL 
Sulfadimethoxine  BDL 2.4 7.1 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Sulfamerazine  BDL 2.1 6.2 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, 3.6* 
Sulfamethazine   BDL 4.0 12 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Sulfamethizole   BDL 4.2 13 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Sulfamethoxazole  BDL 4.1 12 6.9*, 14 BDL, 6.2* 5.1,* 7.0* BDL, 7.3* 4.5*, 10* 29, 77 16, 30 
Sulfanilamide  BDL 2.9 8.6 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 6.3*, 20 BDL, BDL 
Sulfathiazole  BDL 2.6 8 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
Testosterone 12.4 1.1 3.2 2.2*, 13 BDL, 4.5 1.5*, 9.1 6.4, 38 1.4*, 7.0 BDL, BDL BDL, BDL 
Thiabendazole  BDL 1.8 5.3 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 
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Triclocarban BDL 0.5 1.4 2.6, 16 BDL, BDL BDL, BDL BDL, BDL BDL, BDL 3.9, 9.9 BDL, BDL 
Triclosan 5.4 0.5 1.6 9.9, 41 0.8*, 2.1 3.0, 16 2.7, 7.4 1.4*, 6.5 7.7, 24 5.0, 11 
Trimethoprim  BDL 3.4 10 BDL, 3.4* BDL, BDL BDL, 6.0* BDL, BDL BDL, BDL 17, 52 6.9*, 13 
 
*Value above MDL, but below MQL.
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Table 4: PPCPs Levels in Sediment from Lake Michigan (Compounds listed in Table 3 that were not detected above the MDL 
in the sediment samples are omitted from this table) 
  
  
SS Outfall 
1.6 km East 
(1 mi. East) 
1.6 km South 
(1 mi. South) 
3.2 km East 
(2 mi. East) 
3.2 km South 
(2 mi. South) JI Outfall South Gap 
  MDL MQL Mean Mean Mean Mean Mean Mean Mean 
  ng g-1 ng g-1 ng g-1 ng g-1 ng g-1 ng g-1 ng g-1 ng g-1 ng g-1 
Acetaminophen  2.5 7.5 BDL 18 29 BDL BDL BDL 29 
Azithromycin 3.7 11 490 16 72 19 25 59 350 
Caffeine 3.1 9.3 25 BDL 24 30 14 4.2* BDL 
Carbadox 3.4 10 BDL BDL BDL BDL BDL BDL 14 
Ciprofloxacin  3.3 9.9 42 7.7* 9.0* 46 52 43 BDL 
Clarithromycin  3.2 9.6 33 28 130 5* 120 90 BDL 
Codeine  3.6 11 BDL BDL BDL BDL BDL 4* BDL 
Cotinine  3.5 11 8.0* BDL BDL BDL BDL 39 BDL 
Digoxigenin  4.4 13 BDL BDL BDL BDL BDL 4.9* 9.2* 
Diltiazem 3.5 10 4.0* BDL BDL BDL BDL 5.2* 3.9* 
Diphenhydramine  3.6 11 81 13 43 7.3* 82 150 160 
Enrofloxacin  1.4 4.1 BDL BDL BDL 6.6 BDL BDL BDL 
Erythromycin 9.9 30 BDL BDL BDL BDL BDL 25* BDL 
Flumequine  5.2 16 BDL BDL BDL 6.9* BDL BDL 6.0* 
Fluoxetine  3.5 11 7.6* BDL BDL BDL BDL 20 12 
Ibrupoven 4.7 14 BDL BDL 8.8* BDL BDL BDL No Data 
Lincomycin  3.1 9.3 BDL BDL BDL BDL BDL BDL 5* 
Metformin 0.51 1.5 50 43 3.8 16 2.3 59 140 
Miconazole  2.7 8.1 7.6 BDL BDL BDL BDL 3.7* 8.4 
Naproxen  0.97 2.9 4.8 1.0* BDL BDL BDL 2.6* No Data 
Norfloxacin  5.1 15 BDL BDL BDL 12* 36 BDL BDL 
Ofloxacin  3.9 12 4.3* BDL BDL 7.7* BDL BDL 7.3* 
Oxacillin  2.5 7.4 BDL BDL BDL BDL 2.8* BDL 9.1 
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Paraxanthine 6.1 18 BDL BDL BDL BDL BDL BDL 15* 
Roxithromycin 4.3 13 28 BDL 31 BDL 44 71 BDL 
Sarafloxacin  5.4 16 BDL BDL BDL 9.9* BDL BDL BDL 
Thiabendazole  1.8 5.3 BDL 230 BDL 68 BDL BDL BDL 
Triclocarban  0.48 1.4 170 4.5 33 BDL 11 510 No Data 
Triclosan 0.53 1.6 37 18 22 26 12 150 No Data 
Tylosin  3.5 11 9.4* 12 3.9* BDL 14 20 BDL 
 
*Value above MDL, but below MQL.
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Figure 5. Lake Michigan and the Sampling locations in Lake Michigan near Milwaukee, 
Wisconsin, USA. Boxes represent the two WWTPs discussed: JIWRF and SSWRF.  
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a 
b 
 
Figure 6. Concentration of metformin (a) and carbamazepine (b) in wastewater effluent 
and in Lake Michigan on six dates 
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Figure 7. Risk Quotient for 14 PPCPs in Wastewater Effluent and in Lake Michigan (RQ 
> 1 is high risk, RQ from 0.1 to 1 is medium risk, and RQ < 0.1 is low risk 
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Chapter 4:  ASSESSING CURRENT WASTEWATER REGULATIONS TO 
MINIMIZE THE RISK QUOTIENT OF PHARMACEUTICALS 
AND PERSONAL CARE PRODUCTS (PPCPS): A CASE 
STUDY IN WISCONSIN, USA  
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Abstract 
Phosphorus and pharmaceutical and personal care products (PPCPs) are pollutants that 
can cause a wide array of negative environmental impacts. Phosphorus is a regulated 
pollutant in many industrial countries, while PPCPs are widely unregulated. Since many 
technologies designed to remove phosphorus from wastewater also have the potential to 
remove PPCPs, the purpose of this work is to explore the ability of these technologies to 
also reduce the emission of unregulated PPCPs. We examine this potential ancillary 
benefit by presenting a novel method using the PPCPs’ risk quotient (RQ) to measure the 
effectiveness of different wastewater treatment technologies. The RQ is then applied via 
a case study that uses the phosphorus effluent regulations in Wisconsin, USA to 
determine the ability of the recommended technologies to also mitigate PPCPs. The result 
show that the tertiary membrane bioreactor and nanofiltration processes recommended to 
remove phosphorus can reduce the median risk quotient from PPCPs by 71% and 81%, 
respectively. The ultrafiltration technology was estimated to reduce the median risk 
quotient from PPCPs by 28% with no cost in addition to the costs expected under the 
current phosphorus effluent regulations. Additionally, higher quality effluent is expected 
with a membrane bioreactor and the cost of upgrading to this technology from a low-
pressure membrane system was found to be $11.76 per capita per year. Using these 
results, we discuss the management implications, including watershed management, 
alternative PPCPs reduction strategies, adaptive management, and water quality trading. 
In conclusion, this study suggests the management of practices to remove regulated 
pollutants could significantly reduce the emission of PPCPs from wastewater. 
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1. Introduction.  
When establishing a regulatory framework to reduce the emission of a specific 
pollutant (e.g. phosphorus), the ancillary benefit of removing unregulated pollutants is 
often ignored. In this work, we focus on the regulations to remove phosphorus from 
wastewater and the potential concurrent removal of unregulated pharmaceuticals and 
personal care products (PPCPs). An emphasis is placed on phosphorus and PPCPs 
because the levels of these pollutants in the environmental may be damaging to aquatic 
organisms and the ecosystem (Anderson et al., 2002; Blair et al., 2013a; Verlicchi et al., 
2011). For example, PPCPs have the potential to cause endocrine disruption, changes in 
growth, and changes in behaviors important to feeding, reproduction, and predator 
avoidance in aquatic organisms while excess phosphorus has the potential to cause 
eutrophication, deoxygenation of the water, and harmful algal blooms (Anderson et al., 
2002; Brausch and Rand, 2011; Brodin et al., 2013; Kidd et al., 2007; Nassef et al., 2010; 
Weinberger and Klaper 2013).  
Policies have been implemented to reduce phosphorus emissions into the 
environment (e.g. US Federal Water Pollution Control Act 2002); however, no 
regulations exist for PPCPs in drinking or natural waters in the United States (Ryu et al., 
2014). Recently, calls have been made for the initiation of programs that would remove 
PPCPs from wastewater in the United States and the European Union (EC 2013; 
Molinos-Senante et al., 2013; USEPA 2013a). The European Commission has proposed 
adding three PPCPs (17 alpha-ethinylestradiol, 17 beta-estradiol, Diclofenac) to the list of 
pollutants that are monitored and controlled in European Union waters (EC 2013). 
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Likewise, a number of state and local governments across the United States have started 
to develop programs to reduce the amount of PPCPs entering the aquatic environment 
(Kotchen et al., 2009).  
Current municipal wastewater treatment plant (WWTP) configurations are 
ineffective at removing many PPCPs and have difficulty meeting ultra-low phosphorus 
(<0.1 mg P /L) effluent concentrations (Michael et al., 2013; Outlon et al., 2010; 
Verlicchi et al., 2011). To meet the ultra-low phosphorus effluent regulations, tertiary 
technologies such as membrane bioreactors and membrane filtration are being considered 
for municipal WWTPs and these technologies also have the potential to remove PPCPs 
from wastewater (Strand Associates, 2008; Snyder et al., 2007).  However, many of the 
tertiary wastewater treatment processes that are being implemented to meet phosphorus 
effluent regulations also have the potential to remove PPCPs (Oulton et al., 2010; Wenzel 
et al., 2008).  
In general, there is no consensus regarding the best method to manage PPCPs in 
the aquatic environment. The most commonly implemented programs focus on the 
disposal of unused PPCPs through take-back programs or education regarding trash 
disposal (Daughton, 2010; Kotchen et al., 2009). However, many PPCPs enter the waste 
stream through normal use: orally consumed PPCPs are excreted through urine or feces 
unchanged or partly metabolized (Kasprzyk-Hordern et al., 2009). In addition, people can 
use PPCPs topically and wash them off, for example, triclosan, a widely used 
antibacterial agent used in soaps. Therefore, programs focusing on the disposal of unused 
PPCPs are only partially effective at mitigating the risk from these pollutants. Along with 
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the efforts advocating trash disposal or take-back programs of unused PPCPs, the 
currently proposed solutions consist of tertiary wastewater treatment, urine separation, 
dilution through watershed management, producing pharmaceuticals that would cause 
less harm to the environment, selecting PPCPs possessing environment-friendly excretion 
profiles, improving drug delivery, and prescribing patients the minimum therapeutic 
dosage (Borsuk et al., 2008; Cook et al., 2012; Daughton and Ruhoy, 2013; Eckstein and 
Sherk, 2012; Khetan and Collins, 2007; Glassmeyer et al., 2009; Schimmelpfennig et al., 
2012). Nevertheless, establishing a regulatory framework to reduce the damage from 
PPCPs is challenging. This is because we have an incomplete understanding of the 
ecological and human health impacts, a limited capability to effectively remove PPCPs 
from wastewater using conventional technologies, and face high costs associated with 
systems shown to minimize PPCPs emissions (Blair et al., 2013b; Brodin et al., 2013; EC 
2013; Molinos-Senante et al., 2013; Verlicchi et al., 2012).  
The goal of this work is to assess via case study the feasibility of utilizing a 
regulation requiring ultra-low phosphorus effluent levels in wastewater to also achieve a 
meaningful reduction in PPCPs. It is critical to assess the removal of unregulated 
pollutants when evaluating processes to meet updated regulatory standards, particularly 
when it involves significant capital upgrades.  To demonstrate the potential ancillary 
benefits of a phosphorus reduction policy, this study will assess the change in the RQ for 
11 PPCPs across four different phosphorus reduction technologies. At this time, no study 
has quantitatively assessed the change in the PPCPs risk quotient (RQ) from the 
implementation of a policy to remove phosphorus from wastewater. We then apply the 
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RQ to a case study that uses the recently modified phosphorus effluent regulations in 
Wisconsin, USA to explore whether a phosphorus reduction policy could minimize the 
release of unregulated PPCPs into the environment. The purpose is not to provide an 
exhaustive review of PPCPs removal using different WWTP configurations. Rather, this 
study will provide an illustration of the potential ancillary benefits from reducing 
regulated pollutants from wastewater, along with a recommendation to prioritize research 
on the potential impacts of PPCPs on environmental health. We will also address 
management implications including the use of alternative PPCPs strategies, adaptive 
management including water quality trading, and site-specific concerns. An emphasis 
will also be placed on the estimated cost of these technologies.  
This chapter proceeds as follows: section 1.1 of this article provides a review of 
the policies related to phosphorus reduction in the State of Wisconsin; section 1.2 
presents the RQ and the application in understanding environmental damage from PPCPs. 
Section 2 provides the data analytic methods and the development of the RQ. Section 3.1 
provides the results from the meta-analysis; section 3.2 provides the limitations of the 
meta-analysis and data collection; section 4.0 discusses the management implications; 
and section 4.1 presents the cost of the technologies. Section 5.0 offers an overall 
conclusion. 
1.1. Summary of Phosphorus Reduction Regulations in Wisconsin. 
In the United States, the adoption of nutrient reduction policies will require the 
significant advancement of statewide nutrient reduction efforts. Many of these efforts will 
focus on agricultural practices and enhancing wastewater treatment. States within the 
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United States are encouraged to establish numeric criteria for nutrients (phosphorus and 
nitrogen) in all bodies of water in compliance with the EPA’s National Strategy for 
Development of Regional Nutrient Criteria under the Clean Water Act (USEPA 1998). 
However, only 10% of states in the United States currently have statewide numeric 
criteria for phosphorus in streams and rivers and only 12% of states have these criteria for 
lakes and reservoirs (USEPA 2012a). Wisconsin and New Jersey are the only states 
currently with statewide phosphorus criteria for lakes/reservoirs and rivers/streams 
(USEPA 2012a). 
We use the State of Wisconsin for a case study because they recently set some of 
the lowest effluent standards for municipal wastewater treatment facilities in the United 
States and the wastewater phosphorus effluent limits will be as low as 50 µg/L (WI Code 
NR102 and WI Code NR217). Based on the EPA nutrient criteria guidelines, the State of 
Wisconsin implemented changes to the Natural Resources (NR) Codes 102 (2010) and 
217 (2010) to address phosphorus loading in surface waters. At this time, there are no 
water quality standards criteria for total nitrogen in Wisconsin (WIDNR 2013a). The 
Wisconsin Legislature and Wisconsin Department of Natural Resources (DNR) have 
enacted surface water phosphorus limits and modified the point and nonpoint regulations 
to meet the desired surface water phosphorus concentration.  
Wisconsin NR Code 102 outlines the phosphorus limits to be achieved in surface 
waters. The surface water levels range from 5-7 µg/L for Lake Superior and Lake 
Michigan to 100 µg/L for specifically identified rivers. The overarching foundation 
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behind the changes to Wisconsin NR Code 102 sets the limits at levels that are near 
naturally occurring levels for a given body of water.  
To meet these surface water levels, Wisconsin NR Code 217 set the effluent 
standards for municipal wastewater treatment facilities. Phosphorus emission limits are 
variable for each WWTP and the limits are a function of the water quality criterion from 
NR102, receiving water flow, effluent flow, fraction of the effluent flow withdrawn from 
the receiving water, and the upstream concentration. The phosphorus wastewater effluent 
limit for reservoirs and lakes is equal to the level in the receiving water or downstream 
water. The wastewater phosphorus effluent limits may be as low as 50 µg/L. However, 
for the majority of the wastewater treatment plants, the effluent limit will be in the range 
of 100 µg/L. The previous effluent standard for phosphorus in Wisconsin was 1.0 mg/L. 
The Wisconsin DNR estimated that the changes to these policies will require additional 
WWTP capital and operating/maintenance costs between $1.1 and $2.1 billion (WIDNR 
2012).  
1.2 Phosphorus Removal from Wastewater. 
The engineering challenges are significant to meet ultra-low phosphorus effluent 
limits. Once the total phosphorus limit drops below 0.1 mg/L, separate stages of chemical 
precipitation/solids separation and filtration tend to be required (Strand Associates, 2008; 
Metcalf Eddy, 2013). The average phosphorus effluent concentration in Wisconsin was 
found to 0.59 mg/L and wastewater treatment plants are expected to use several 
technological upgrades to meet these required phosphorus levels (Strand Associates, 
2008).  This article will evaluate four tertiary technologies that reduce phosphorus that 
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also have the potential to remove PPCPs from wastewater: 1) ultrafiltration (UF) which 
uses a pressure-driven membrane filtration process that typically employs hollow-fiber 
membranes with a pore size range of approximately 0.01 – 0.05 µm; 2) microfiltration 
(MF) a pressure-driven membrane filtration process that typically employs hollow-fiber 
membranes with a pore size range of approximately 0.1 – 0.2 µm; 3) tertiary membrane 
bioreactor (MBR) which uses a suspended growth bioreactor paired with MF or UF; and 
4) nanofiltration (NF) a pressure-driven membrane separation process with a pore size of 
0.001–0.01 µm that employs the principles of reverse osmosis to remove dissolved 
contaminants from water, but at a lower operating pressure than reverse osmosis (USEPA 
2005, USEPA 2013b). A rapid mix and flocculation step will likely precede these 
technologies (Strand Associates 2008). MF and UF are the technologies expected to be 
implemented to meet the phosphorus regulations, however, the MBR and NF 
technologies will also be assessed due to their ability to remove phosphorus and 
potentially mitigate PPCPs pollution.   
Based on pore size, MF, UF, and NF are expected to remove the particulate 
phosphorus as an operational definition of particulate phosphorus is that it is retained by a 
0.45-micron membrane filter paper, however, in practice, defects in the membrane can 
cause colloidal particles to escape to the product water (WERF, 2008). Under similar 
operating and influent conditions, the removal of total phosphorus is the greatest for NF, 
followed by MBR, UF, and MF. It is important to note that the observed removal 
efficiency of total phosphorus may not be the best benchmark for comparing these 
technologies, since the makeup of total phosphorus (soluble and particulate) can vary 
82 
 
 
 
significantly. To illustrate this relationship, MF and UF have 0 to 2% rejection of 
phosphate ions while NF has the ability to reject these ions (Metcalf Eddy, 2013; 
Visvanathan and Roy, 1997). In addition, the type and amount of coagulant used will 
significantly alter the removal efficiency (Metcalf Eddy, 2013). In general, with adequate 
coagulation and flocculation, these technologies have the potential to meet the lower 
required Wisconsin effluent regulations for phosphorus (50 µg/L) under normal operating 
and influent conditions (Chon et al., 2012; Gnirss and Dittrich, 2000; Strand Associates 
2008).  
1.3 Assessing Environmental Damage from PPCPs using the Risk Quotient. 
Many of the wastewater treatment processes that are being implemented to meet 
phosphorus effluent regulations also have the potential to remove PPCPs. However, we 
must evaluate the potential damage associated with PPCPs concentrations in comparison 
to a toxicity endpoint. The RQ (also referred to as the hazard quotient or risk index) is 
often used to estimate the risks associated with low levels of PPCPs on environmental 
health and is defined as the ratio between the measured PPCPs concentration and its 
corresponding predicted no-effect concentration (PNEC) (Al Aukidy et al., 2012; Blair et 
al., 2013a; Christensen et al., 2009; Deblonde et al., 2011; Valcárcel et al., 2011). 
However, at this time, no study has quantitatively assessed the change in the PPCPs risk 
quotient (RQ) from the implementation of a policy to remove regulated pollutants from 
wastewater. In addition, calculating the RQ can be challenging due to a lack of 
information regarding the effects of PPCPs in the environment and difficulty in 
establishing the PNEC. Recent studies have found PPCPs of high or medium RQs in 
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wastewater effluent, waste sludge, and the aquatic environment (Tewari et al., 2013; 
Valcárcel et al., 2011; Verlicchi et al., 2012; Yu et al., 2013). By compiling the data 
related to PPCPs in wastewater, we can begin to assess the total PPCPs and RQ reduction 
from the changes to the Wisconsin NR codes. 
2. Methods. 
2.1. Data Analytic Plan. 
  This assessment focused on four different tertiary technologies for phosphorus 
removal as a possible addition to a conventional activated sludge (CAS) WWTP: UF, 
MF, MBR, and NF. These technologies were selected due to their ability to meet the 
phosphorus effluent regulations and the potential to remove PPCPs. These technologies 
were then assessed for their ability to remove PPCPs and a meta-analysis was completed 
to evaluate the removal efficiencies of pollutants based on different wastewater treatment 
facility configurations and technologies. For the meta-analysis, 1,085 influent 
concentration and removal efficiency data points were compiled from 57 peer-reviewed 
articles for 11 PPCPs. The data were compiled from recent papers along with guidance 
from the recent reviews by Verlicchi et al. (2012) and Oulton et al. (2010). We used 
observed concentrations from the literature review for the influent concentration. Bench 
scale or experiments with spiked PPCPs concentration, along with observed 
concentrations, were used for the removal efficiencies. Appendix E presents the 
concentrations and removal efficiencies, along with the corresponding citations.  
From the meta-analysis, we collected data for the influent concentration and the 
removal efficiencies for CAS, MBR, MF, UF, and NF treatment processes. To determine 
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the range of PPCPs concentrations and removal efficiencies, resampling was completed 
using 10,000 iterations of a Monte Carlo Simulation using bootstrapping (Efron, 1987) 
for each variable using Matlab R2011a. Negative removal rates, where the effluent 
concentration was greater than the influent concentration, were changed to zero removal 
efficiency in the simulation, although many scenarios can explain the negative removal 
efficiencies (Blair et al., 2013b). Appendix E includes an example of the code used for 
ibuprofen. To determine the effluent concentration for each technology for each PPCP, 
we applied the relationship shown in equation 1 to the resampled distributions: 
Effluent Concentration = Influent Concentration * (1 - Removal Efficiency)    (1) 
In addition, we determined the worst-case scenario, defined as the maximum observed 
concentration and minimum observed removal efficiency, for each PPCP with each 
technology.  
2.2 Risk Quotient.  
The RQ was calculated using the aquatic ecological PNEC with a safety factor 
(SF) of 1000 (Hernando et al., 2006). Equation 2 was used to calculate the RQ:  
RQ =  Observed Concentration * SF / PNEC  (2) 
An RQ greater than 1 is defined as high risk, an RQ from 0.1 to 1 is medium risk, and an 
RQ less than 0.1 is low risk. We used PNEC values from Verlicchi et al., (2012), 
ECOSAR v1.11 (USEPA 2012b), along with other published values. Appendix E shows 
these values, and the corresponding citations. When the values found in the literature 
were from an older version of ECOSAR, or if the data were not available, we used the 
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lowest freshwater toxicity value from ECOSAR v1.11. The PNEC selected from these 
values included the acute and chronic values from ECOSAR.  
2.3. Present Value Calculations  
 Present value costs were calculated for the tertiary technologies. Cost information 
was obtained for UF and MF (Simultaneous Compliance Tool), MBR (AMTA, 2007), 
and NF (Costa and Pinho, 2006). For the comparison, capital, O&M, and annual costs 
were converted to a 20-year present value. A discount rate of 4.375 percent was used, as 
recommended by the WI DNR NR 110.09(1)(a), Wisconsin Administrative Code. 
3. Results and Discussion. 
3.1. Tertiary Wastewater Treatment to Remove PPCPs and Phosphorus. 
The influent concentration range for the 11 PPCPs selected for this study was 
found to cover less than approximately one order of magnitude for the 25
th
 to 75
th
 
percentiles, as shown in Figure 8. In addition, a summary from the meta-analysis 
displaying the mean influent concentration and removal efficiency is shown in Table 5.  
Many PPCPs detected in wastewater effluent at high or medium RQ levels have 
the ability to be removed to lower RQ levels. We use the RQ to compare the 
effectiveness of technologies to remove PPCPs: this allows the use of a metric to 
determine what levels of the most harmful PPCPs are removed from wastewater, rather 
than just assessing the removal efficiency. For example, Figure 9a shows a simulation 
conducted for the concentration of the nonsteroidal anti-inflammatory drug ibuprofen 
after treatment by a conventional activated sludge system (labeled WWTP) and then with 
the addition of the four different tertiary treatment technologies selected to remove 
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phosphorus from wastewater. Figure 9b presents the RQ for ibuprofen, revealing that the 
majority of the effluent concentrations from a WWTP without tertiary treatment were 
high risk. However, the technologies used to remove phosphorus can potentially reduce 
the RQ. The findings reveal that MF and UF have limited potential to remove ibuprofen. 
A MBR is expected to reduce the median value from high to medium risk, but the 
removal efficiencies have a wide range, so the 25
th
 percentile is considered low risk and 
the maximum is considered high risk. With NF, the 25
th
 to 75
th
 percentile range decrease 
from high to low risk.  
In contrast to ibuprofen, the RQ for some PPCPs can only be partially reduced 
with the use of the tertiary treatment processes used to remove phosphorus. Figure 10a 
and 10b show the concentration and RQ respectively for the anti-epileptic and mood 
stabilizing drug carbamazepine. Similar to ibuprofen, the carbamazepine effluent values 
from a WWTP without tertiary treatment were found to be high risk. However, with NF, 
the the 25
th
 to 75
th
 percentile range decreases from high to medium risk. The findings 
show that MBR, MF and UF have a limited potential to remove carbamazepine.  
After treatment by a CAS WWTP, 100% of the maximum concentrations and 
64% of the median concentrations were found to have a high RQ. Figure 11 reveals the 
maximum and median RQs across the different treatment technologies for 11 PPCPs. MF 
was found to have a minimal impact on the RQ. The MF technology may be able to 
remove PPCPs via adsorption on to membrane polymers or interaction with natural 
organic matter in wastewater (Luo et al., 2014), however, this low-pressure membrane 
has pore sizes that are insufficient to retain PPCPs (Oulton et al., 2010). The results show 
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that the median RQ decreased by 7% with the MF the technology. This also confirms that 
the MF used in a tertiary MBR process will provide limited removal of pharmaceuticals 
and the removal of PPCPs through a MBR using MF is completed primarily by biological 
degradation and sorption to solids (Snyder et al., 2007).  
The results indicate that using NF, MBR, or UF technologies have the ability to 
reduce the RQ. The UF was found to reduce the worst-case scenario RQ by 21% and the 
median RQ by 28%. Similar to MF, UF has pore sizes insufficient to remove PPCPs, 
however, potential electrostatic repulsion or adsorption may explain the increased 
observed removal (Oulton et al., 2010). NF lowered the total PPCPs concentration and 
RQ more than the other treatment processes. For the worst-case scenario, using NF 
reduced the aggregate RQ by 72%. For median concentration values, the aggregate RQ 
decreased by 81% with NF. The MBR had removal rates approaching the removal seen 
by NF, lowering the maximum RQ by 69% and the median RQ by 71%.  
3.2. Limitations. 
Pharmaceuticals consumption patterns vary by region and the occurrence pattern 
of PPCPs is not static (Dickenson et al., 2011). Therefore, using observed influent data 
from one region may not represent the influent characteristics for other regions or 
WWTPs. In addition, different treatment processes within the same category have a wide 
range of removal efficiencies, even with the same PPCPs being assessed. For example, 
Chon et al. (2012) assessed three different nanofiltration membranes and the removal 
efficiencies had a range of 50% or more for the same pharmaceutical with different 
nanofiltration membranes. Further research must examine removal efficiencies for full-
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scale WWTPs, especially membrane filters and their change in removal efficiencies 
under different conditions and with fouling (Bellona et al., 2004; Xu et al., 2006; Botton 
et al., 2012). Also, the chemical coagulation used for phosphorus or suspended solids 
removal is inadequate for PPCPs removal and a further understanding of the relationship 
between hydrophobicity and the removal of PPCPs is required (Alexander et al., 2012). 
Other variables have the potential to impact removal of PPCPs from wastewater, 
such as the solids retention time, hydraulic retention time, concentration of suspended 
solids, fraction of autotrophic biomass, pH, and other operating and influent conditions 
(Constantine et al., 2006; Majewsky et al., 2011a; Majewsky et al., 2011b; Morton et al., 
2013; Oulton et al., 2010; Verlicchi et al., 2012). An additional understanding of these 
variables is necessary to predict the removal of PPCPs from wastewater. Future models 
have the potential to include a mechanistic approach to predicting the removal 
efficiencies.  
The PNEC values for PPCPs must constantly evolve as a better understanding of 
the environmental impacts of these pollutants and their metabolites becomes available. 
Using a model such as ECOSAR will allow an initial investigation to determine PPCPs of 
concern, but these models are not a replacement for complete toxicological testing of 
individual PPCPs and their mixtures on aquatic organisms. Additionally, we need an 
understanding of the impacts that PPCPs at low levels have on mammals, birds, and 
amphibians (Boxall et al., 2012). The incomplete aquatic toxicity data echoes the call for 
mandated toxicity testing of chemicals and epidemiologic monitoring of exposed human 
populations, particularly children (Landrigan and Goldman, 2011). Also, the PNEC may 
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not be adequate and a more thorough ranking may be needed, such as that reflected in the 
process developed by Kumar et al. (2010) or Ortiz de García et al. (2013).  
The treatment options presented in this analysis do not represent all of the 
technologies available for the removal of phosphorus, and other systems have been 
shown to have high removal of phosphorus and PPCPs. For example, a system that pairs 
a 20 mg/L dosage of powdered activated charcoal paired with a ferric chloride coagulant 
demonstrated PPCP removal rates ranging between 67% and 97% for ten different 
PPCPs, and the phosphorus effluent levels were at concentrations between 20 and 50 
µg/L (Treguer et al., 2012). Other systems that are potentially effective at removing 
phosphorus and PPCPs are reverse osmosis and advanced oxidation processes (Kim et al., 
2007; Larsen et al., 2004; Luo et al., 2014; Oulton et al., 2010; Snyder et al., 2007; 
Urtiaga et al., 2013).  
Developing a model to predict the removal of PPCPs from all configurations of 
WWTPs is not feasible at this time and it is critical to develop a better understanding of 
the mechanisms that determine the removal of PPCPs. Furthermore, the number of 
studies assessing the removal of PPCPs through tertiary MBR and membrane filtration is 
low and more studies are needed. Currently, over 3,000 PPCPs are in use and further 
monitoring of PPCPs is necessary since many of the widely prescribed pharmaceuticals 
lack environmental monitoring (Daughton, 2014; Monteiro and Boxall, 2010).   
4.0. Management Implications. 
The potential abatement of PPCPs from wastewater is a particularly timely issue 
due to the expected increase in worldwide PPCP usage and the potential for regulation of 
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PPCPs in the environment (Boxall et al., 2012; EC 2013; Eckstein and Sherk, 2011; 
Eckstein, 2012; USEPA 2013a). Numerous management implications emerge from this 
work. First, federal, state, and municipal policy makers and wastewater managers should 
consider the ability to meet phosphorus effluent regulations while minimizing the 
environmental damage from PPCPs and other pollutants. Due to the substantial costs 
affiliated with phosphorus reduction (USEPA, 2008), we recommend a broad monitoring 
study prior to implementing a phosphorus reduction technology to assess the level of 
PPCPs in the effluent. If these pollutants are found at concentrations that imply medium 
or high risk, a tertiary process should be considered that could meet both the phosphorus 
effluent regulations and reduce the risk from the contaminants of emerging concern.  
Wastewater treatment plant managers and policy makers must consider whether 
the fate and transport of PPCPs along with dilution will mitigate the risk from PPCPs, as 
discussed by Al Aukidy et al., (2012) and Gros et al. (2010). Therefore, the ratio of the 
flow rate of a WWTP to the flow rate or volume of receiving water must be evaluated. 
Dilution may not be adequate to minimize the risk from PPCPs from large, urban 
WWTPs, even in bodies of water as large as the Great Lakes (Blair et al., 2013a). 
Additionally, we must consider the number of WWTPs in a watershed before we can 
model the total loading of PPCPs and the fate and transport of PPCPs and nutrients for a 
watershed (Schimmelpfennig et al., 2012). We should also identify other sources of 
PPCPs for a watershed, such as agricultural sources or from land application of biosolids 
(Lapen et al., 2008; Xia et al., 2005). The fate and transport of PPCPs in varying 
watersheds must be further addressed. As PPCPs effluent discharge increases with 
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expanding populations, the dilution afforded by receiving waters is expected to diminish 
(Daughton, 2003).  
The technologies used for tertiary treatment could also eliminate many other 
pollutants such as metals, total suspended solids, and viruses, thereby further improving 
the quality of the wastewater effluent (USEPA 2013b).  For example, the technology with 
the smallest pore size assessed in this research, NF, was found to reject between 58% and 
>99% of copper ions, but influent concentration and operating conditions such as 
pressure, pH, and biofouling were found to impact overall removal efficiency (Al-Rashdi 
et al., 2013). Likewise, NF and UF are both expected to remove viruses (USEPA 2013b), 
whereas MF will have a limited impact on viruses (Metcalf Eddy, 2013). In contrast, 
recent research has determined that high-pressure membrane filtration does not 
consistently achieve total nitrogen levels less than 1.0 mg/L and further treatment would 
be needed to reduce this concentration (Merlo et al., 2012). Overall, the removal of 
PPCPs and additional pollutants would potentially make it easier to treat water 
downstream for the production of drinking water. Policy makers should consider these 
benefits, particularly due to the unknown human health impacts from long-term 
exposures of PPCPs in drinking water (Bruce et al., 2010; Kumar et al., 2010; Jelic et al., 
2012). 
Tertiary treatment may not adequately remove some PPCPs such as 
carbamazepine and further actions may be necessary to achieve the desired level of 
environmental protection. If monitoring has indicated a specific pollutant has reliable 
occurrence above the RQ, the tertiary technology is not expected to adequately reduce the 
92 
 
 
 
RQ, and dilution is not sufficient to reduce the RQ, the next objective would be to 
address other alternative strategies. Potential short-term management options include 
discouraging disposal down the toilet/sink and encouraging medical providers to 
prescribe the minimum therapeutic dosage or drug alternatives (Cook et al., 2012; 
Daughton and Ruhoy, 2013). Potential long-term solutions include encouraging the 
development of green pharmaceuticals, using innovative toilet technologies, watershed 
management, and additional tertiary treatment for WWTPs such as NF, reverse osmosis, 
or advanced oxidation processes (Borsuk et al., 2008; Daughton, 2003; Eckstein and 
Sherk, 2012; Khetan and Collins, 2007; Luo et al., 2014; Schimmelpfennig et al., 2012; 
Snyder et al., 2007). 
As an additional long-term solution, the ancillary benefits of phosphorus 
reduction technologies could be integrated into water quality trading (WQT). Wisconsin 
is implementing an adaptive management policy that allows phosphorus trading within a 
watershed between point and nonpoint sources (WIDNR 2013b). Water quality trading 
would allow WWTPs to purchase offsets from nonpoint sources, primarily the 
agricultural sector, rather than adding a tertiary treatment technology or upgrading 
current technologies to meet the desired phosphorus discharge levels. Although this 
strategy has the potential to meet the desired water quality standards for phosphorus, it 
overlooks the additional benefits of PPCPs risk mitigation from wastewater treatment for 
phosphorus. This information should be incorporated in the WQT assessment.  For 
example, the removal of PPCPs with tertiary wastewater treatment using ozonation may 
have a positive economic environmental benefit of avoiding the discharge of 
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contaminants into water bodies (Molinos-Senante et al., 2013) and these values should be 
integrated in the WQT framework.   
4.1. Cost of Technologies.  
  NF is expected to be the most costly process proposed in this article, followed by 
the tertiary MBR, UF, and MF, respectively, as shown in Table 6. Determining the costs 
of a tertiary treatment process depends on the selected technology, the quality and 
characteristics of the secondary effluent, the flow rate, the size/footprint constraints, 
along with other site specific demands and the values in Table 6 can vary based on these 
variables.   
UF was found to reduce the RQ from PPCPs with no costs in addition to the 
expected cost to meet the phosphorus effluent limits. In Wisconsin, policy makers and 
WWTP managers will likely prefer the MF or UF technologies to meet these effluent 
regulations due to the relative lower costs. UF was estimated to reduce the median RQ by 
28% and MF was found to reduce the median RQ by 7%. Therefore, the UF technology 
could be recommended over the MF technology to meet the phosphorus effluent limits 
due to the negligible different in cost and the ancillary benefit of increased PPCPs 
removal. 
  As an illustration of the cost of phosphorus reduction in Wisconsin, the 
Milwaukee Metropolitan Sewerage District (MMSD) in Wisconsin USA estimated it 
would cost $600 million (20 year present value) to meet the effluent regulations using a 
UF or MF range filtration process (Strand Associates, 2008). Using the same 
relationships shown in Table 6, the estimated costs for MMSD (two plants, design flow 
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of 140 MGD and 120 MGD and assuming these systems are bypassed during rain events) 
were estimated. The UF and MF technologies were found to have a 20 year present value 
of $533.0 million, the MBR was $791.7 million, and NF was $1,373 million.  
  For this municipality, upgrading from a UF or MF to a tertiary MBR would cost 
an estimated $259 million over 20 years. Knowing that MMSD serves 1.1 million 
individuals (NRDC, 2011), the estimated cost to upgrade from UF or MF to MBR would 
be $11.76 per capita per year. To put this into context, the willingness to pay to support 
pharmaceuticals take-back programs was estimated to be $14 per year per capita 
(Kotchen et al., 2009). It is not possible to assume that individuals are willing to pay 
similar amounts for infrastructure upgrades to remove PPCPs from wastewater as they 
would for take-back programs, however, this displays that upgrading from UF or MF to 
an MBR to increase PPCPs removal is a potentially feasible recommendation. Additional 
research is currently being conducted to assess the relationship between willingness to 
pay and tertiary wastewater treatment to reduce PPCPs.  
  The Wisconsin DNR estimated the net benefit of the phosphorus reduction rules 
to be $18.8 million, with a standard deviation of $97.1 million (WIDNR 2012). However, 
this analysis did not include the ancillary benefit of PPCPs removal. Under these rules, 
many WWTPs will upgrade their current configuration to include UF technologies which 
was estimated to reduce the RQ from PPCPs by 28%. Including the ancillary benefit of 
this reduction in the RQ is critical to assessing the net benefit of a policy and further 
research is needed on the valuation of PPCPs reduction.  
  Previous research has found that investment in advanced waste or drinking water 
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treatment to remove PPCPs is opposed by both wastewater treatment companies and 
drinking water suppliers (Titz and Döll, 2008). Therefore, utilizing existing regulations, 
such as those to remove phosphorus, may overcome the resistance to implementing 
technologies for PPCPs removal, particularly when significant capital infrastructure costs 
are involved.  
5.0. Conclusion. 
The presence of excess phosphorus and PPCPs in treated wastewater and surface 
waters are a significant environmental concern. This study assessed the change in PPCPs 
emissions, and the corresponding change in RQs, from WWTPs under a statewide 
phosphorus reduction policy that is similar to policies implemented across the world. 
This study found that it is possible to implement a wastewater treatment infrastructure 
that can mitigate the environmental damage from PPCPs while meeting strict phosphorus 
regulations. UF was estimated to reduce the median RQ from PPCPs by 28% while 
meeting the phosphorus effluent limits. In addition, the MBR and NF reduced the median 
RQ from PPCPs by an estimated 71% and 81%, respectively. However, the MBR and NF 
technologies come at a greater cost than the MF or UF technologies.  
Using the results from our meta-analysis, this study presented numerous 
management options regarding the removal of PPCPs from wastewater. Primarily, it 
recommended the use of a meta-analysis, along with the utilization of the RQ, to 
determine the potential reduction in environment harm from PPCPs. From these results, 
managers and policy makers can then prioritize the specific needs of the WWTP and the 
watershed. If the findings revealed a specific PPCP had poor removal with tertiary 
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treatment technologies and insufficient dilution to mitigate the RQ, the study presented 
mechanisms that have the potential to mitigate PPCPs pollution. These options include 
short-term and long-term alternative mitigation strategies and adaptive management 
including water quality trading.  
With the expansion of nutrient criteria for watersheds, nutrient abatement efforts, 
and the expected increase in PPCPs usage, this is an ideal time to address both nutrient 
and PPCPs reduction. At an estimated cost of $11.76 per capita per year to use a tertiary 
MBR rather than UF or MF, this upgrade should be considered by WWTP managers and 
policy makers. With the opposition by both wastewater treatment companies and drinking 
water suppliers to expand infrastructure to reduce PPCPs (Titz and Döll, 2008), utilizing 
existing regulations may overcome the resistance to implementing technologies for 
PPCPs removal. 
Enhancing the wastewater treatment infrastructure to remove phosphorus and 
PPCPs is an essential long-term goal to minimize the environmental and human health 
impacts from wastewater. Overall, the novel approach developed in this research 
validated that phosphorus reduction policies can be utilized to reduce the environmental 
damage caused by PPCPs and we recommend this approach be integrated into future 
nutrient abatement policies and regulations.  
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Table 5: Summary from meta-analysis of influent concentration and fraction removed for 
11 PPCPs and 4 tertiary technologies. 
    Mean  Mean Fraction Removed 
 Pollutant Classification Influent (ng/L) CAS MBR UF NF MF 
Acetaminophen Antipyretic, analgesic 50,000 0.95 1.00 0.06 0.40 0.04 
Caffeine Stimulant 22,000 0.85 0.99 0.07 1.00 0.00 
Carbamazepine   Anticonvulsant 420 0.17 0.15 0.14 0.73 0.11 
Estradiol (E2) Sex Hormone 33 0.85 0.96 0.97 0.52 0.00 
Estriol (E3) Sex Hormone 160 0.84 0.99 0.41 0.98 0.00 
Gemfibrozil Antilipemic 1,100 0.42 0.63 0.07 0.50 0.00 
Ibuprofen Analgesic 39,000 0.87 0.91 0.08 1.00 0.55 
Naproxen NSAID 3,800 0.61 0.80 0.18 0.86 0.00 
Sulfamethoxazole Sulfonamide antibiotic 280 0.45 0.58 0.09 0.64 0.00 
Triclosan Antimicrobial 2,500 0.73 0.78 0.44 0.99 0.00 
Trimethoprim Pyrimidine antibiotic 370 0.51 0.47 0.20 0.95 0.00 
 
 
 
  
107 
 
 
 
Table 6: Estimated 20 year present value (PV, in millions of US dollars, using i=4.875%) 
for selected technologies with a design flow of 100 MGD.  
  
Estimated 20 Year PV 
(in millions) Source 
UF $205.0 Simultaneous Compliance Tool 
MF $205.0 Simultaneous Compliance Tool 
MBR $304.5 AMTA 2007 
NF $528.0 Costa and Pinho, 2006 
 
 
  
108 
 
 
 
 
Figure 8: Influent concentration results of 11 PPCPs from meta-analysis. Box plot 
represents minimum, 25
th
 percentile, 75
th
 percentile, and maximum.  
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Figure 9: Effluent risk quotient for ibuprofen after treatment from a CAS then tertiary 
treatment with MBR, UF, NF, and MF systems. Central mark is the median, the edges of 
the box are the 25th and 75th percentiles, and the whiskers extend to the most extreme 
data points not considered outliers. 
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Figure 10: Effluent risk quotient for carbamazepine after treatment from a CAS then 
tertiary treatment with MBR, UF, NF, and MF systems. Central mark is the median, the 
edges of the box are the 25th and 75th percentiles, and the whiskers extend to the most 
extreme data points not considered outliers. 
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Figure 11: (a) Maximum RQ and (b) Median RQ for 11 PPCPs 
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Chapter 5:  CONCLUSION AND DISCUSSION 
 
The omnipresent usage of pharmaceuticals and personal care products (PPCPs) 
has led to detection in the aquatic environmental at levels that are potentially damaging to 
aquatic organisms (Blair et al., 2013a; Brodin et al. 2013; Christensen et al., 2009; 
Valcárcel et al., 2011; Verlicchi et al., 2011). The chapters of this dissertation presented 
noteworthy advances in the understanding of PPCPs in wastewater and the environment, 
with an emphasis on the potential environmental harm from these pollutants. The 
recommendations for future research based on each data chapter are presented below. In 
addition, debating and evaluating the feasibility of the various solutions recommended to 
reduce PPCPs emissions is needed.  Therefore, a section comparing the current 
recommended solutions to mitigate PPCPs pollution is included.  
Future Research 
The Fate of PPCPs in Wastewater  
  Predicting the removal of PPCPs from wastewater is challenging. However, 
modeling efforts based on the known chemical characteristics has been found to advance 
the prediction of the fate of these complex pollutants. Overall, a further understanding of 
the variables that influence fate of PPCPs in a wastewater treatment plant is required to 
predict the removal of PPCPs from aerobic treatment processes. A critical characteristic 
necessary to determine the removal efficiency of PPCPs from a conventional activated 
sludge wastewater treatment plant is the biological degradation rate constant (Kb), 
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however, the Kb values have not been developed for many of the commonly used PPCPs 
(Dickenson et al., 2010). The predominant method to assess biological degradation of 
PPCPs is pseudo-first-order kinetics (Joss et al., 2006; Schwarzenbach et al., 2003). 
Recent research has raised concerns regarding the inability to assess the activity of the 
total suspended solids using pseudo-first-order kinetics and methods have been developed 
to assess the activity of the biomass (Majewsky et al., 2011a). Therefore, future research 
will examine the relationship between the activity of the biomass in activated sludge and 
the biological degradation rate of PPCPs.  
  Many studies assessing the fate of PPCPs in wastewater have encountered issues 
with negative removal efficiencies, where lower concentrations were seen in the influent 
than the effluent and this requires further research. As summarized by Blair et al. 
(2013b), reasons have been proposed to explain the observed negative removal 
efficiency. These include improperly addressing the fluid dynamics of a WWTP 
(Majewsky et al., 2011b; Ort et al., 2010), the conjugate compounds that are not detected 
at the influent could be retransformed into the original compound due to biological 
processes (Monteiro and Boxall, 2010; Salgado et al., 2012), desorption from the return 
activated sludge may occur during the secondary treatment process (Salgado et al., 2012), 
and PPCPs may be released from fecal particles as the feces are being broken down by 
microbes (Göbel et al., 2007). Understanding the cause of negative removal efficiencies 
is a future research goal.  
Ecological Risk and Occurrence of PPCPs in Lake Michigan: 
  It was found that the distribution of PPCPs in a large lake system was more 
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widespread than previously thought and the levels detected are of concern. Future 
research on PPCPs in wastewater and the environment will require an interdisciplinary 
approach combining engineering, environmental science, economics, policy, and 
management. It is critical to point out that further research is needed on the fate and 
corresponding ecological and human health impacts surrounding PPCPs in the aquatic 
environment. In particular, experimental data assessing the potential impacts and 
biological degradation of PPCPs in the aquatic environment are needed since the QSAR 
models used in this dissertation have significant limitations. Future research on large lake 
systems should also more closely assess the hydrodynamic characteristics of these 
systems to further evaluate the distribution in the aquatic environment.  
  A better understanding the various point and nonpoint sources of PPCPs is 
needed. An unexplored potential source of PPCPs is from meat processing plants. In 
Wisconsin, many slaughterhouses and meat packing facilities discharge into the waste 
stream without pretreatment (UW Extension, 2012). As an example, a widely used 
veterinary pharmaceutical in the treatment of bacterial infection in swine is carbadox. 
This pharmaceutical is not to be used 42 days prior to slaughter in the United States and 
has been banned for use in Canada, the European Union, and Australia due to the 
potential carcinogenic properties and the potential to cause birth defects (Human 
Metabolome Database, 2013). Carbadox was detected at SSWRF and Lake Michigan in 
the 2009-2010 study and consistently during the more recent 2013 study. It is unknown 
whether the source was from agricultural sources, which are sparse in the Milwaukee 
area, or one of the swine processing plants, which are numerous in Milwaukee, and more 
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research is needed on this potential, unexplored, source of pharmaceuticals entering the 
waste stream.  
 Using Phosphorus Regulations to Mitigate the Risk from PPCPs: 
  When assessing the recommended technologies to meet wastewater effluent 
standards, it is recommended to consider the net environmental benefit of the 
technologies rather than focusing on a single pollutant. Therefore, completing a Life 
Cycle Assessment (LCA) on the technologies to remove PPCPs from wastewater would 
be a valuable assessment to determine the overall change in emissions from the use of 
advanced tertiary technologies. The objective of wastewater treatment is to increase the 
effluent quality through the reduction of endpoints such as environmental toxicity, 
hormone effects, and pathogenic effects of the effluent. Using a LCA, it would be 
possible to assess the environmental trade-off since the increased quality of the effluent 
will happen at the expense of increased resource and energy consumption (Wenzel et al., 
2008). Future research would assess the technologies implemented to remove regulated 
pollutants and determine their abilities to remove PPCPs and other unregulated 
pollutants.  
  Overall, the need for economic, management, and policy research on PPCPs in 
the aquatic environment is significant. Future research should focus on comparing the 
marginal benefits of removal with the marginal abatement costs. It is possible to evaluate 
the public’s perception of the environmental impacts PPCPs and to estimate the marginal 
abatement costs. In addition, expert stakeholders’ views on the management of 
pharmaceuticals in the environment has been assessed (Doerr-MacEwen and Haight, 
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2006), however, applying other policy research tools to these issues is an additional 
future research goal.   
Recommendations for PPCPs Mitigation. 
  Debating and evaluating the feasibility of the various solutions recommended to 
reduce PPCPs emissions is needed. Short-term and long-term alternative PPCPs 
mitigation strategies were presented in Chapter 4 and some of these concepts are more 
plausible than others. The advantages and limitations of the current efforts to reduce 
PPCPs pollution will now be presented where the proposed solutions will consist of: 
disposal of unused PPCPs through trash disposal or take-back programs, green 
pharmaceuticals, minimum therapeutic doses, utilizing toilets with waste separation, and 
advanced wastewater treatment technologies.  
  The majority of the current efforts to reduce PPCPs from entering the aquatic 
environment focus on disposal of unused PPCPs (Daughton, 2010; Kotchen et al., 2009). 
The major goals of disposing unused PPCPs are to prevent accident exposure or abuse 
along with protecting the environment. For some PPCPs, such as narcotics and fentanyl 
transdermal patches, it has been determined that the potential for accidental exposure or 
abuse outweighs the environmental protection concerns at this time, and these 
pharmaceuticals are recommended for toilet disposal (USFDA, 2012).  
  PPCPs mitigation through the efforts advocating non-toilet disposal options may 
face diminishing returns. Along with some PPCPs being recommended for toilet disposal, 
it is also important to note that disposal of unused pharmaceuticals through take-back 
programs or trash disposal does not address an overarching problem with PPCPs: many 
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PPCPs are excreted from the body remaining partially unchanged when excreted 
(Kasprzyk-Hordern et al., 2009). It was found that 0% – 17% of respondents in the UK 
and 28% of respondents in the US disposed of unused pharmaceuticals in the toilet/drain 
and the majority of respondents disposed of their pharmaceuticals in the trash bin (Bound 
et al., 2005; Kotchen et al., 2009). Disposal to trash also increases the possibility of 
human or pet exposure to unused PPCPs and could also allow environmental 
contamination (Glassmeyer et al., 2009). Overall, the efforts to encourage trash disposal 
may have a limited overall impact on the amount of PPCPs entering the environment. 
  Pharmaceutical take-back programs have shown limited success, such as in 
Wisconsin, where an estimated 2% of unused pharmaceuticals were recovered (WIDNR 
2012). In addition, no studies have succeeded in linking drug collection programs to 
either reductions in environmental levels or to reductions in human poisonings 
(Daughton, 2010). Due to the limited number of take-back options, take-back programs 
could increase the risk of accidental poisonings, diversion, or abuse due to stockpiling of 
unused medications awaiting take-back (Cook et al., 2012a). Concerns have also been 
raised regarding the net environmental benefit of incineration and pollution from 
transportation of PPCPs returned through take-back programs (Cook et al., 2012b).  
  Pharmaceutical take-back programs currently have significant regulatory issues in 
the United States. Under the Controlled Substances Act, the U.S. Drug Enforcement 
Administration requires controlled substances to be surrendered to the proper law 
enforcement officials (Lubick 2010). Therefore, take-back programs for medical 
employees (e.g. nursing home employees) are subject to the same rules that are meant to 
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keep controlled substances from reentering the supply chain either legally or illegally 
which has caused stockpiling of unused pharmaceuticals in medical settings. In addition, 
most pharmacies across the United States cannot accept unused pharmaceuticals due to 
regulations under the Controlled Substance Act (Barlas, 2009; Lubick, 2010). 
  The green pharmaceutical movement calls for pharmaceutical developers and 
manufacturers to increase uptake of the compound by the body (thereby requiring lower 
doses), creating compounds that maximize their susceptibility to environmental 
biodegradation or photolysis, or creating compounds that are less dangerous to the 
environment (Daughton 2003). Meeting these requirements is difficult at this time due to 
the cost and issues associated with the development of pharmaceuticals (Adams and 
Brantner, 2006; Sumpter, 2010) and the environmental release of pharmaceuticals from 
wastewater is largely unregulated across the world at this time (Ryu et al., 2014). Overall, 
the incentives to develop new compounds that have an increased uptake or lower 
environmental toxicity do not currently exist.  
  Using the minimum therapeutic dosage or drug alternatives has been proposed to 
lower the concentration of PPCPs in wastewater (Daughton and Ruhoy 2013). However, 
over the last 10 years, the percentage of Americans who took at least one prescription 
drug in the past month increased from 44% to 48%, the percentage who use  two or more 
drugs increased from 25% to 31%, and the percentage who use five or more drugs 
increased from 6% to 11% (CDC 2010). In addition, resistance may be met by critical 
stakeholders (e.g. medical doctors) due to a primary goal of pharmaceutical interventions 
is to get patients to the therapeutic range as fast as possible and starting at the minimum 
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therapeutic dosage could cause additional hospital visits and testing. Therefore, the 
possibility of reversing this trend or requesting patients to start their dosage at the 
minimum dosage rather than the mean dosage is challenging at this time.  
  Human waste separation combined with onsite treatment to remove PPCPs has 
shown to be a promising concept (Borsuk et al., 2008; Lamichhane, 2012). However, the 
high cost associated with upgrading all toilets (public and private), along with the 
regulatory framework needed, causes this concept to be difficult to implement in the 
short-term. In addition, many PPCPs are rinsed off and this concept would not address 
these pollutants.  
  As discussed in Chapter 4, advanced wastewater treatment technologies have the 
potential to remove PPCPs, but also carry significant capital, operating, and maintenance 
costs. In addition, further expanding a WWTPs capability to remove PPCPs may also be 
beneficial due to some pharmaceuticals being recommended for disposal in toilets to 
lower accidental contact risks, such as fentanyl transdermal patches and narcotics 
(USFDA 2012). In addition, advanced wastewater treatment processes can remove other 
contaminants of concerns, such as heavy metals, viruses, industrial chemicals, and 
household chemicals. Overall, additional wastewater treatment would have the potential 
to remove PPCPs that are disposed of through the toilet/drain, PPCPs that are excreted in 
feces or urine, and PPCPs that are rinsed or washed off, thereby removing a majority of 
the PPCPs in the waste stream.  
 Overall, a multifaceted approach is the best long-term solution to prevent PPCPs 
emissions into the environment. While reducing the disposal of PPCPs through the 
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toilet/drain is a great first step, exploring other safe disposal methods is needed. In 
addition, green pharmaceuticals, waste separating toilets, and recommending the 
minimum therapeutic dosage are useful concepts that warrant further research, but have 
significant obstacles to their implementation. Updating wastewater treatment plants is 
costly, but infrastructure upgrades have the potential to offer significant environmental 
benefits and research should continue to evaluate the feasibility of advanced wastewater 
treatment technologies.  
Conclusion. 
  The chapters of this dissertation presented advances in the understanding of 
PPCPs in wastewater and the environment. The experiments carried out in this 
investigation provided data that are essential for obtaining a comprehensive 
understanding of the occurrence, fate, and transport of PPCPs in a conventional active 
sludge wastewater treatment plant and Lake Michigan. This work also furthered the 
debate on how to achieve meaningful reduction in PPCPs from wastewater through the 
optimization of current regulations that utilize tertiary treatment technologies.  
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Appendix A: Supporting Data for Chapter 2. All units are ng/L. 
  
Metformin Albuterol Cimetidine Ranitidine Acetaminophen 
 
MDL 0.51 1.4 1.3 0.87 2.5 
 
MQL 1.5 4.2 3.8 2.6 7.5 
Raw Influent 5/15/2009 34000 
No 
Detection 
No 
Detection 10 26000 
Primary Effluent 5/15/2009 38000 
No 
Detection 
No 
Detection 
No 
Detection 8000 
Secondary 
Effluent 5/15/2009 33000 
No 
Detection 
No 
Detection 
No 
Detection 29 
Final Effluent 5/15/2009 38000 
No 
Detection 
No 
Detection 
No 
Detection 0 
Raw Influent 6/15/2009 75000 
No 
Detection 
No 
Detection 130 150000 
Primary Effluent 6/15/2009 34000 
No 
Detection 
No 
Detection 91 150000 
Secondary 
Effluent 6/15/2009 33000 
No 
Detection 
No 
Detection 
No 
Detection 29 
Final Effluent 6/15/2009 47000 
No 
Detection 
No 
Detection 13 650 
Raw Influent 8/18/2009 100000 23 
No 
Detection 
No 
Detection 12000 
Primary Effluent 8/18/2009 78000 14 
No 
Detection 
No 
Detection 12000 
Secondary 
Effluent 8/18/2009 15000 12 
No 
Detection 
No 
Detection 54 
Final Effluent 8/18/2009 19000 
No 
Detection 
No 
Detection 
No 
Detection 85 
Raw Influent 10/19/2009 100000 19 
No 
Detection 1.3 14000 
Primary Effluent 10/19/2009 92000 19 
No 
Detection 330 16000 
Secondary 
Effluent 10/19/2009 No Data No Data No Data No Data No Data 
Final Effluent 10/19/2009 11000 
No 
Detection 
No 
Detection 4.3 52 
Raw Influent 4/9/2010 22000 
No 
Detection 14 21 5900 
Primary Effluent 4/9/2010 46000 
No 
Detection 9.6 16 9700 
Secondary 
Effluent 4/9/2010 27000 
No 
Detection 7.2 18 0 
Final Effluent 4/9/2010 33000 
No 
Detection 
No 
Detection 
No 
Detection 14 
Raw Influent 6/15/2010 3200 13 39 28 22000 
Primary Effluent 6/15/2010 9800 69 120 89 22000 
Secondary 
Effluent 6/15/2010 800 9 18 29 22000 
Final Effluent 6/15/2010 640 2.6 
No 
Detection 
No 
Detection 27 
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Azithromycin Caffeine Carbadox Carbamazepine Ciprofloxacin 
 
MDL 3.7 3.1 3.4 2.7 3.3 
 
MQL 11 9.3 10 8.2 9.9 
Raw Influent 5/15/2009 5.9 34000 44 230 No Detection 
Primary Effluent 5/15/2009 14 26000 68 96 No Detection 
Secondary Effluent 5/15/2009 6.5 1000 No Detection 170 No Detection 
Final Effluent 5/15/2009 16 1400 6.9 150 No Detection 
Raw Influent 6/15/2009 280 130000 No Detection 310 No Detection 
Primary Effluent 6/15/2009 340 110000 No Detection 310 No Detection 
Secondary Effluent 6/15/2009 6.5 1000 No Detection 170 No Detection 
Final Effluent 6/15/2009 350 580 15 340 No Detection 
Raw Influent 8/18/2009 No Detection 9400 No Detection 73 No Detection 
Primary Effluent 8/18/2009 No Detection 8600 No Detection 70 No Detection 
Secondary Effluent 8/18/2009 No Detection 34 No Detection 88 No Detection 
Final Effluent 8/18/2009 230 940 No Detection 230 No Detection 
Raw Influent 10/19/2009 No Detection 9000 No Detection 51 87 
Primary Effluent 10/19/2009 No Detection 10000 No Detection 76 19 
Secondary Effluent 10/19/2009 No Data No Data No Data No Data No Data 
Final Effluent 10/19/2009 No Detection No Detection No Detection 160 No Detection 
Raw Influent 4/9/2010 No Detection 3300 11 21 No Detection 
Primary Effluent 4/9/2010 No Detection 4200 21 24 No Detection 
Secondary Effluent 4/9/2010 No Detection 71 No Detection 33 No Detection 
Final Effluent 4/9/2010 No Detection 43 No Detection 27 No Detection 
Raw Influent 6/15/2010 32 8800 No Detection 72 13 
Primary Effluent 6/15/2010 47 7800 No Detection 59 16 
Secondary Effluent 6/15/2010 47 7800 No Detection 59 16 
Final Effluent 6/15/2010 210 19 No Detection 200 No Detection 
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Clarithromycin Codeine Cotinine Digoxigenin Diltiazem 
 
MDL 3.2 3.6 3.5 4.4 3.5 
 
MQL 9.6 11 11 13 10 
Raw Influent 5/15/2009 No Detection 160 No Detection No Detection 170 
Primary Effluent 5/15/2009 No Detection 84 No Detection No Detection 150 
Secondary Effluent 5/15/2009 No Detection 170 No Detection No Detection 160 
Final Effluent 5/15/2009 No Detection 82 No Detection No Detection 57 
Raw Influent 6/15/2009 No Detection 540 No Detection 850 640 
Primary Effluent 6/15/2009 No Detection 460 No Detection 710 720 
Secondary Effluent 6/15/2009 No Detection 170 No Detection No Detection 160 
Final Effluent 6/15/2009 No Detection 230 No Detection No Detection 510 
Raw Influent 8/18/2009 No Detection 36 37 No Detection 46 
Primary Effluent 8/18/2009 No Detection 15 65 No Detection 34 
Secondary Effluent 8/18/2009 No Detection 9.6 No Detection No Detection No Detection 
Final Effluent 8/18/2009 No Detection 120 No Detection No Detection 220 
Raw Influent 10/19/2009 No Detection 37 36 61 57 
Primary Effluent 10/19/2009 No Detection 42 56 76 44 
Secondary Effluent 10/19/2009 No Data No Data No Data No Data No Data 
Final Effluent 10/19/2009 No Detection No Detection No Detection No Detection No Detection 
Raw Influent 4/9/2010 No Detection 15 No Detection No Detection 20 
Primary Effluent 4/9/2010 No Detection 28 No Detection No Detection 17 
Secondary Effluent 4/9/2010 No Detection 62 No Detection No Detection 22 
Final Effluent 4/9/2010 No Detection 33 No Detection No Detection No Detection 
Raw Influent 6/15/2010 5.6 54 130 52 41 
Primary Effluent 6/15/2010 No Detection 43 810 68 38 
Secondary Effluent 6/15/2010 No Detection 43 810 68 38 
Final Effluent 6/15/2010 19 150 No Detection No Detection 34 
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Paraxanthine Diphenhydramine Fluoxetine Lincomycin 
 
MDL 6.1 3.6 3.5 3.1 
 
MQL 18 11 11 9.3 
Raw Influent 5/15/2009 5700 75 61 No Detection 
Primary Effluent 5/15/2009 5000 78 100 No Detection 
Secondary Effluent 5/15/2009 540 140 25 No Detection 
Final Effluent 5/15/2009 770 87 41 No Detection 
Raw Influent 6/15/2009 15000 420 95 25 
Primary Effluent 6/15/2009 13000 420 120 29 
Secondary Effluent 6/15/2009 540 140 25 No Detection 
Final Effluent 6/15/2009 210 360 96 15 
Raw Influent 8/18/2009 3000 33 18 3.2 
Primary Effluent 8/18/2009 2800 21 9.6 No Detection 
Secondary Effluent 8/18/2009 25 5.8 5 No Detection 
Final Effluent 8/18/2009 370 98 78 No Detection 
Raw Influent 10/19/2009 2400 37 23 3.7 
Primary Effluent 10/19/2009 3100 26 12 4 
Secondary Effluent 10/19/2009 No Data No Data No Data No Data 
Final Effluent 10/19/2009 No Detection No Detection No Detection No Detection 
Raw Influent 4/9/2010 740 11 6.1 No Detection 
Primary Effluent 4/9/2010 1500 7 4 No Detection 
Secondary Effluent 4/9/2010 31 10 7 No Detection 
Final Effluent 4/9/2010 14 5.6 5.1 No Detection 
Raw Influent 6/15/2010 4500 34 12 No Detection 
Primary Effluent 6/15/2010 2700 22 8.3 No Detection 
Secondary Effluent 6/15/2010 2700 22 8.3 No Detection 
Final Effluent 6/15/2010 30 22 14 No Detection 
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Lomefloxacin Miconazole Norfloxacin Ofloxacin 
 
MDL 4.7 2.7 5.1 3.9 
 
MQL 14 8.1 15 12 
Raw Influent 5/15/2009 No Detection 36 No Detection 200 
Primary Effluent 5/15/2009 No Detection 15 No Detection 150 
Secondary 
Effluent 5/15/2009 No Detection 6.4 No Detection 220 
Final Effluent 5/15/2009 No Detection 10 No Detection 88 
Raw Influent 6/15/2009 No Detection 81 No Detection 980 
Primary Effluent 6/15/2009 No Detection 69 No Detection 530 
Secondary 
Effluent 6/15/2009 No Detection 6.4 No Detection 220 
Final Effluent 6/15/2009 No Detection 6 No Detection 670 
Raw Influent 8/18/2009 No Detection No Detection No Detection No Detection 
Primary Effluent 8/18/2009 No Detection No Detection No Detection No Detection 
Secondary 
Effluent 8/18/2009 No Detection No Detection No Detection No Detection 
Final Effluent 8/18/2009 No Detection 25 No Detection 200 
Raw Influent 10/19/2009 No Detection No Detection No Detection 32 
Primary Effluent 10/19/2009 No Detection No Detection No Detection 6.1 
Secondary 
Effluent 10/19/2009 No Data No Data No Data No Data 
Final Effluent 10/19/2009 No Detection No Detection No Detection No Detection 
Raw Influent 4/9/2010 No Detection No Detection No Detection No Detection 
Primary Effluent 4/9/2010 No Detection No Detection No Detection No Detection 
Secondary 
Effluent 4/9/2010 No Detection No Detection No Detection 11 
Final Effluent 4/9/2010 No Detection No Detection No Detection No Detection 
Raw Influent 6/15/2010 No Detection No Detection No Detection No Detection 
Primary Effluent 6/15/2010 No Detection No Detection No Detection No Detection 
Secondary 
Effluent 6/15/2010 No Detection No Detection No Detection No Detection 
Final Effluent 6/15/2010 No Detection No Detection No Detection No Detection 
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Oxacillin Roxithromycin Sarafloxacin Sulfachloropyridazine 
 
MDL 2.5 4.3 5.4 4.1 
 
MQL 7.4 13 16 12 
Raw Influent 5/15/2009 No Detection 420 No Detection No Detection 
Primary Effluent 5/15/2009 No Detection 64 No Detection No Detection 
Secondary 
Effluent 5/15/2009 No Detection No Detection No Detection No Detection 
Final Effluent 5/15/2009 No Detection 28 No Detection No Detection 
Raw Influent 6/15/2009 No Detection 1500 No Detection No Detection 
Primary Effluent 6/15/2009 No Detection 88 No Detection No Detection 
Secondary 
Effluent 6/15/2009 No Detection No Detection No Detection No Detection 
Final Effluent 6/15/2009 No Detection 110 No Detection No Detection 
Raw Influent 8/18/2009 No Detection No Detection No Detection No Detection 
Primary Effluent 8/18/2009 No Detection No Detection No Detection No Detection 
Secondary 
Effluent 8/18/2009 No Detection No Detection No Detection No Detection 
Final Effluent 8/18/2009 No Detection 18 No Detection No Detection 
Raw Influent 10/19/2009 No Detection No Detection No Detection No Detection 
Primary Effluent 10/19/2009 No Detection No Detection No Detection No Detection 
Secondary 
Effluent 10/19/2009 No Data No Data No Data No Data 
Final Effluent 10/19/2009 No Detection No Detection No Detection No Detection 
Raw Influent 4/9/2010 No Detection No Detection No Detection No Detection 
Primary Effluent 4/9/2010 No Detection No Detection No Detection No Detection 
Secondary 
Effluent 4/9/2010 No Detection No Detection No Detection No Detection 
Final Effluent 4/9/2010 No Detection No Detection No Detection No Detection 
Raw Influent 6/15/2010 No Detection No Detection No Detection No Detection 
Primary Effluent 6/15/2010 No Detection No Detection No Detection No Detection 
Secondary 
Effluent 6/15/2010 No Detection No Detection No Detection No Detection 
Final Effluent 6/15/2010 No Detection No Detection No Detection No Detection 
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Sulfadiazine Sulfadimethoxine Sulfamerazine Sulfamethazine 
 
MDL 2.8 2.4 2.1 4 
 
MQL 8.5 7.1 6.2 12 
Raw Influent 5/15/2009 No Detection No Detection No Detection No Detection 
Primary Effluent 5/15/2009 No Detection No Detection 1.3 No Detection 
Secondary 
Effluent 5/15/2009 No Detection No Detection 3.2 No Detection 
Final Effluent 5/15/2009 No Detection No Detection 1.6 No Detection 
Raw Influent 6/15/2009 No Detection No Detection No Detection No Detection 
Primary Effluent 6/15/2009 No Detection No Detection No Detection 48 
Secondary 
Effluent 6/15/2009 No Detection No Detection 3.2 No Detection 
Final Effluent 6/15/2009 No Detection No Detection No Detection No Detection 
Raw Influent 8/18/2009 No Detection No Detection No Detection No Detection 
Primary Effluent 8/18/2009 No Detection No Detection No Detection No Detection 
Secondary 
Effluent 8/18/2009 No Detection No Detection No Detection No Detection 
Final Effluent 8/18/2009 No Detection 13 No Detection No Detection 
Raw Influent 10/19/2009 No Detection No Detection No Detection No Detection 
Primary Effluent 10/19/2009 No Detection No Detection No Detection No Detection 
Secondary 
Effluent 10/19/2009 No Data No Data No Data No Data 
Final Effluent 10/19/2009 No Detection No Detection No Detection No Detection 
Raw Influent 4/9/2010 No Detection No Detection No Detection No Detection 
Primary Effluent 4/9/2010 No Detection No Detection No Detection No Detection 
Secondary 
Effluent 4/9/2010 3 No Detection No Detection No Detection 
Final Effluent 4/9/2010 No Detection No Detection No Detection No Detection 
Raw Influent 6/15/2010 2.8 No Detection No Detection No Detection 
Primary Effluent 6/15/2010 No Detection No Detection No Detection No Detection 
Secondary 
Effluent 6/15/2010 No Detection No Detection No Detection No Detection 
Final Effluent 6/15/2010 5.7 No Detection No Detection No Detection 
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Sulfamethizole Sulfamethoxazole Sulfanilamide Sulfathiazole 
 
MDL 4.2 4.1 2.9 2.6 
 
MQL 13 12 8.6 7.8 
Raw Influent 5/15/2009 No Detection 210 500 No Detection 
Primary Effluent 5/15/2009 No Detection 110 No Detection No Detection 
Secondary 
Effluent 5/15/2009 No Detection 300 68 No Detection 
Final Effluent 5/15/2009 No Detection 150 69 No Detection 
Raw Influent 6/15/2009 No Detection 1200 900 2.5 
Primary Effluent 6/15/2009 No Detection 1300 2500 5 
Secondary 
Effluent 6/15/2009 No Detection 300 68 No Detection 
Final Effluent 6/15/2009 No Detection 810 900 No Detection 
Raw Influent 8/18/2009 No Detection 110 59 3.8 
Primary Effluent 8/18/2009 No Detection 75 42 4.2 
Secondary 
Effluent 8/18/2009 No Detection 67 42 No Detection 
Final Effluent 8/18/2009 No Detection 360 No Detection No Detection 
Raw Influent 10/19/2009 No Detection 120 55 No Detection 
Primary Effluent 10/19/2009 No Detection 160 93 4.2 
Secondary 
Effluent 10/19/2009 No Data No Data No Data No Data 
Final Effluent 10/19/2009 No Detection 31 49 No Detection 
Raw Influent 4/9/2010 No Detection 54 No Detection No Detection 
Primary Effluent 4/9/2010 No Detection 21 No Detection No Detection 
Secondary 
Effluent 4/9/2010 No Detection 34 No Detection No Detection 
Final Effluent 4/9/2010 No Detection 17 No Detection No Detection 
Raw Influent 6/15/2010 No Detection 170 No Detection No Detection 
Primary Effluent 6/15/2010 No Detection 57 No Detection No Detection 
Secondary 
Effluent 6/15/2010 No Detection 57 No Detection No Detection 
Final Effluent 6/15/2010 No Detection 210 No Detection No Detection 
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Thiabendazole Trimethoprim Triclosan Triclocarban Naproxen 
 
MDL 1.8 3.4 0.53 0.48 0.97 
 
MQL 5.3 10 1.6 1.4 2.9 
Raw Influent 5/15/2009 5.4 220 4300 5200 4200 
Primary Effluent 5/15/2009 7.2 120 1600 1200 2800 
Secondary Effluent 5/15/2009 9.5 260 120 120 520 
Final Effluent 5/15/2009 11 62 74 150 250 
Raw Influent 6/15/2009 26 590 9100 5900 9400 
Primary Effluent 6/15/2009 19 510 5700 2800 11000 
Secondary Effluent 6/15/2009 9.5 260 120 120 520 
Final Effluent 6/15/2009 16 660 270 250 320 
Raw Influent 8/18/2009 No Detection 36 89 3.3 2900 
Primary Effluent 8/18/2009 No Detection 31 330 120 260 
Secondary Effluent 8/18/2009 No Detection 21 24 74 110 
Final Effluent 8/18/2009 14 190 850 980 580 
Raw Influent 10/19/2009 No Detection 52 130 35 1800 
Primary Effluent 10/19/2009 No Detection 54 530 400 3100 
Secondary Effluent 10/19/2009 No Data No Data No Data No Data No Data 
Final Effluent 10/19/2009 No Detection No Detection No Detection 27 8.3 
Raw Influent 4/9/2010 No Detection 18 610 110 780 
Primary Effluent 4/9/2010 No Detection 19 250 17 460 
Secondary Effluent 4/9/2010 No Detection 41 150 61 19 
Final Effluent 4/9/2010 No Detection 13 46 40 26 
Raw Influent 6/15/2010 No Detection 45 680 140 3100 
Primary Effluent 6/15/2010 No Detection 34 350 67 4000 
Secondary Effluent 6/15/2010 No Detection 34 350 67 4000 
Final Effluent 6/15/2010 2.8 170 120 99 19 
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Gemfibrozil Ibuprofen Estriol 17-alpha-estradiol 
 
MDL 1.6 4.7 2 1.2 
 
MQL 4.8 14 6.1 3.5 
Raw Influent 5/15/2009 29 3000 No Detection No Detection 
Primary Effluent 5/15/2009 62 No Detection No Detection No Detection 
Secondary 
Effluent 5/15/2009 85 No Detection No Detection No Detection 
Final Effluent 5/15/2009 53 No Detection No Detection No Detection 
Raw Influent 6/15/2009 150 11000 10 No Detection 
Primary Effluent 6/15/2009 220 14000 44 No Detection 
Secondary 
Effluent 6/15/2009 85 No Detection No Detection No Detection 
Final Effluent 6/15/2009 270 No Detection No Detection No Detection 
Raw Influent 8/18/2009 200 1300 No Detection No Detection 
Primary Effluent 8/18/2009 460 No Detection No Detection No Detection 
Secondary 
Effluent 8/18/2009 420 210 No Detection No Detection 
Final Effluent 8/18/2009 66 No Detection No Detection No Detection 
Raw Influent 10/19/2009 97 840 No Detection No Detection 
Primary Effluent 10/19/2009 630 No Detection No Detection No Detection 
Secondary 
Effluent 10/19/2009 No Data No Data No Data No Data 
Final Effluent 10/19/2009 30 No Detection No Detection No Detection 
Raw Influent 4/9/2010 510 670 22 10000 
Primary Effluent 4/9/2010 550 520 6 7500 
Secondary 
Effluent 4/9/2010 1100 No Detection No Detection 2900 
Final Effluent 4/9/2010 750 No Detection No Detection 4700 
Raw Influent 6/15/2010 1200 4800 No Data No Data 
Primary Effluent 6/15/2010 1100 4000 41 760000 
Secondary 
Effluent 6/15/2010 1100 4000 6.1 No Detection 
Final Effluent 6/15/2010 1100 No Detection No Data No Data 
 
 
 
 
 
 
135 
 
 
 
 
  
Estrone 17-Beta-estradiol Testosterone Androsterone 
 
MDL 2.2 1.3 1.1 0.55 
 
MQL 6.7 3.8 3.2 1.6 
Raw Influent 5/15/2009 64 No Detection 1.7 48 
Primary Effluent 5/15/2009 52 No Detection No Detection No Detection 
Secondary 
Effluent 5/15/2009 No Detection 0.91 No Detection No Detection 
Final Effluent 5/15/2009 No Detection No Detection No Detection No Detection 
Raw Influent 6/15/2009 350 9.4 19 470 
Primary Effluent 6/15/2009 290 11 13 520 
Secondary 
Effluent 6/15/2009 No Detection 0.91 No Detection No Detection 
Final Effluent 6/15/2009 No Detection No Detection No Detection 14 
Raw Influent 8/18/2009 No Detection No Detection No Detection No Detection 
Primary Effluent 8/18/2009 No Detection No Detection No Detection No Detection 
Secondary 
Effluent 8/18/2009 No Detection No Detection No Detection No Detection 
Final Effluent 8/18/2009 No Detection 2.8 No Detection No Detection 
Raw Influent 10/19/2009 No Detection No Detection No Detection No Detection 
Primary Effluent 10/19/2009 No Detection No Detection No Detection No Detection 
Secondary 
Effluent 10/19/2009 No Data No Data No Data No Data 
Final Effluent 10/19/2009 No Detection No Detection No Detection No Detection 
Raw Influent 4/9/2010 200 No Detection 25 380 
Primary Effluent 4/9/2010 120 No Detection 2.7 57 
Secondary 
Effluent 4/9/2010 No Detection No Detection No Detection No Detection 
Final Effluent 4/9/2010 No Detection No Detection No Detection No Detection 
Raw Influent 6/15/2010 No Data No Data No Data No Data 
Primary Effluent 6/15/2010 No Detection No Detection No Detection No Detection 
Secondary 
Effluent 6/15/2010 No Detection No Detection No Detection No Detection 
Final Effluent 6/15/2010 No Data No Data No Data No Data 
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5-alpha-androstane-3,17-
dione 4-androstene-3,17-dione Progesterone 
 
MDL 2.3 0.48 0.66 
 
MQL 6.9 1.4 2 
Raw Influent 5/15/2009 No Detection 12 3.7 
Primary Effluent 5/15/2009 No Detection 1.7 5.7 
Secondary 
Effluent 5/15/2009 No Detection No Detection 0.82 
Final Effluent 5/15/2009 24 0.35 No Detection 
Raw Influent 6/15/2009 No Detection 88 6.9 
Primary Effluent 6/15/2009 No Detection 73 8.7 
Secondary 
Effluent 6/15/2009 No Detection No Detection 0.82 
Final Effluent 6/15/2009 No Detection 2.3 2.9 
Raw Influent 8/18/2009 No Detection No Detection No Detection 
Primary Effluent 8/18/2009 No Detection No Detection No Detection 
Secondary 
Effluent 8/18/2009 No Detection No Detection No Detection 
Final Effluent 8/18/2009 No Detection No Detection No Detection 
Raw Influent 10/19/2009 No Detection No Detection No Detection 
Primary Effluent 10/19/2009 No Detection No Detection No Detection 
Secondary 
Effluent 10/19/2009 No Data No Data No Data 
Final Effluent 10/19/2009 No Detection No Detection No Detection 
Raw Influent 4/9/2010 No Detection 150 23 
Primary Effluent 4/9/2010 No Detection 13 No Detection 
Secondary 
Effluent 4/9/2010 No Detection 1.9 No Detection 
Final Effluent 4/9/2010 No Detection 1.1 No Detection 
Raw Influent 6/15/2010 No Data No Data No Data 
Primary Effluent 6/15/2010 No Detection No Detection No Detection 
Secondary 
Effluent 6/15/2010 No Detection No Detection No Detection 
Final Effluent 6/15/2010 No Data No Data No Data 
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17,20-dihydroxyprogesterone Boldenone 
 
MDL 1.4 1.3 
 
MQL 4.2 4 
Raw Influent 5/15/2009 No Detection 13 
Primary Effluent 5/15/2009 No Detection No Detection 
Secondary 
Effluent 5/15/2009 0.82 No Detection 
Final Effluent 5/15/2009 No Detection No Detection 
Raw Influent 6/15/2009 3.8 56 
Primary Effluent 6/15/2009 2.9 15 
Secondary 
Effluent 6/15/2009 0.82 No Detection 
Final Effluent 6/15/2009 No Detection No Detection 
Raw Influent 8/18/2009 No Detection No Detection 
Primary Effluent 8/18/2009 No Detection No Detection 
Secondary 
Effluent 8/18/2009 No Detection No Detection 
Final Effluent 8/18/2009 No Detection No Detection 
Raw Influent 10/19/2009 No Detection No Detection 
Primary Effluent 10/19/2009 No Detection No Detection 
Secondary 
Effluent 10/19/2009 No Data No Data 
Final Effluent 10/19/2009 No Detection No Detection 
Raw Influent 4/9/2010 No Detection 170 
Primary Effluent 4/9/2010 No Detection 16 
Secondary 
Effluent 4/9/2010 No Detection No Detection 
Final Effluent 4/9/2010 No Detection No Detection 
Raw Influent 6/15/2010 No Data No Data 
Primary Effluent 6/15/2010 No Detection No Detection 
Secondary 
Effluent 6/15/2010 No Detection No Detection 
Final Effluent 6/15/2010 No Data No Data 
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Melengestrol Melengestrol acetate 
 
MDL 1.3 0.58 
 
MQL 4 1.7 
Raw Influent 5/15/2009 No Detection No Detection 
Primary Effluent 5/15/2009 No Detection No Detection 
Secondary 
Effluent 5/15/2009 No Detection No Detection 
Final Effluent 5/15/2009 No Detection No Detection 
Raw Influent 6/15/2009 43 No Detection 
Primary Effluent 6/15/2009 49 No Detection 
Secondary 
Effluent 6/15/2009 No Detection No Detection 
Final Effluent 6/15/2009 0.86 0.51 
Raw Influent 8/18/2009 No Detection No Detection 
Primary Effluent 8/18/2009 No Detection No Detection 
Secondary 
Effluent 8/18/2009 No Detection No Detection 
Final Effluent 8/18/2009 No Detection No Detection 
Raw Influent 10/19/2009 No Detection No Detection 
Primary Effluent 10/19/2009 No Detection No Detection 
Secondary 
Effluent 10/19/2009 No Data No Data 
Final Effluent 10/19/2009 No Detection No Detection 
Raw Influent 4/9/2010 19 1300 
Primary Effluent 4/9/2010 No Detection No Detection 
Secondary 
Effluent 4/9/2010 No Detection No Detection 
Final Effluent 4/9/2010 No Detection No Detection 
Raw Influent 6/15/2010 No Data No Data 
Primary Effluent 6/15/2010 No Detection No Detection 
Secondary 
Effluent 6/15/2010 No Detection No Detection 
Final Effluent 6/15/2010 No Data No Data 
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Appendix B: BIOWIN4 Calculations  
Compound 
A
ce
ta
m
in
o
p
h
en
 
C
af
fe
in
e 
C
ar
b
am
az
ep
in
e 
C
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d
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n
e 
C
o
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n
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e 
D
il
ti
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em
 
Number of Applicable 
Samples 
5 5 5 5 4 5 
Biowin 4 Value* 3.8748 3.5676 3.5068 3.1895 3.7802 3.4732 
Intrinsic Half Life (hr) 13.3 27.1 31.1 64.6 16.6 33.6 
Predicted Kbiol  
(L gss 
-1
 hr 
-1
) 
0.05 0.02 0.02 0.01 0.04 0.02 
Predicted Removal 
Efficiency In Aeration 
Basin (%) 
0.59 0.35 0.32 0.17 0.51 0.30 
Predicted Removal 
Efficiency in 
Secondary Clarifier 
(%) 
0.18 0.09 0.08 0.04 0.15 0.08 
Sum Aeration Basin 
and Secondary 
Clarifier Removal 
Efficiency (%) 
0.77 0.45 0.40 0.21 0.66 0.37 
Observed Median 
Removal Efficiency 
(%) 
1.00 1.00 0.00 0.00 1.00 0.08 
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Compound 
D
ip
h
en
h
y
d
ra
m
in
e 
F
lu
o
x
et
in
e 
Ib
u
p
ro
fe
n
 
M
et
fo
rm
in
 
N
ap
ro
x
en
 
O
fl
o
x
ac
in
 
Number of Applicable 
Samples 
4 3 3 5 5 3 
Biowin 4 Value* 3.1914 3.2523 3.7986 3.6614 3.9097 2.9163 
Intrinsic Half Life (hr) 64.4 55.9 15.9 21.8 12.3 121.3 
Predicted Kbiol 
 (L gss 
-1
 hr 
-1
) 
0.011 0.012 0.044 0.032 0.056 0.006 
Predicted Removal Efficiency 
In Aeration Basin (%) 
0.17 0.19 0.52 0.42 0.62 0.09 
Predicted Removal Efficiency 
in Secondary Clarifier (%) 
0.04 0.05 0.15 0.11 0.19 0.02 
Sum Aeration Basin and 
Secondary Clarifier Removal 
Efficiency (%) 
0.21 0.24 0.68 0.53 0.81 0.11 
Observed Median Removal 
Efficiency (%) 
0.22 0.52 1.00 0.41 0.96 0.00 
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Compound 
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T
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p
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Number of 
Applicable 
Samples 
5 3 5 5 5 5 
Biowin 4 
Value* 
3.5878 3.1927 3.3054 2.8964 3.0508 3.3749 
Half Life (hr) 25.8 64.2 49.5 126.9 89.0 42.2 
Predicted 
Kbiol  
(L gss 
-1
 hr 
-1
) 
0.027 0.011 0.014 0.005 0.008 0.016 
Predicted 
Removal 
Efficiency In 
Aeration 
Basin (%) 
0.37 0.17 0.21 0.09 0.12 0.24 
Predicted 
Removal 
Efficiency in 
Secondary 
Clarifier (%) 
0.10 0.04 0.05 0.02 0.03 0.06 
Sum Aeration 
Basin and 
Secondary 
Clarifier 
Removal 
Efficiency 
(%) 
0.46 0.21 0.26 0.11 0.15 0.30 
Observed 
Median 
Removal 
Efficiency 
(%) 
0.99 0.22 0.10 0.64 0.92 0.02 
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Appendix C: Detection Frequency and Classification of Compounds 
 
Table C1: Detection frequency at five locations with varying proximities to SSWRF, two 
locations in the Milwaukee Harbor, and the average across all seven sampling sites.  
 
SS Outfall 
1 Mile 
East 
1 Mile 
South 
2 Miles 
East 
2 Miles 
South JI Outfall South Gap Average 
 
Detection 
Frequency 
Detection 
Frequency 
Detection 
Frequency 
Detection 
Frequency 
Detection 
Frequency 
Detection 
Frequency 
Detection 
Frequency 
Detection 
Frequency 
Metformin 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
Caffeine   83.3% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 97.6% 
Sulfamethoxazole   83.3% 66.7% 100.0% 66.7% 66.7% 100.0% 100.0% 83.3% 
Triclosan 50.0% 66.7% 50.0% 83.3% 50.0% 100.0% 100.0% 71.4% 
Paraxanthine   50.0% 16.7% 50.0% 16.7% 33.3% 83.3% 66.7% 45.2% 
Carbadox   66.7% 50.0% 50.0% 16.7% 33.3% 33.3% 33.3% 40.5% 
Diphenhydramine   33.3% 33.3% 33.3% 33.3% 33.3% 33.3% 33.3% 33.3% 
4-androstene-3,17-dione 33.3% 50.0% 16.7% 50.0% 20.0% 16.7% 33.3% 31.4% 
Diltiazem   33.3% 16.7% 33.3% 33.3% 16.7% 33.3% 33.3% 28.6% 
Codeine   16.7% 0.0% 33.3% 16.7% 16.7% 50.0% 66.7% 28.6% 
Trimethoprim   16.7% 0.0% 33.3% 0.0% 0.0% 66.7% 66.7% 26.2% 
Acetaminophen   33.3% 16.7% 0.0% 0.0% 16.7% 50.0% 50.0% 23.8% 
Naproxen 33.3% 0.0% 16.7% 0.0% 0.0% 50.0% 66.7% 23.8% 
Azithromycin   0.0% 33.3% 16.7% 33.3% 33.3% 16.7% 33.3% 23.8% 
Roxithromycin   33.3% 16.7% 16.7% 33.3% 16.7% 16.7% 16.7% 21.4% 
Carbamazepine   16.7% 0.0% 0.0% 0.0% 0.0% 66.7% 66.7% 21.4% 
Cotinine   16.7% 16.7% 16.7% 33.3% 16.7% 16.7% 16.7% 19.0% 
Progesterone 33.3% 16.7% 16.7% 16.7% 20.0% 0.0% 0.0% 14.8% 
Testosterone 16.7% 16.7% 16.7% 33.3% 20.0% 0.0% 0.0% 14.8% 
Estriol 0.0% 33.3% 0.0% 33.3% 0.0% 0.0% 33.3% 14.3% 
Triclocarban 16.7% 0.0% 0.0% 0.0% 0.0% 66.7% 0.0% 11.9% 
Fluoxetine   16.7% 0.0% 16.7% 0.0% 0.0% 16.7% 16.7% 9.5% 
17-Beta-estradiol 16.7% 0.0% 0.0% 0.0% 0.0% 0.0% 33.3% 7.1% 
Sulfadiazine   0.0% 0.0% 16.7% 0.0% 0.0% 33.3% 0.0% 7.1% 
Sulfamerazine   0.0% 0.0% 0.0% 0.0% 16.7% 16.7% 16.7% 7.1% 
Albuterol 0.0% 0.0% 16.7% 0.0% 0.0% 20.0% 0.0% 5.2% 
Sulfanilamide   0.0% 0.0% 0.0% 0.0% 0.0% 33.3% 0.0% 4.8% 
Thiabendazole   0.0% 0.0% 0.0% 0.0% 0.0% 33.3% 0.0% 4.8% 
Ranitidine 0.0% 0.0% 0.0% 0.0% 0.0% 20.0% 0.0% 2.9% 
Estrone 0.0% 0.0% 0.0% 0.0% 20.0% 0.0% 0.0% 2.9% 
Ofloxacin   16.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 2.4% 
Oxacillin   0.0% 0.0% 0.0% 16.7% 0.0% 0.0% 0.0% 2.4% 
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Table C2: List of compounds assessed and their general classification  
 Classification 
  
   
17,20-dihydroxyprogesterone Sex Hormone 
17-alpha-estradiol Sex Hormone 
17-beta-estradiol Sex Hormone 
4-androstene-3,17-dione Sex Hormone 
5-alpha-androstane-3,17-dione Anabolic Agent 
Acetaminophen   Antipyretic, Analgesic 
Albuterol Antiasthmatic 
Azithromycin Macrolide Antibiotic 
Boldenone Anabolic Steroid 
Caffeine Stimulant 
Carbadox Quinoxaline Antibiotic 
Carbamazepine   Anticonvulsant 
Cimetidine Anti-acid reflux 
Ciprofloxacin   Quinoline antibiotic 
Clarithromycin   Macrolide antibiotic 
Codeine   Opiate 
Cotinine   Nicotine metabolite 
Digoxigenin   Cardanolide Steroid 
Diltiazem Antihypertensive 
Diphenhydramine Antihistamine 
Estriol Sex Hormone 
Estrone Sex Hormone 
Fluoxetine   SSRI Antidepressant 
Gemfibrozil Antilipemic 
Ibuprofen Analgesic 
Lincomycin   Lincosamide antibiotic 
Lomefloxacin   Quinoline antibiotic 
Melengestrol Steroid Hormone 
Melengestrol Acetate Steroid Hormone 
Metformin Anti-diabetic drug 
Miconazole   Tetracycline antibiotic 
Naproxen NSAIDs 
Norfloxacin   Quinoline antibiotic 
Ofloxacin   Quinoline antibiotic 
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Oxacillin   β-lactam antibiotics 
Paraxanthine   Caffeine Metabolite 
Progesterone Sex Hormone 
Ranitidine Anti-acid reflux 
Roxithromycin Macrolide antibiotic 
Sarafloxacin   Fluoroquinolone antibiotic 
Sulfachloropyridazine   Sulfonamide antibiotic 
Sulfadiazine   Sulfonamide antibiotic 
Sulfadimethoxine   Sulfonamide antibiotic 
Sulfamerazine   Sulfonamide antibiotic 
Sulfamethazine   Sulfonamide antibiotic 
Sulfamethizole   Sulfonamide antibiotic 
Sulfamethoxazole   Sulfonamide antibiotic 
Sulfanilamide   Sulfonamide antibiotic 
Sulfathiazole   Sulfonamide antibiotic 
Testosterone Sex Hormone 
Thiabendazole   Fungicide 
Triclocarban Antimicrobial 
Triclosan Antimicrobial 
Trimethoprim   Pyrimidine antibiotic 
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Appendix D: Supporting information for Chapter 3. All units ng/L.  
Note: Concentration of "0" is equal to below the BDL, it does not mean a concentration of zero.  
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ng/L ng/L ng/L ng/L ng/L ng/L ng/L ng/L 
 
MDL 0.5 1.4 1.3 0.9 2.5 3.7 3.1 3.4 
 
MQL 1.5 4.2 3.8 2.6 7.5 11.0 9.3 10.1 
1 Mile East 5/15/2009 249.8 0.0 0.0 0.0 0.0 12.0 5.0 1.9 
1 Mile East 6/15/2009 142.2 0.0 0.0 0.0 0.0 11.1 29.8 16.7 
1 Mile East 8/18/2009 60.8 0.0 0.0 0.0 0.0 0.0 41.7 0.0 
1 Mile East 10/19/2009 818.2 0.0 0.0 3.7 0.0 0.0 10.0 0.0 
1 Mile East 4/9/2010 160.9 0.0 0.0 0.0 0.0 0.0 23.8 0.0 
1 Mile East 6/15/2010 8.7 0.0 0.0 0.0 0.0 0.0 19.0 0.0 
1 Mile South 5/15/2009 836.0 0.0 0.0 0.0 0.0 12.3 85.5 13.4 
1 Mile South 6/15/2009 130.4 0.0 0.0 0.0 0.0 0.0 42.5 49.0 
1 Mile South 8/18/2009 77.4 0.0 0.0 0.0 0.0 0.0 42.5 0.0 
1 Mile South 10/19/2009 87.8 5.9 0.0 0.0 0.0 0.0 10.8 0.0 
1 Mile South 4/9/2010 258.5 0.0 0.0 0.0 0.0 0.0 17.8 0.0 
1 Mile South 6/15/2010 205.0 0.0 0.0 0.0 0.0 0.0 25.0 6.6 
2 Miles East 5/15/2009 133.6 0.0 0.0 0.0 0.0 6.8 18.6 0.0 
2 Miles East 6/15/2009 122.8 0.0 0.0 0.0 0.0 7.5 34.9 0.0 
2 Miles East 8/18/2009 74.6 0.0 0.0 0.0 0.0 0.0 16.6 0.0 
2 Miles East 10/19/2009 92.6 0.0 0.0 0.0 0.0 0.0 12.0 0.0 
2 Miles East 4/9/2010 126.0 0.0 0.0 0.0 0.0 0.0 18.9 6.0 
2 Miles East 6/15/2010 160.0 0.0 0.0 0.0 0.0 0.0 23.0 0.0 
2 Miles South 5/15/2009 114.0 0.0 0.0 0.0 0.0 11.4 39.3 6.8 
2 Miles South 6/15/2009 155.4 0.0 0.0 0.0 2.5 5.7 22.7 33.5 
2 Miles South 8/18/2009 63.2 0.0 0.0 0.0 0.0 0.0 24.0 0.0 
2 Miles South 10/19/2009 105.2 0.0 0.0 0.0 0.0 0.0 9.2 0.0 
2 Miles South 4/9/2010 
No 
Data 
No 
Data 
No 
Data 
No 
Data 
0.0 0.0 16.7 0.0 
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2 Miles South 6/15/2010 
No 
Data 
No 
Data 
No 
Data 
No 
Data 
0.0 0.0 29.1 0.0 
JI Outfall 5/15/2009 4285.3 0.0 0.0 0.0 72.8 0.0 226.6 0.0 
JI Outfall 6/15/2009 3709.3 0.0 0.0 0.0 15.8 21.7 80.2 22.4 
JI Outfall 8/18/2009 3168.0 0.0 0.0 0.0 0.0 0.0 10.6 0.0 
JI Outfall 10/19/2009 9240.0 4.3 0.0 26.9 0.0 0.0 13.5 0.0 
JI Outfall 4/9/2010 
No 
Data 
No 
Data 
No 
Data 
No 
Data 
13.0 0.0 32.1 0.0 
JI Outfall 6/15/2010 94.3 0.0 0.0 0.0 0.0 0.0 41.7 14.0 
Southgap 5/15/2009 2434.0 0.0 0.0 0.0 44.8 5.7 189.4 5.7 
Southgap 6/15/2009 362.0 0.0 0.0 0.0 19.1 12.3 118.1 0.0 
Southgap 8/18/2009 1192.0 0.0 0.0 0.0 0.0 0.0 15.5 0.0 
Southgap 10/19/2009 688.0 0.0 0.0 0.0 0.0 0.0 19.2 0.0 
Southgap 4/9/2010 776.8 0.0 0.0 0.0 14.1 0.0 46.5 0.0 
Southgap 6/15/2010 1954.0 0.0 0.0 0.0 0.0 0.0 40.0 19.4 
SS Outfall 5/15/2009 2108.0 0.0 0.0 0.0 3.6 0.0 108.3 7.0 
SS Outfall 6/15/2009 331.6 0.0 0.0 0.0 0.0 0.0 54.2 20.1 
SS Outfall 8/18/2009 3752.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 10/19/2009 264.0 0.0 0.0 0.0 0.0 0.0 32.0 0.0 
SS Outfall 4/9/2010 901.8 0.0 0.0 0.0 21.3 0.0 40.2 5.5 
SS Outfall 6/15/2010 12.6 0.0 0.0 0.0 0.0 0.0 26.8 10.6 
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ng/L ng/L ng/L ng/L ng/L ng/L ng/L ng/L ng/L 
 
MDL 2.7 3.3 3.2 3.6 3.5 4.4 3.5 6.1 3.6 
 
MQL 8.2 9.9 9.6 10.7 10.6 13.2 10.4 18.2 10.9 
1 Mile East 5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 4.7 
1 Mile East 6/15/2009 0.0 0.0 0.0 8.7 6.5 0.0 5.5 0.0 6.6 
1 Mile East 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.7 0.0 
1 Mile East 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile East 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile East 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.4 0.0 
1 Mile South 5/15/2009 0.0 0.0 0.0 5.5 5.0 0.0 5.9 39.4 6.6 
1 Mile South 6/15/2009 0.0 0.0 0.0 9.2 0.0 0.0 7.8 0.0 9.2 
1 Mile South 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.8 0.0 
1 Mile South 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 
2 Miles East 5/15/2009 0.0 0.0 0.0 5.4 6.1 0.0 2.0 0.0 4.4 
2 Miles East 6/15/2009 0.0 0.0 0.0 0.0 6.1 0.0 2.3 0.0 4.9 
2 Miles East 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles East 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 0.0 
2 Miles East 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles East 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles 
South 
5/15/2009 0.0 0.0 0.0 0.0 11.3 0.0 1.8 0.0 4.1 
2 Miles 
South 
6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.7 
2 Miles 
South 
8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.0 
2 Miles 
South 
10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles 
South 
4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
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2 Miles 
South 
6/15/2010 0.0 0.0 0.0 7.2 0.0 0.0 0.0 8.7 0.0 
JI Outfall 5/15/2009 24.2 0.0 0.0 10.9 0.0 0.0 16.3 57.0 19.6 
JI Outfall 6/15/2009 38.2 0.0 0.0 0.0 20.4 0.0 21.3 14.6 43.2 
JI Outfall 8/18/2009 14.8 0.0 0.0 0.0 0.0 0.0 0.0 5.5 0.0 
JI Outfall 10/19/2009 12.2 0.0 0.0 0.0 0.0 0.0 0.0 7.4 0.0 
JI Outfall 4/9/2010 0.0 0.0 0.0 9.0 0.0 0.0 0.0 8.2 0.0 
JI Outfall 6/15/2010 0.0 0.0 0.0 6.2 0.0 0.0 0.0 0.0 0.0 
Southgap 5/15/2009 10.2 0.0 0.0 15.0 0.0 0.0 10.0 26.4 9.6 
Southgap 6/15/2009 7.2 0.0 0.0 4.2 20.9 0.0 8.1 44.5 12.1 
Southgap 8/18/2009 17.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 0.0 
Southgap 4/9/2010 0.0 0.0 0.0 7.5 0.0 0.0 0.0 11.9 0.0 
Southgap 6/15/2010 4.2 0.0 0.0 5.4 0.0 0.0 0.0 0.0 0.0 
SS Outfall 5/15/2009 6.2 0.0 0.0 11.2 0.0 0.0 7.2 23.3 10.8 
SS Outfall 6/15/2009 0.0 0.0 0.0 0.0 7.4 0.0 7.9 0.0 13.7 
SS Outfall 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.6 0.0 
SS Outfall 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.5 0.0 
SS Outfall 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
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ng/L ng/L ng/L ng/L ng/L ng/L ng/L ng/L ng/L ng/L ng/L 
 
MDL 3.5 3.1 4.7 2.7 5.1 3.9 2.5 4.3 5.4 4.1 2.8 
 
MQL 10.5 9.3 14.2 8.1 15.3 11.7 7.4 13.0 16.3 12.3 8.5 
1 Mile East 5/15/2009 2.1 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.0 
1 Mile East 6/15/2009 0.0 0.0 0.0 0.0 0.0 20.5 0.0 0.0 0.0 0.0 0.0 
1 Mile East 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile East 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile East 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile East 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.5 0.0 0.0 0.0 
1 Mile South 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 6/15/2010 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 
2 Miles East 5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 17.2 15.1 0.0 0.0 0.0 
2 Miles East 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.7 0.0 0.0 0.0 
2 Miles East 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles East 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles East 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles East 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles South 5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 38.9 0.0 0.0 0.0 
2 Miles South 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles South 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles South 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles South 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
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2 Miles 
South 
6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 6/15/2009 49.3 0.0 0.0 0.0 0.0 0.0 0.0 9.2 0.0 0.0 0.0 
JI Outfall 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 
JI Outfall 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 
Southgap 5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 6/15/2009 61.6 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 
Southgap 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 5/15/2009 1.8 0.0 0.0 0.0 0.0 0.0 0.0 8.7 0.0 0.0 0.0 
SS Outfall 6/15/2009 0.0 0.0 0.0 0.0 0.0 60.7 0.0 3.1 0.0 0.0 0.0 
SS Outfall 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
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2 Miles 
South 
6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 6/15/2009 49.3 0.0 0.0 0.0 0.0 0.0 0.0 9.2 0.0 0.0 0.0 
JI Outfall 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 
JI Outfall 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 
Southgap 5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 6/15/2009 61.6 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 
Southgap 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 5/15/2009 1.8 0.0 0.0 0.0 0.0 0.0 0.0 8.7 0.0 0.0 0.0 
SS Outfall 6/15/2009 0.0 0.0 0.0 0.0 0.0 60.7 0.0 3.1 0.0 0.0 0.0 
SS Outfall 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
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ng/L ng/L ng/L ng/L ng/L ng/L ng/L ng/L ng/L ng/L 
 
MDL 2.4 2.1 4.0 4.2 4.1 2.9 2.6 1.8 3.4 0.5 
 
MQL 7.1 6.2 12.1 12.7 12.4 8.6 7.8 5.3 0.0 1.6 
1 Mile East 5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 
1 Mile East 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile East 8/18/2009 0.0 1.5 0.0 0.0 4.8 0.0 0.0 0.0 0.0 0.0 
1 Mile East 10/19/2009 0.0 0.0 0.0 0.0 6.2 0.0 0.0 0.0 0.0 0.5 
1 Mile East 4/9/2010 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.0 0.0 2.1 
1 Mile East 6/15/2010 0.0 0.0 0.0 0.0 6.2 0.0 0.0 0.0 0.0 1.9 
1 Mile South 5/15/2009 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 16.1 
1 Mile South 6/15/2009 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 6.0 0.0 
1 Mile South 8/18/2009 0.0 0.0 0.0 0.0 4.5 0.0 0.0 0.0 0.0 0.0 
1 Mile South 10/19/2009 0.0 0.0 0.0 0.0 6.3 0.0 0.0 0.0 0.0 0.0 
1 Mile South 4/9/2010 0.0 0.0 0.0 0.0 6.6 0.0 0.0 0.0 0.0 1.3 
1 Mile South 6/15/2010 0.0 0.0 0.0 0.0 7.0 0.0 0.0 0.0 2.8 0.6 
2 Miles East 5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.4 
2 Miles East 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 
2 Miles East 8/18/2009 0.0 0.0 0.0 0.0 5.2 0.0 0.0 0.0 0.0 4.3 
2 Miles East 10/19/2009 0.0 0.0 0.0 0.0 6.4 0.0 0.0 0.0 0.0 0.0 
2 Miles East 4/9/2010 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.0 0.0 1.2 
2 Miles East 6/15/2010 0.0 0.0 0.0 0.0 7.3 0.0 0.0 0.0 0.0 1.7 
2 Miles South 5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.5 
2 Miles South 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles South 8/18/2009 0.0 1.8 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.0 
2 Miles South 10/19/2009 0.0 0.0 0.0 0.0 6.7 0.0 0.0 0.0 0.0 0.0 
2 Miles South 4/9/2010 0.0 0.0 0.0 0.0 7.7 0.0 0.0 0.0 0.0 1.2 
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2 Miles South 6/15/2010 0.0 0.0 0.0 0.0 10.0 0.0 0.0 0.0 0.0 0.9 
JI Outfall 5/15/2009 0.0 1.3 0.0 0.0 21.5 0.0 0.0 1.3 34.8 24.1 
JI Outfall 6/15/2009 0.0 0.0 0.0 0.0 77.1 0.0 0.0 0.9 52.4 11.6 
JI Outfall 8/18/2009 0.0 0.0 0.0 0.0 33.6 20.3 0.0 0.0 0.0 5.5 
JI Outfall 10/19/2009 0.0 0.0 0.0 0.0 21.5 17.7 0.0 0.0 0.0 0.7 
JI Outfall 4/9/2010 0.0 0.0 0.0 0.0 7.7 0.0 0.0 0.0 5.4 2.2 
JI Outfall 6/15/2010 0.0 0.0 0.0 0.0 14.5 0.0 0.0 0.0 7.3 2.3 
Southgap 5/15/2009 0.0 0.0 0.0 0.0 15.8 0.0 0.0 0.0 12.5 5.0 
Southgap 6/15/2009 0.0 0.0 0.0 0.0 30.3 0.0 0.0 0.0 13.4 11.1 
Southgap 8/18/2009 0.0 3.6 0.0 0.0 11.9 0.0 0.0 0.0 0.0 5.8 
Southgap 10/19/2009 0.0 0.0 0.0 0.0 13.2 0.0 0.0 0.0 0.0 1.4 
Southgap 4/9/2010 0.0 0.0 0.0 0.0 8.0 0.0 0.0 0.0 6.5 3.3 
Southgap 6/15/2010 0.0 0.0 0.0 0.0 13.8 0.0 0.0 0.0 9.1 3.3 
SS Outfall 5/15/2009 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 3.4 41.5 
SS Outfall 6/15/2009 0.0 0.0 0.0 0.0 13.6 0.0 0.0 0.0 0.0 13.8 
SS Outfall 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 10/19/2009 0.0 0.0 0.0 0.0 9.9 0.0 0.0 0.0 0.0 0.0 
SS Outfall 4/9/2010 0.0 0.0 0.0 0.0 7.0 0.0 0.0 0.0 0.0 4.2 
SS Outfall 6/15/2010 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.0 0.0 0.0 
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ng/L ng/L ng/L ng/L ng/L ng/L ng/L ng/L 
 
MDL 0.5 1.0 1.6 4.7 2.0 2.2 1.3 1.1 
 
MQL 1.4 2.9 4.8 14.0 6.1 6.7 3.8 3.2 
1 Mile East 5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.5 
1 Mile East 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile East 8/18/2009 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile East 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile East 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile East 6/15/2010 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.0 
1 Mile South 5/15/2009 0.0 15.3 0.0 0.0 0.0 0.0 0.0 9.1 
1 Mile South 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles East 5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 38.0 
2 Miles East 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 
2 Miles East 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles East 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles East 4/9/2010 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 
2 Miles East 6/15/2010 0.0 0.0 0.0 0.0 5.0 0.0 0.0 0.0 
2 Miles 
South 
5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.0 
2 Miles 
South 
6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles 
South 
8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles 
South 
10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles 
South 
4/9/2010 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 
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2 Miles 
South 
6/15/2010 0.0 0.0 
No 
Data 
No 
Data 
No 
Data 
No 
Data 
No 
Data 
No 
Data 
JI Outfall 5/15/2009 6.3 30.8 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 6/15/2009 9.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 8/18/2009 4.3 13.8 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 10/19/2009 2.8 5.9 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 5/15/2009 0.0 18.1 0.0 0.0 0.0 0.0 1.3 0.0 
Southgap 6/15/2009 0.0 5.0 0.0 0.0 0.0 0.0 0.8 0.0 
Southgap 8/18/2009 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 10/19/2009 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 4/9/2010 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 
Southgap 6/15/2010 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 
SS Outfall 5/15/2009 15.7 18.8 0.0 0.0 0.0 0.0 1.7 13.2 
SS Outfall 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 4/9/2010 0.0 10.6 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
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ng/L ng/L ng/L ng/L ng/L ng/L ng/L ng/L 
 
MDL 2.3 0.5 0.7 1.4 1.3 1.3 0.6 1.2 
 
MQL 6.9 1.4 2.0 4.2 4.0 4.0 1.7 3.5 
1 Mile East 5/15/2009 0.0 2.0 4.9 0.0 0.0 0.0 0.0 0.0 
1 Mile East 6/15/2009 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 
1 Mile East 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile East 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile East 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile East 6/15/2010 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 5/15/2009 0.0 5.3 8.7 0.0 0.0 0.0 0.0 0.0 
1 Mile South 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
1 Mile South 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles East 5/15/2009 0.0 16.6 88.2 0.0 0.0 0.0 0.0 0.0 
2 Miles East 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles East 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles East 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles East 4/9/2010 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles East 6/15/2010 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles South 5/15/2009 0.0 3.5 13.1 0.0 0.0 0.0 0.0 0.0 
2 Miles South 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles South 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles South 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 Miles South 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
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2 Miles 
South 
6/15/2010 
No 
Data 
No 
Data 
No 
Data 
No 
Data 
No 
Data 
No 
Data 
No 
Data 
No 
Data 
JI Outfall 5/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 4/9/2010 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 
JI Outfall 6/15/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 5/15/2009 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 6/15/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Southgap 6/15/2010 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 5/15/2009 0.0 7.3 11.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 6/15/2009 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 
SS Outfall 8/18/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 10/19/2009 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 4/9/2010 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
SS Outfall 6/15/2010 0.0 577.6 0.0 0.0 0.0 0.0 0.0 0.0 
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Appendix E: Supporting Data for Chapter 4 
Type Compound 
Concentration or 
Removal Cite 
Influent Concentration 
(ng/L) Acetaminophen 61000.00 Benotti et al., 2007 
Influent Concentration 
(ng/L) Acetaminophen 26000.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Acetaminophen 150000.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Acetaminophen 12000.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Acetaminophen 14000.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Acetaminophen 5900.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Acetaminophen 22000.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Acetaminophen 56944.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Acetaminophen 34021.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Acetaminophen 18729.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Acetaminophen 22325.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Acetaminophen 48097.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Acetaminophen 25461.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Acetaminophen 22706.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Acetaminophen 13046.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Acetaminophen 18286.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Acetaminophen 28756.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Acetaminophen 23407.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Acetaminophen 13284.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Acetaminophen 
29000.00 Gómez et al., 2007   
Influent Concentration 
(ng/L) Acetaminophen 
246000.00 Gómez et al., 2007   
Influent Concentration 
(ng/L) Acetaminophen 134000.00 
Gómez et al., 2007   
Influent Concentration 
(ng/L) Acetaminophen 
68107.00 
Kasprzyk-Hordern et al., 
2009  
Influent Concentration 
(ng/L) Acetaminophen 
482687.00 
Kasprzyk-Hordern et al., 
2009  
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Influent Concentration 
(ng/L) Acetaminophen 
10400.00 Khan and Ongerth, 2005   
Influent Concentration 
(ng/L) Acetaminophen 
710.00 
Radjenovic et al., 2009 
Influent Concentration 
(ng/L) Acetaminophen 
1140.00 
Radjenovic et al., 2009 
Influent Concentration 
(ng/L) Acetaminophen 
5529.00 
Roberts and Thomas, 
2006   
Influent Concentration 
(ng/L) Acetaminophen 6924.00 
Roberts and Thomas, 
2006   
Influent Concentration 
(ng/L) Acetaminophen 69570.00 
Roberts and Thomas, 
2006   
Influent Concentration 
(ng/L) Acetaminophen 
23202.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Acetaminophen 37458.00 
Rosal et al., 2010  
Influent Concentration 
(ng/L) Acetaminophen 1571.00 
Rosal et al., 2010  
Influent Concentration 
(ng/L) Acetaminophen 
17200.00 Snyder et al., 2006  
Influent Concentration 
(ng/L) Acetaminophen 
960.00 Yu et al., 2006 
MBR Removal Acetaminophen 1.00 Kim et al., 2007 
MBR Removal Acetaminophen 1.00 Kim et al., 2007 
MBR Removal Acetaminophen 1.00 Radjenovic et al., 2007 
MBR Removal Acetaminophen 1.00 Radjenovic et al., 2009 
MBR Removal Acetaminophen 0.99 Radjenovic et al., 2009 
MBR Removal Acetaminophen 1.00 Snyder et al., 2007 
Microfiltration Removal Acetaminophen 0.04 Snyder et al., 2007 
Nanofiltration Removal Acetaminophen 0.13 Chon et al., 2012 
Nanofiltration Removal Acetaminophen 0.16 Chon et al., 2012 
Nanofiltration Removal Acetaminophen 0.31 Chon et al., 2012 
Nanofiltration Removal Acetaminophen 1.00 Kim et al., 2007 
Primary + CAS Removal Acetaminophen 1.00 Blair et al., 2013 
Primary + CAS Removal Acetaminophen 1.00 Blair et al., 2013 
Primary + CAS Removal Acetaminophen 1.00 Blair et al., 2013 
Primary + CAS Removal Acetaminophen 1.00 Blair et al., 2013 
Primary + CAS Removal Acetaminophen 0.00 Blair et al., 2013 
Primary + CAS Removal Acetaminophen 1.00 Choi et al., 2008 
Primary + CAS Removal Acetaminophen 1.00 Choi et al., 2008 
Primary + CAS Removal Acetaminophen 1.00 Choi et al., 2008 
Primary + CAS Removal Acetaminophen 1.00 Choi et al., 2008 
Primary + CAS Removal Acetaminophen 1.00 Choi et al., 2008 
Primary + CAS Removal Acetaminophen 1.00 Choi et al., 2008 
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Primary + CAS Removal Acetaminophen 1.00 Choi et al., 2008 
Primary + CAS Removal Acetaminophen 1.00 Choi et al., 2008 
Primary + CAS Removal Acetaminophen 1.00 Choi et al., 2008 
Primary + CAS Removal Acetaminophen 1.00 Choi et al., 2008 
Primary + CAS Removal Acetaminophen 1.00 Choi et al., 2008 
Primary + CAS Removal Acetaminophen 1.00 Choi et al., 2008 
Primary + CAS Removal Acetaminophen 1.00 Gómez et al., 2007   
Primary + CAS Removal Acetaminophen 0.87 Jones et al., 2007   
Primary + CAS Removal Acetaminophen 0.94 Jones et al., 2007   
Primary + CAS Removal Acetaminophen 0.95 Jones et al., 2007   
Primary + CAS Removal Acetaminophen 0.94 Jones et al., 2007   
Primary + CAS Removal Acetaminophen 0.94 
Kasprzyk-Hordern et al., 
2009  
Primary + CAS Removal Acetaminophen 1.00 Khan and Ongerth, 2005   
Primary + CAS Removal Acetaminophen 0.98 Radjenovic et al., 2007 
Primary + CAS Removal Acetaminophen 1.00 Radjenovic et al., 2009   
Primary + CAS Removal Acetaminophen 
1.00 
Roberts and Thomas, 
2006   
Primary + CAS Removal Acetaminophen 1.00 Rosal et al., 2010  
Primary + CAS Removal Acetaminophen 1.00 Yu et al., 2006 
Ultrafiltration Removal Acetaminophen 0.06 Snyder et al., 2007 
Influent Concentration 
(ng/L) Caffeine 42000.00 Benotti et al., 2007 
Influent Concentration 
(ng/L) Caffeine 34000.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Caffeine 130000.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Caffeine 9400.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Caffeine 9000.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Caffeine 3300.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Caffeine 8800.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Caffeine 36856.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Caffeine 30615.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Caffeine 18405.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Caffeine 9750.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Caffeine 33821.00 
Choi et al., 2008 
161 
 
 
 
Influent Concentration 
(ng/L) Caffeine 21070.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Caffeine 18706.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Caffeine 14313.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Caffeine 24236.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Caffeine 20750.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Caffeine 29491.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Caffeine 25758.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Caffeine 118000.00 
Gómez et al., 2007   
Influent Concentration 
(ng/L) Caffeine 52000.00 
Gómez et al., 2007   
Influent Concentration 
(ng/L) Caffeine 192000.00 
Gómez et al., 2007   
Influent Concentration 
(ng/L) Caffeine 65625.00 Rosal et al., 2010 
Influent Concentration 
(ng/L) Caffeine 5010.00 Rosal et al., 2010 
Influent Concentration 
(ng/L) Caffeine 22849.00 Rosal et al., 2010 
Influent Concentration 
(ng/L) Caffeine 2170.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Caffeine 2510.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Caffeine 680.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Caffeine 750.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Caffeine 220.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Caffeine 6100.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Caffeine 6000.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Caffeine 11440.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Caffeine 9260.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Caffeine 3840.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Caffeine 2870.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Caffeine 2340.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Caffeine 7370.00 Santos et al., 2009   
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Influent Concentration 
(ng/L) Caffeine 2330.00 Santos et al., 2009 
Influent Concentration 
(ng/L) Caffeine 27900.00 Santos et al., 2009 
Influent Concentration 
(ng/L) Caffeine 4870.00 Santos et al., 2009 
Influent Concentration 
(ng/L) Caffeine 540.00 Santos et al., 2009 
Influent Concentration 
(ng/L) Caffeine 2610.00 Santos et al., 2009 
Influent Concentration 
(ng/L) Caffeine 7090.00 Santos et al., 2009 
Influent Concentration 
(ng/L) Caffeine 750.00 Santos et al., 2009 
Influent Concentration 
(ng/L) Caffeine 43900.00 Santos et al., 2009 
Influent Concentration 
(ng/L) Caffeine 5340.00 Santos et al., 2009 
Influent Concentration 
(ng/L) Caffeine 220.00 Santos et al., 2009 
Influent Concentration 
(ng/L) Caffeine 22000.00 Santos et al., 2009 
Influent Concentration 
(ng/L) Caffeine 2448.00 
Spongberg and Witter, 
2008 
Influent Concentration 
(ng/L) Caffeine 4865.00 
Spongberg and Witter, 
2008 
Influent Concentration 
(ng/L) Caffeine 2769.00 
Spongberg and Witter, 
2008 
Influent Concentration 
(ng/L) Caffeine 628.00 Yu and Chu, 2009   
MBR Removal Caffeine 0.99 Kim et al., 2007 
MBR Removal Caffeine 0.99 Kim et al., 2007 
MBR Removal Caffeine 1.00 Snyder et al., 2007 
MBR Removal Caffeine 1.00 Snyder et al., 2007 
Microfiltration Removal Caffeine 0.00 Snyder et al., 2007 
Nanofiltration Removal Caffeine 1.00 Kim et al., 2007 
Primary + CAS Removal Caffeine 0.64 Benotti et al., 2007 
Primary + CAS Removal Caffeine 0.97 Blair et al., 2013 
Primary + CAS Removal Caffeine 0.99 Blair et al., 2013 
Primary + CAS Removal Caffeine 1.00 Blair et al., 2013 
Primary + CAS Removal Caffeine 0.98 Blair et al., 2013 
Primary + CAS Removal Caffeine 0.11 Blair et al., 2013 
Primary + CAS Removal Caffeine 0.98 Choi et al., 2008 
Primary + CAS Removal Caffeine 0.97 Choi et al., 2008 
Primary + CAS Removal Caffeine 0.99 Choi et al., 2008 
Primary + CAS Removal Caffeine 1.00 Choi et al., 2008 
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Primary + CAS Removal Caffeine 0.98 Choi et al., 2008 
Primary + CAS Removal Caffeine 0.99 Choi et al., 2008 
Primary + CAS Removal Caffeine 1.00 Choi et al., 2008 
Primary + CAS Removal Caffeine 0.97 Choi et al., 2008 
Primary + CAS Removal Caffeine 1.00 Choi et al., 2008 
Primary + CAS Removal Caffeine 0.99 Choi et al., 2008 
Primary + CAS Removal Caffeine 0.99 Choi et al., 2008 
Primary + CAS Removal Caffeine 1.00 Choi et al., 2008 
Primary + CAS Removal Caffeine 0.90 Gómez et al., 2007   
Primary + CAS Removal Caffeine 0.43 Santos et al., 2007 
Primary + CAS Removal Caffeine 0.85 Santos et al., 2007 
Primary + CAS Removal Caffeine 0.73 Santos et al., 2007 
Primary + CAS Removal Caffeine 0.50 Santos et al., 2007 
Primary + CAS Removal Caffeine 0.78 Santos et al., 2009 
Primary + CAS Removal Caffeine 0.50 Santos et al., 2009 
Primary + CAS Removal Caffeine 0.76 Santos et al., 2009 
Primary + CAS Removal Caffeine 0.57 Santos et al., 2009 
Primary + CAS Removal Caffeine 
1.00 
Spongberg and Witter, 
2008 
Primary + CAS Removal Caffeine 1.00 
Spongberg and Witter, 
2008 
Primary + CAS Removal Caffeine 
0.99 
Spongberg and Witter, 
2008 
Primary + CAS Removal Caffeine 0.86 Yu and Chu, 2009   
Ultrafiltration Removal Caffeine 0.07 Snyder et al., 2007 
Influent Concentration 
(ng/L) Carbamazepine   
1680.00 Bendz et al., 2005  
Influent Concentration 
(ng/L) Carbamazepine   
100.00 
Benotti et al., 2007 
Influent Concentration 
(ng/L) Carbamazepine   230.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Carbamazepine   310.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Carbamazepine   73.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Carbamazepine   51.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Carbamazepine   21.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Carbamazepine   72.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Carbamazepine   
13.00 Choi et al., 2008 
Influent Concentration 
(ng/L) Carbamazepine   201.00 
Choi et al., 2008 
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Influent Concentration 
(ng/L) Carbamazepine   203.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Carbamazepine   0.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Carbamazepine   451.00 
Choi et al., 2008 
Influent Concentration 
(ng/L) Carbamazepine   242.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Carbamazepine   0.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Carbamazepine   156.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Carbamazepine   223.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Carbamazepine   6.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Carbamazepine   283.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Carbamazepine   29.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Carbamazepine   
325.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Carbamazepine   
670.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Carbamazepine   
704.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Carbamazepine   
1200.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Carbamazepine   1850.00 
Clara et al., 2005a 
Influent Concentration 
(ng/L) Carbamazepine   
120.00 Gómez et al., 2007  
Influent Concentration 
(ng/L) Carbamazepine   
150.00 Gómez et al., 2007  
Influent Concentration 
(ng/L) Carbamazepine   
310.00 Gómez et al., 2007  
Influent Concentration 
(ng/L) Carbamazepine   
104.00 
Kasprzyk-Hordern et al., 
2009  
Influent Concentration 
(ng/L) Carbamazepine   
3110.00 
Kasprzyk-Hordern et al., 
2009  
Influent Concentration 
(ng/L) Carbamazepine   
500.00 Khan and Ongerth, 2005  
Influent Concentration 
(ng/L) Carbamazepine   
32.00 Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   
24.00 Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   119.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   16.50 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   270.00 
Nakada et al., 2006  
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Influent Concentration 
(ng/L) Carbamazepine   116.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   51.40 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   52.10 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   248.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   60.50 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   80.40 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   100.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   56.20 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   14.90 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   16.70 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   48.50 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Carbamazepine   
54.00 Radjenovic et al., 2009   
Influent Concentration 
(ng/L) Carbamazepine   
220.00 Radjenovic et al., 2009   
Influent Concentration 
(ng/L) Carbamazepine   156.00 
Radjenovic et al., 2009   
Influent Concentration 
(ng/L) Carbamazepine   
106.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Carbamazepine   
173.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Carbamazepine   129.00 
Rosal et al., 2010  
Influent Concentration 
(ng/L) Carbamazepine   120.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Carbamazepine   0.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Carbamazepine   0.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Carbamazepine   0.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Carbamazepine   940.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Carbamazepine   1380.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Carbamazepine   2150.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Carbamazepine   280.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Carbamazepine   300.00 Santos et al., 2007 
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Influent Concentration 
(ng/L) Carbamazepine   290.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Carbamazepine   360.00 Santos et al., 2007 
Influent Concentration 
(ng/L) Carbamazepine   
0.00 Santos et al., 2009  
Influent Concentration 
(ng/L) Carbamazepine   
3780.00 Santos et al., 2009  
Influent Concentration 
(ng/L) Carbamazepine   530.00 
Santos et al., 2009  
Influent Concentration 
(ng/L) Carbamazepine   39.30 
Spongberg and Witter, 
2008 
Influent Concentration 
(ng/L) Carbamazepine   50.90 
Spongberg and Witter, 
2008 
Influent Concentration 
(ng/L) Carbamazepine   24.80 
Spongberg and Witter, 
2008 
Influent Concentration 
(ng/L) Carbamazepine   
660.00 Wick et al, 2009 
Influent Concentration 
(ng/L) Carbamazepine   1662.00 Zhou et al., 2009 
Influent Concentration 
(ng/L) Carbamazepine   1237.00 Zhou et al., 2009 
Influent Concentration 
(ng/L) Carbamazepine   1833.00 Zhou et al., 2009 
MBR Removal Carbamazepine   0.12 Clara et al, 2005b 
MBR Removal Carbamazepine   0.04 Clara et al, 2005b 
MBR Removal Carbamazepine   0.00 Clara et al, 2005b 
MBR Removal Carbamazepine   0.05 Clara et al., 2005a 
MBR Removal Carbamazepine   0.00 Kim et al., 2007 
MBR Removal Carbamazepine   0.00 Kim et al., 2007 
MBR Removal Carbamazepine   0.00 Snyder et al., 2007 
MBR Removal Carbamazepine   0.95 Snyder et al., 2007 
Microfiltration Removal Carbamazepine   0.11 Snyder et al., 2007 
Nanofiltration Removal Carbamazepine   0.41 Chon et al., 2012 
Nanofiltration Removal Carbamazepine   0.72 Chon et al., 2012 
Nanofiltration Removal Carbamazepine   0.82 Chon et al., 2012 
Nanofiltration Removal Carbamazepine   0.98 Kim et al., 2007 
Primary + CAS Removal Carbamazepine   0.30 Bendz et al., 2005   
Primary + CAS Removal Carbamazepine   0.37 Benotti et al., 2007 
Primary + CAS Removal Carbamazepine   0.26 Blair et al., 2013 
Primary + CAS Removal Carbamazepine   0.45 Blair et al., 2013 
Primary + CAS Removal Carbamazepine   0.00 Blair et al., 2013 
Primary + CAS Removal Carbamazepine   0.00 Blair et al., 2013 
Primary + CAS Removal Carbamazepine   0.18 Blair et al., 2013 
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Primary + CAS Removal Carbamazepine   0.54 Choi et al., 2008  
Primary + CAS Removal Carbamazepine   0.43 Choi et al., 2008  
Primary + CAS Removal Carbamazepine   0.47 Choi et al., 2008  
Primary + CAS Removal Carbamazepine   0.65 Choi et al., 2008  
Primary + CAS Removal Carbamazepine   0.57 Choi et al., 2008  
Primary + CAS Removal Carbamazepine   0.01 Choi et al., 2008  
Primary + CAS Removal Carbamazepine   0.46 Choi et al., 2008  
Primary + CAS Removal Carbamazepine   0.00 Choi et al., 2008  
Primary + CAS Removal Carbamazepine   0.50 Choi et al., 2008  
Primary + CAS Removal Carbamazepine   0.00 Choi et al., 2008  
Primary + CAS Removal Carbamazepine   0.00 Clara et al, 2005b 
Primary + CAS Removal Carbamazepine   0.00 Clara et al, 2005b 
Primary + CAS Removal Carbamazepine   0.00 Clara et al, 2005b 
Primary + CAS Removal Carbamazepine   0.14 Clara et al, 2005b 
Primary + CAS Removal Carbamazepine   0.00 Clara et al, 2005b 
Primary + CAS Removal Carbamazepine   0.00 Clara et al, 2005b 
Primary + CAS Removal Carbamazepine   0.00 Clara et al., 2005a 
Primary + CAS Removal Carbamazepine   0.00 Clara et al., 2005a 
Primary + CAS Removal Carbamazepine   0.00 Clara et al., 2005a 
Primary + CAS Removal Carbamazepine   0.13 Gómez et al., 2007   
Primary + CAS Removal Carbamazepine   
0.13 
Kasprzyk-Hordern et al., 
2009  
Primary + CAS Removal Carbamazepine   0.57 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.00 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.00 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.00 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.03 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.00 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.00 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.00 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.00 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.78 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.00 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.47 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.40 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.00 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.24 Nakada et al., 2006 
Primary + CAS Removal Carbamazepine   0.40 Nakada et al., 2006 
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Primary + CAS Removal Carbamazepine   0.00 Santos et al., 2007 
Primary + CAS Removal Carbamazepine   0.00 Santos et al., 2007 
Primary + CAS Removal Carbamazepine   0.00 Santos et al., 2007 
Primary + CAS Removal Carbamazepine   0.00 Santos et al., 2007 
Primary + CAS Removal Carbamazepine   0.00 Santos et al., 2009 
Primary + CAS Removal Carbamazepine   0.00 Santos et al., 2009 
Primary + CAS Removal Carbamazepine   0.00 Santos et al., 2009 
Primary + CAS Removal Carbamazepine   0.00 Santos et al., 2009 
Primary + CAS Removal Carbamazepine   
0.00 
Spongberg and Witter, 
2008 
Primary + CAS Removal Carbamazepine   
0.00 
Spongberg and Witter, 
2008 
Primary + CAS Removal Carbamazepine   
0.00 
Spongberg and Witter, 
2008 
Primary + CAS Removal Carbamazepine   0.07 Suarez et al., 2005  
Primary + CAS Removal Carbamazepine   0.00 Vieno et al., 2007 
Primary + CAS Removal Carbamazepine   0.43 Zhou et al., 2009 
Primary + CAS Removal Carbamazepine   0.49 Zhou et al., 2009 
Primary + CAS Removal Carbamazepine   0.54 Zhou et al., 2009 
Ultrafiltration Removal Carbamazepine   0.16 Snyder et al., 2007 
Ultrafiltration Removal Carbamazepine   0.13 Snyder et al., 2006  
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 15.80 Anderson et al., 2003 
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 54.00 Clara et al, 2005b 
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 82.00 Clara et al, 2005b 
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 125.00 Clara et al, 2005b 
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 24.50 Clara et al., 2005b 
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 67.00 Clara et al., 2005b 
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 46.00 Clara et al., 2005b 
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 4.90 Joss et al., 2004   
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 7.60 Joss et al., 2004   
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 11.00 Joss et al., 2004   
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 14.10 Nakada et al.,  2006  
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 13.30 Nakada et al.,  2006  
Influent Concentration Estradiol (17B -   20.60 Nakada et al.,  2006  
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(ng/L) E2) 
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 25.80 Nakada et al.,  2006  
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 22.90 Nakada et al.,  2006  
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 20.00 Thomas et al., 2007 
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 44.00 Thomas et al., 2007 
Influent Concentration 
(ng/L) 
Estradiol (17B -   
E2) 3.00 Thomas et al., 2007 
MBR Removal 
Estradiol (17B -   
E2) 
1.00 
Clara et al, 2005b 
MBR Removal 
Estradiol (17B -   
E2) 
0.96 
Clara et al, 2005b 
MBR Removal 
Estradiol (17B -   
E2) 
0.95 
Clara et al, 2005b 
MBR Removal 
Estradiol (17B -   
E2) 
0.92 
Joss et al., 2004   
Microfiltration Removal 
Estradiol (17B -   
E2) 
0.00 
Snyder et al., 2007 
Nanofiltration Removal 
Estradiol (17B -   
E2) 
0.52 
Yoon et al., 2006 
Primary + CAS Removal 
Estradiol (17B -   
E2) 
0.94 
Anderson et al., 2003 
Primary + CAS Removal 
Estradiol (17B -   
E2) 
0.96 
Clara et al, 2005b 
Primary + CAS Removal 
Estradiol (17B -   
E2) 
0.95 
Clara et al, 2005b 
Primary + CAS Removal 
Estradiol (17B -   
E2) 
1.00 
Clara et al, 2005b 
Primary + CAS Removal 
Estradiol (17B -   
E2) 
0.80 
Clara et al., 2005b 
Primary + CAS Removal 
Estradiol (17B -   
E2) 
0.93 
Clara et al., 2005b 
Primary + CAS Removal 
Estradiol (17B -   
E2) 
0.89 
Clara et al., 2005b 
Primary + CAS Removal 
Estradiol (17B -   
E2) 
0.80 
Joss et al., 2004   
Primary + CAS Removal 
Estradiol (17B -   
E2) 
0.93 
Joss et al., 2004   
Primary + CAS Removal 
Estradiol (17B -   
E2) 
0.95 
Joss et al., 2004   
Primary + CAS Removal 
Estradiol (17B -   
E2) 
0.84 
Nakada et al., 2006 
Primary + CAS Removal 
Estradiol (17B -   
E2) 0.84 Nakada et al., 2006 
Primary + CAS Removal 
Estradiol (17B -   
E2) 
0.90 
Nakada et al., 2006 
Primary + CAS Removal 
Estradiol (17B -   
E2) 
0.85 
Thomas et al., 2007 
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Primary + CAS Removal 
Estradiol (17B -   
E2) 0.22 Zorita et al., 2009  
Ultrafiltration Removal 
Estradiol (17B -   
E2) 
0.99 
Snyder et al., 2007 
Ultrafiltration Removal 
Estradiol (17B -   
E2) 
0.95 
Yoon et al., 2006 
Influent Concentration 
(ng/L) Estriol (E3) 0.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Estriol (E3) 10.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Estriol (E3) 0.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Estriol (E3) 0.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Estriol (E3) 22.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Estriol (E3) 336.00 Clara et al, 2005b 
Influent Concentration 
(ng/L) Estriol (E3) 23.50 Clara et al, 2005b 
Influent Concentration 
(ng/L) Estriol (E3) 143.00 Clara et al, 2005b 
Influent Concentration 
(ng/L) Estriol (E3) 372.00 Clara et al, 2005b 
Influent Concentration 
(ng/L) Estriol (E3) 660.00 Clara et al., 2005b 
Influent Concentration 
(ng/L) Estriol (E3) 326.00 Clara et al., 2005b 
Influent Concentration 
(ng/L) Estriol (E3) 129.00 Nakada et al., 2006 
Influent Concentration 
(ng/L) Estriol (E3) 225.00 Nakada et al., 2006 
Influent Concentration 
(ng/L) Estriol (E3) 137.00 Nakada et al., 2006 
Influent Concentration 
(ng/L) Estriol (E3) 92.60 Nakada et al., 2006 
Influent Concentration 
(ng/L) Estriol (E3) 83.00 Nakada et al., 2006 
Influent Concentration 
(ng/L) Estriol (E3) 128.00 Thomas et al., 2007 
Influent Concentration 
(ng/L) Estriol (E3) 54.00 Thomas et al., 2007 
Influent Concentration 
(ng/L) Estriol (E3) 237.00 Thomas et al., 2007 
MBR Removal Estriol (E3) 1.00 Clara et al, 2005b 
MBR Removal Estriol (E3) 1.00 Clara et al, 2005b 
MBR Removal Estriol (E3) 1.00 Clara et al, 2005b 
MBR Removal Estriol (E3) 0.97 Kim et al., 2007 
MBR Removal Estriol (E3) 0.97 Kim et al., 2007 
MBR Removal Estriol (E3) 0.99 Snyder et al., 2007 
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Microfiltration Removal Estriol (E3) 0.00 Snyder et al., 2007 
Nanofiltration Removal Estriol (E3) 0.98 Kim et al., 2007 
Primary + CAS Removal Estriol (E3) 0.18 Clara et al, 2005b 
Primary + CAS Removal Estriol (E3) 0.28 Clara et al, 2005b 
Primary + CAS Removal Estriol (E3) 0.99 Clara et al, 2005b 
Primary + CAS Removal Estriol (E3) 1.00 Clara et al, 2005b 
Primary + CAS Removal Estriol (E3) 1.00 Clara et al., 2005b 
Primary + CAS Removal Estriol (E3) 1.00 Clara et al., 2005b 
Primary + CAS Removal Estriol (E3) 1.00 Nakada et al., 2006 
Primary + CAS Removal Estriol (E3) 1.00 Nakada et al., 2006 
Primary + CAS Removal Estriol (E3) 1.00 Nakada et al., 2006 
Primary + CAS Removal Estriol (E3) 0.98 Thomas et al., 2007 
Ultrafiltration Removal Estriol (E3) 0.41 Snyder et al., 2007 
Influent Concentration 
(ng/L) Gemfibrozil 
710.00 Bendz et al., 2005  
Influent Concentration 
(ng/L) Gemfibrozil 29.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Gemfibrozil 150.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Gemfibrozil 200.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Gemfibrozil 97.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Gemfibrozil 510.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Gemfibrozil 1200.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Gemfibrozil 
1500.00 Khan and Ongerth, 2005  
Influent Concentration 
(ng/L) Gemfibrozil 
453.00 Lishman et al., 2006  
Influent Concentration 
(ng/L) Gemfibrozil 
2000.00 Radjenovic et al., 2009  
Influent Concentration 
(ng/L) Gemfibrozil 
5900.00 Radjenovic et al., 2009  
Influent Concentration 
(ng/L) Gemfibrozil 3080.00 
Radjenovic et al., 2009  
Influent Concentration 
(ng/L) Gemfibrozil 
415.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Gemfibrozil 
3525.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Gemfibrozil 
415.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Gemfibrozil 181.80 
Spongberg and Witter, 
2008 
Influent Concentration 
(ng/L) Gemfibrozil 450.20 
Spongberg and Witter, 
2008 
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Influent Concentration 
(ng/L) Gemfibrozil 451.30 
Spongberg and Witter, 
2008 
Influent Concentration 
(ng/L) Gemfibrozil 
410.00 Yu et al., 2006 
MBR Removal Gemfibrozil 0.42 Radjenovic et al., 2009 
MBR Removal Gemfibrozil 0.33 Radjenovic et al., 2009 
MBR Removal Gemfibrozil 0.86 Snyder et al., 2007  
MBR Removal Gemfibrozil 0.89 Snyder et al., 2007  
Microfiltration Removal Gemfibrozil 0.00 Snyder et al., 2007 
Nanofiltration Removal Gemfibrozil 0.50 Yoon et al., 2006 
Primary + CAS Removal Gemfibrozil 0.75 Bendz et al., 2005   
Primary + CAS Removal Gemfibrozil 0.00 Blair et al., 2013 
Primary + CAS Removal Gemfibrozil 0.43 Blair et al., 2013 
Primary + CAS Removal Gemfibrozil 0.00 Blair et al., 2013 
Primary + CAS Removal Gemfibrozil 0.00 Blair et al., 2013 
Primary + CAS Removal Gemfibrozil 0.08 Blair et al., 2013 
Primary + CAS Removal Gemfibrozil 0.85 Khan and Ongerth, 2005  
Primary + CAS Removal Gemfibrozil 0.96 Lee et al., 2003 
Primary + CAS Removal Gemfibrozil 0.27 Lee et al., 2003 
Primary + CAS Removal Gemfibrozil 0.28 Lee et al., 2003 
Primary + CAS Removal Gemfibrozil 0.25 Lee et al., 2003 
Primary + CAS Removal Gemfibrozil 0.24 Lee et al., 2003 
Primary + CAS Removal Gemfibrozil 0.00 Lee et al., 2003 
Primary + CAS Removal Gemfibrozil 0.41 Lee et al., 2003 
Primary + CAS Removal Gemfibrozil 0.00 Lee et al., 2003 
Primary + CAS Removal Gemfibrozil 0.46 Lishman et al., 2006   
Primary + CAS Removal Gemfibrozil 1.00 
Spongberg and Witter, 
2008 
Primary + CAS Removal Gemfibrozil 
0.91 
Spongberg and Witter, 
2008 
Primary + CAS Removal Gemfibrozil 
0.81 
Spongberg and Witter, 
2008 
Primary + CAS Removal Gemfibrozil 0.68 Yu et al., 2006  
Ultrafiltration Removal Gemfibrozil 0.00 Snyder et al., 2007 
Ultrafiltration Removal Gemfibrozil 0.21 Snyder et al., 2006 
Ultrafiltration Removal Gemfibrozil 0.00 Yoon et al., 2006 
Influent Concentration 
(ng/L) Ibuprofen 
3590.00 Bendz et al., 2005   
Influent Concentration 
(ng/L) Ibuprofen 
3590.00 Bendz et al., 2005   
Influent Concentration 
(ng/L) Ibuprofen 3000.00 
Blair et al., 2013 
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Influent Concentration 
(ng/L) Ibuprofen 11000.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Ibuprofen 1300.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Ibuprofen 840.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Ibuprofen 670.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Ibuprofen 4800.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Ibuprofen 
2750.00 Carballa et al., 2004 
Influent Concentration 
(ng/L) Ibuprofen 
5700.00 Carballa et al., 2004 
Influent Concentration 
(ng/L) Ibuprofen 
2640.00 Carballa et al., 2004 
Influent Concentration 
(ng/L) Ibuprofen 
1480.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Ibuprofen 
2679.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Ibuprofen 
2448.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Ibuprofen 
2300.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Ibuprofen 
1200.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Ibuprofen 
34000.00 Gómez et al., 2007  
Influent Concentration 
(ng/L) Ibuprofen 
84000.00 Gómez et al., 2007  
Influent Concentration 
(ng/L) Ibuprofen 168000.00 
Gómez et al., 2007  
Influent Concentration 
(ng/L) Ibuprofen 
984.00 
Kasprzyk-Hordern et al., 
2009  
Influent Concentration 
(ng/L) Ibuprofen 
6328.00 
Kasprzyk-Hordern et al., 
2009  
Influent Concentration 
(ng/L) Ibuprofen 
2700.00 Khan and Ongerth, 2005   
Influent Concentration 
(ng/L) Ibuprofen 
40.00 Kimura et al., 2007   
Influent Concentration 
(ng/L) Ibuprofen 
8840.00 Lishman et al., 2006 
Influent Concentration 
(ng/L) Ibuprofen 
8450.00 Lishman et al., 2006   
Influent Concentration 
(ng/L) Ibuprofen 
1050.00 Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 
694.00 Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 706.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 746.00 
Nakada et al., 2006  
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Influent Concentration 
(ng/L) Ibuprofen 545.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 806.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 513.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 479.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 748.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 1130.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 756.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 636.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 381.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 650.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 407.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 452.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Ibuprofen 
5700.00 Quintana et al., 2005   
Influent Concentration 
(ng/L) Ibuprofen 
14600.00 Radjenovic et al., 2009  
Influent Concentration 
(ng/L) Ibuprofen 
31300.00 Radjenovic et al., 2009  
Influent Concentration 
(ng/L) Ibuprofen 
33764.00 
Roberts and Thomas, 
2006   
Influent Concentration 
(ng/L) Ibuprofen 27979.00 
Roberts and Thomas, 
2006   
Influent Concentration 
(ng/L) Ibuprofen 7741.00 
Roberts and Thomas, 
2006   
Influent Concentration 
(ng/L) Ibuprofen 0.00 
Rosal et al., 2010 
Influent Concentration 
(ng/L) Ibuprofen 
2687.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Ibuprofen 0.00 
Rosal et al., 2010  
Influent Concentration 
(ng/L) Ibuprofen 
4113.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Ibuprofen 
4113.00 Rosal et al., 2010   
Influent Concentration 
(ng/L) Ibuprofen 
2687.00 Rosal et al., 2010   
Influent Concentration 
(ng/L) Ibuprofen 
0.00 Rosal et al., 2010   
Influent Concentration 
(ng/L) Ibuprofen 
115000.00 Santos et al., 2009 
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Influent Concentration 
(ng/L) Ibuprofen 
603000.00 Santos et al., 2009 
Influent Concentration 
(ng/L) Ibuprofen 0.00 
Santos et al., 2009 
Influent Concentration 
(ng/L) Ibuprofen 294000.00 
Santos et al., 2009 
Influent Concentration 
(ng/L) Ibuprofen 84400.00 
Santos et al., 2009 
Influent Concentration 
(ng/L) Ibuprofen 0.00 
Santos et al., 2009 
Influent Concentration 
(ng/L) Ibuprofen 105000.00 
Santos et al., 2009 
Influent Concentration 
(ng/L) Ibuprofen 319000.00 
Santos et al., 2009 
Influent Concentration 
(ng/L) Ibuprofen 0.00 
Santos et al., 2009 
Influent Concentration 
(ng/L) Ibuprofen 
12130.00 Santos et al., 2007, 
Influent Concentration 
(ng/L) Ibuprofen 
373110.00 Santos et al., 2007, 
Influent Concentration 
(ng/L) Ibuprofen 
3730.00 Santos et al., 2009   
Influent Concentration 
(ng/L) Ibuprofen 
69700.00 Santos et al., 2009   
Influent Concentration 
(ng/L) Ibuprofen 
353000.00 Santos et al., 2009   
Influent Concentration 
(ng/L) Ibuprofen 
10800.00 Thomas and Foster, 2005  
Influent Concentration 
(ng/L) Ibuprofen 
9500.00 Thomas and Foster, 2005  
Influent Concentration 
(ng/L) Ibuprofen 
14700.00 Thomas and Foster, 2005  
Influent Concentration 
(ng/L) Ibuprofen 178.00 Thomas et al., 2007 
Influent Concentration 
(ng/L) Ibuprofen 
6900.00 Zorita et al., 2009 
MBR Removal Ibuprofen 0.99 Clara et al, 2005b 
MBR Removal Ibuprofen 0.99 Clara et al, 2005b 
MBR Removal Ibuprofen 0.97 Clara et al, 2005b 
MBR Removal Ibuprofen 0.98 Clara et al., 2005a 
MBR Removal Ibuprofen 0.99 Kim et al., 2007 
MBR Removal Ibuprofen 0.98 Kim et al., 2007 
MBR Removal Ibuprofen 0.95 Kimura et al, 2007 
MBR Removal Ibuprofen 0.98 Kimura et al, 2007 
MBR Removal Ibuprofen 0.97 Quintana et al., 2005   
MBR Removal Ibuprofen 0.99 Radjenovic et al., 2009 
MBR Removal Ibuprofen 1.00 Radjenovic et al., 2009 
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MBR Removal Ibuprofen 1.00 Snyder et al., 2007 
MBR Removal Ibuprofen 0.00 Snyder et al., 2007 
Microfiltration Removal Ibuprofen 0.55 Snyder et al., 2007 
Nanofiltration Removal Ibuprofen 1.00 Kim et al., 2007 
Primary + CAS Removal Ibuprofen 0.96 Bendz et al., 2005   
Primary + CAS Removal Ibuprofen 1.00 Blair et al., 2013 
Primary + CAS Removal Ibuprofen 1.00 Blair et al., 2013 
Primary + CAS Removal Ibuprofen 0.84 Blair et al., 2013 
Primary + CAS Removal Ibuprofen 1.00 Blair et al., 2013 
Primary + CAS Removal Ibuprofen 0.17 Blair et al., 2013 
Primary + CAS Removal Ibuprofen 1.00 Buser et al., 1999   
Primary + CAS Removal Ibuprofen 0.99 Buser et al., 1999   
Primary + CAS Removal Ibuprofen 0.96 Buser et al., 1999   
Primary + CAS Removal Ibuprofen 0.63 Carballa et al., 2004 
Primary + CAS Removal Ibuprofen 0.63 Carballa et al., 2004 
Primary + CAS Removal Ibuprofen 0.67 Carballa et al., 2004 
Primary + CAS Removal Ibuprofen 0.00 Clara et al, 2005b 
Primary + CAS Removal Ibuprofen 0.92 Clara et al, 2005b 
Primary + CAS Removal Ibuprofen 0.98 Clara et al, 2005b 
Primary + CAS Removal Ibuprofen 0.99 Clara et al, 2005b 
Primary + CAS Removal Ibuprofen 0.99 Clara et al, 2005b 
Primary + CAS Removal Ibuprofen 0.99 Clara et al, 2005b 
Primary + CAS Removal Ibuprofen 0.99 Clara et al., 2005a 
Primary + CAS Removal Ibuprofen 0.00 Clara et al., 2005a 
Primary + CAS Removal Ibuprofen 0.98 Clara et al., 2005a 
Primary + CAS Removal Ibuprofen 0.92 Gómez et al., 2007   
Primary + CAS Removal Ibuprofen 
0.94 
Kasprzyk-Hordern et al., 
2009  
Primary + CAS Removal Ibuprofen 0.97 Khan and Ongerth, 2005  
Primary + CAS Removal Ibuprofen 0.98 Kimura et al, 2007 
Primary + CAS Removal Ibuprofen 1.00 Lee et al., 2003 
Primary + CAS Removal Ibuprofen 0.83 Lee et al., 2003 
Primary + CAS Removal Ibuprofen 0.88 Lee et al., 2003 
Primary + CAS Removal Ibuprofen 0.80 Lee et al., 2003 
Primary + CAS Removal Ibuprofen 0.99 Lee et al., 2003 
Primary + CAS Removal Ibuprofen 0.85 Lee et al., 2003 
Primary + CAS Removal Ibuprofen 0.98 Lee et al., 2003 
Primary + CAS Removal Ibuprofen 0.84 Lee et al., 2003 
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Primary + CAS Removal Ibuprofen 0.94 Lee et al., 2003 
Primary + CAS Removal Ibuprofen 0.95 Lishman et al., 2006   
Primary + CAS Removal Ibuprofen 0.92 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.90 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.96 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.84 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.97 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.96 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.94 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.96 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.99 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 1.00 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.99 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.93 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.97 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 1.00 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.99 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.99 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.99 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.00 Nakada et al., 2006 
Primary + CAS Removal Ibuprofen 0.88 Santos et al., 2007 
Primary + CAS Removal Ibuprofen 0.90 Santos et al., 2007 
Primary + CAS Removal Ibuprofen 0.92 Santos et al., 2007 
Primary + CAS Removal Ibuprofen 0.99 Santos et al., 2007 
Primary + CAS Removal Ibuprofen 0.94 Santos et al., 2009 
Primary + CAS Removal Ibuprofen 0.92 Santos et al., 2009 
Primary + CAS Removal Ibuprofen 0.90 Santos et al., 2009 
Primary + CAS Removal Ibuprofen 0.93 Santos et al., 2009 
Primary + CAS Removal Ibuprofen 0.82 Suarez et al., 2005 
Primary + CAS Removal Ibuprofen 0.65 Thomas et al., 2007 
Primary + CAS Removal Ibuprofen 0.72 Yu and Chu, 2009   
Primary + CAS Removal Ibuprofen 0.76 Yu and Chu, 2009   
Primary + CAS Removal Ibuprofen 0.87 Yu et al., 2006  
Primary + CAS Removal Ibuprofen 0.99 Zorita et al., 2009  
Ultrafiltration Removal Ibuprofen 0.08 Snyder et al., 2007 
Influent Concentration 
(ng/L) Naproxen 
3650.00 Bendz et al., 2005  
Influent Concentration 
(ng/L) Naproxen 4200.00 
Blair et al., 2013 
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Influent Concentration 
(ng/L) Naproxen 9400.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Naproxen 2900.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Naproxen 1800.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Naproxen 780.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Naproxen 3100.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Naproxen 
1790.00 Carballa et al., 2004 
Influent Concentration 
(ng/L) Naproxen 
4600.00 Carballa et al., 2004 
Influent Concentration 
(ng/L) Naproxen 3450.00 
Carballa et al., 2004 
Influent Concentration 
(ng/L) Naproxen 
620.00 
Kasprzyk-Hordern et al., 
2009   
Influent Concentration 
(ng/L) Naproxen 
3504.00 
Kasprzyk-Hordern et al., 
2009   
Influent Concentration 
(ng/L) Naproxen 
6500.00 Khan and Ongerth, 2005   
Influent Concentration 
(ng/L) Naproxen 
276.00 Kimura et al., 2007   
Influent Concentration 
(ng/L) Naproxen 
5580.00 Lishman et al., 2006   
Influent Concentration 
(ng/L) Naproxen 38.00 Nakada et al.,  2006  
Influent Concentration 
(ng/L) Naproxen 
100.00 Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 
230.00 Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 162.00 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 103.00 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 230.00 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 80.60 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 173.00 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 138.00 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 97.60 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 61.00 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 145.00 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 164.00 
Nakada et al., 2006   
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Influent Concentration 
(ng/L) Naproxen 116.00 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 68.30 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 89.40 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 72.60 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 54.60 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 38.00 
Nakada et al., 2006   
Influent Concentration 
(ng/L) Naproxen 
130.00 Radjenovic et al., 2009   
Influent Concentration 
(ng/L) Naproxen 
670.00 Radjenovic et al., 2009   
Influent Concentration 
(ng/L) Naproxen 463.00 
Radjenovic et al., 2009   
Influent Concentration 
(ng/L) Naproxen 
1196.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Naproxen 
5228.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Naproxen 2363.00 
Rosal et al., 2010  
Influent Concentration 
(ng/L) Naproxen 2020.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Naproxen 2050.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Naproxen 1600.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Naproxen 1100.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Naproxen 7230.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Naproxen 26640.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Naproxen 27400.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Naproxen 9100.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Naproxen 4040.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Naproxen 11140.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Naproxen 5180.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Naproxen 5070.00 
Santos et al., 2007 
Influent Concentration 
(ng/L) Naproxen 
10000.00 Suárez et al., 2005   
Influent Concentration 
(ng/L) Naproxen 
10300.00 Thomas and Foster, 2005  
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Influent Concentration 
(ng/L) Naproxen 
12800.00 Thomas and Foster, 2005  
Influent Concentration 
(ng/L) Naproxen 11700.00 
Thomas and Foster, 2005  
Influent Concentration 
(ng/L) Naproxen 
3200.00 Yu et al., 2006  
Influent Concentration 
(ng/L) Naproxen 
4900.00 Zorita et al., 2009 
MBR Removal Naproxen 0.36 Kim et al., 2007 
MBR Removal Naproxen 0.41 Kim et al., 2007 
MBR Removal Naproxen 0.96 Kimura et al, 2007 
MBR Removal Naproxen 0.96 Kimura et al, 2007 
MBR Removal Naproxen 0.72 Quintana et al., 2005   
MBR Removal Naproxen 0.91 Radjenovic et al., 2009 
MBR Removal Naproxen 0.92 Radjenovic et al., 2009 
MBR Removal Naproxen 0.96 Snyder et al., 2007 
MBR Removal Naproxen 1.00 Snyder et al., 2007 
Microfiltration Removal Naproxen 0.00 Snyder et al., 2007 
Nanofiltration Removal Naproxen 0.44 Chon et al., 2012 
Nanofiltration Removal Naproxen 1.00 Chon et al., 2012 
Nanofiltration Removal Naproxen 1.00 Chon et al., 2012 
Nanofiltration Removal Naproxen 1.00 Kim et al., 2007 
Primary + CAS Removal Naproxen 0.93 Bendz et al., 2005   
Primary + CAS Removal Naproxen 0.88 Blair et al., 2013 
Primary + CAS Removal Naproxen 0.94 Blair et al., 2013 
Primary + CAS Removal Naproxen 0.96 Blair et al., 2013 
Primary + CAS Removal Naproxen 0.98 Blair et al., 2013 
Primary + CAS Removal Naproxen 0.00 Blair et al., 2013 
Primary + CAS Removal Naproxen 0.55 Carballa et al., 2004 
Primary + CAS Removal Naproxen 0.43 Carballa et al., 2004 
Primary + CAS Removal Naproxen 0.46 Carballa et al., 2004 
Primary + CAS Removal Naproxen 0.58 Hollender et al., 2009 
Primary + CAS Removal Naproxen 0.86 
Kasprzyk-Hordern et al., 
2009  
Primary + CAS Removal Naproxen 0.95 Khan and Ongerth, 2005   
Primary + CAS Removal Naproxen 0.64 Kimura et al, 2007 
Primary + CAS Removal Naproxen 0.51 Lee et al., 2003 
Primary + CAS Removal Naproxen 0.92 Lee et al., 2003 
Primary + CAS Removal Naproxen 0.62 Lee et al., 2003 
Primary + CAS Removal Naproxen 0.49 Lee et al., 2003 
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Primary + CAS Removal Naproxen 0.42 Lee et al., 2003 
Primary + CAS Removal Naproxen 0.72 Lee et al., 2003 
Primary + CAS Removal Naproxen 0.84 Lee et al., 2003 
Primary + CAS Removal Naproxen 0.68 Lee et al., 2003 
Primary + CAS Removal Naproxen 0.75 Lee et al., 2003 
Primary + CAS Removal Naproxen 0.92 Lishman et al., 2006   
Primary + CAS Removal Naproxen 0.59 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.65 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.00 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.95 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.72 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.34 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.65 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.63 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.20 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.23 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.49 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.37 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.15 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.23 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.47 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.68 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.00 Nakada et al., 2006   
Primary + CAS Removal Naproxen 0.89 Nakada et al., 2006 
Primary + CAS Removal Naproxen 0.89 Santos et al., 2007 
Primary + CAS Removal Naproxen 0.35 Santos et al., 2007 
Primary + CAS Removal Naproxen 0.65 Santos et al., 2007 
Primary + CAS Removal Naproxen 0.61 Santos et al., 2007 
Primary + CAS Removal Naproxen 0.43 Santos et al., 2009   
Primary + CAS Removal Naproxen 0.80 Santos et al., 2009 
Primary + CAS Removal Naproxen 0.54 Santos et al., 2009 
Primary + CAS Removal Naproxen 0.61 Santos et al., 2009 
Primary + CAS Removal Naproxen 0.68 Suárez et al., 2005   
Primary + CAS Removal Naproxen 0.88 Yu et al.,  2006 
Primary + CAS Removal Naproxen 0.93 Zorita et al., 2009  
Ultrafiltration Removal Naproxen 0.13 Snyder et al., 2007 
Ultrafiltration Removal Naproxen 0.24 Snyder et al., 2006  
Influent Concentration Sulfamethoxazole 20.00 Bendz et al., 2005  
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(ng/L) 
Influent Concentration 
(ng/L) Sulfamethoxazole 
360.00 Benotti et al., 2007 
Influent Concentration 
(ng/L) Sulfamethoxazole 210.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Sulfamethoxazole 1200.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Sulfamethoxazole 110.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Sulfamethoxazole 120.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Sulfamethoxazole 54.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Sulfamethoxazole 170.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Sulfamethoxazole 
390.00 Brown et al., 2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 310.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 1000.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 0.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 0.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 0.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 0.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 400.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 0.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 
0.00 Carballa et al., 2004 
Influent Concentration 
(ng/L) Sulfamethoxazole 
0.00 Carballa et al., 2004 
Influent Concentration 
(ng/L) Sulfamethoxazole 
580.00 Carballa et al., 2004 
Influent Concentration 
(ng/L) Sulfamethoxazole 
381.00 Choi et al., 2008  
Influent Concentration 
(ng/L) Sulfamethoxazole 
316.00 Choi et al., 2008  
Influent Concentration 
(ng/L) Sulfamethoxazole 984.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Sulfamethoxazole 300.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Sulfamethoxazole 611.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Sulfamethoxazole 660.00 
Choi et al., 2008  
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Influent Concentration 
(ng/L) Sulfamethoxazole 156.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Sulfamethoxazole 221.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Sulfamethoxazole 849.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Sulfamethoxazole 263.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Sulfamethoxazole 652.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Sulfamethoxazole 877.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Sulfamethoxazole 
145.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Sulfamethoxazole 
0.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Sulfamethoxazole 
0.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Sulfamethoxazole 
0.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Sulfamethoxazole 
78.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Sulfamethoxazole 
25.00 Clara et al., 2005a 
Influent Concentration 
(ng/L) Sulfamethoxazole 159.00 
Ghosh et al., 2009  
Influent Concentration 
(ng/L) Sulfamethoxazole 184.00 
Ghosh et al., 2009  
Influent Concentration 
(ng/L) Sulfamethoxazole 177.00 
Ghosh et al., 2009  
Influent Concentration 
(ng/L) Sulfamethoxazole 
230.00 
Gobel et al., 2005 
Influent Concentration 
(ng/L) Sulfamethoxazole 
430.00 Gobel et al., 2005 
Influent Concentration 
(ng/L) Sulfamethoxazole 570.00 Gobel et al., 2005 
Influent Concentration 
(ng/L) Sulfamethoxazole 
1250.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 
170.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 560.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 130.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 350.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 450.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 250.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Sulfamethoxazole 
20.00 
Kasprzyk-Hordern et al., 
2009  
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Influent Concentration 
(ng/L) Sulfamethoxazole 
274.00 
Kasprzyk-Hordern et al., 
2009  
Influent Concentration 
(ng/L) Sulfamethoxazole 
674.00 Lindberg et al., 2005 
Influent Concentration 
(ng/L) Sulfamethoxazole 144.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Sulfamethoxazole 0.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Sulfamethoxazole 0.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Sulfamethoxazole 0.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Sulfamethoxazole 231.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Sulfamethoxazole 337.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Sulfamethoxazole 0.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Sulfamethoxazole 302.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Sulfamethoxazole 0.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Sulfamethoxazole 
250.00 Radjenovic et al., 2009  
Influent Concentration 
(ng/L) Sulfamethoxazole 
1300.00 Radjenovic et al., 2009  
Influent Concentration 
(ng/L) Sulfamethoxazole 93.00 
Radjenovic et al., 2009  
Influent Concentration 
(ng/L) Sulfamethoxazole 
279.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Sulfamethoxazole 
162.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Sulfamethoxazole 
530.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Sulfamethoxazole 261.00 
Spongberg and Witter, 
2008 
Influent Concentration 
(ng/L) Sulfamethoxazole 158.70 
Spongberg and Witter, 
2008 
Influent Concentration 
(ng/L) Sulfamethoxazole 13.50 
Spongberg and Witter, 
2008 
Influent Concentration 
(ng/L) Sulfamethoxazole 125.00 Thomas et al., 2007 
Influent Concentration 
(ng/L) Sulfamethoxazole 
360.00 Watkinson et al., 2007  
Influent Concentration 
(ng/L) Sulfamethoxazole 250.00 
Watkinson et al., 2009  
Influent Concentration 
(ng/L) Sulfamethoxazole 
16.00 Xu et al., 2007 
Influent Concentration 
(ng/L) Sulfamethoxazole 118.00 Xu et al., 2007 
Influent Concentration 
(ng/L) Sulfamethoxazole 10.00 Xu et al., 2007 
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Influent Concentration 
(ng/L) Sulfamethoxazole 25.00 Xu et al., 2007 
Influent Concentration 
(ng/L) Sulfamethoxazole 49.00 Zhou et al., 2009 
Influent Concentration 
(ng/L) Sulfamethoxazole 110.00 Zhou et al., 2009 
Influent Concentration 
(ng/L) Sulfamethoxazole 181.00 Zhou et al., 2009 
MBR Removal Sulfamethoxazole 0.64 Kim et al., 2007 
MBR Removal Sulfamethoxazole 0.70 Kim et al., 2007 
MBR Removal Sulfamethoxazole 0.81 Radjenovic et al., 2009 
MBR Removal Sulfamethoxazole 0.78 Radjenovic et al., 2009 
MBR Removal Sulfamethoxazole 0.00 Snyder et al., 2007 
MBR Removal Sulfamethoxazole 0.57 Snyder et al., 2007 
Microfiltration Removal Sulfamethoxazole 0.00 Snyder et al., 2007 
Microfiltration Removal Sulfamethoxazole 
 
Watkinson et al., 2007 
Nanofiltration Removal Sulfamethoxazole 0.38 Chon et al., 2012 
Nanofiltration Removal Sulfamethoxazole 0.46 Chon et al., 2012 
Nanofiltration Removal Sulfamethoxazole 0.73 Chon et al., 2012 
Nanofiltration Removal Sulfamethoxazole 0.99 Kim et al., 2007 
Primary + CAS Removal Sulfamethoxazole 0.75 Batt et al., 2007   
Primary + CAS Removal Sulfamethoxazole 0.77 Batt et al., 2007   
Primary + CAS Removal Sulfamethoxazole 0.36 Batt et al., 2007   
Primary + CAS Removal Sulfamethoxazole 0.36 Batt et al., 2007   
Primary + CAS Removal Sulfamethoxazole 0.00 Bendz et al., 2005   
Primary + CAS Removal Sulfamethoxazole 0.61 Benotti et al., 2007 
Primary + CAS Removal Sulfamethoxazole 0.00 Blair et al., 2013 
Primary + CAS Removal Sulfamethoxazole 0.75 Blair et al., 2013 
Primary + CAS Removal Sulfamethoxazole 0.39 Blair et al., 2013 
Primary + CAS Removal Sulfamethoxazole 0.37 Blair et al., 2013 
Primary + CAS Removal Sulfamethoxazole 0.66 Blair et al., 2013 
Primary + CAS Removal Sulfamethoxazole 0.57 Carballa et al., 2004 
Primary + CAS Removal Sulfamethoxazole 0.83 Choi et al., 2008  
Primary + CAS Removal Sulfamethoxazole 0.43 Choi et al., 2008  
Primary + CAS Removal Sulfamethoxazole 0.80 Choi et al., 2008  
Primary + CAS Removal Sulfamethoxazole 0.92 Choi et al., 2008  
Primary + CAS Removal Sulfamethoxazole 0.70 Choi et al., 2008  
Primary + CAS Removal Sulfamethoxazole 0.58 Choi et al., 2008  
Primary + CAS Removal Sulfamethoxazole 0.80 Choi et al., 2008  
Primary + CAS Removal Sulfamethoxazole 0.33 Choi et al., 2008  
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Primary + CAS Removal Sulfamethoxazole 0.63 Choi et al., 2008  
Primary + CAS Removal Sulfamethoxazole 0.17 Choi et al., 2008  
Primary + CAS Removal Sulfamethoxazole 0.72 Choi et al., 2008  
Primary + CAS Removal Sulfamethoxazole 0.44 Choi et al., 2008  
Primary + CAS Removal Sulfamethoxazole 0.35 Gobel et al., 2005 
Primary + CAS Removal Sulfamethoxazole 0.00 Gobel et al., 2007 
Primary + CAS Removal Sulfamethoxazole 0.09 Gobel et al., 2007 
Primary + CAS Removal Sulfamethoxazole 0.00 Gobel et al., 2007 
Primary + CAS Removal Sulfamethoxazole 0.00 Gobel et al., 2007 
Primary + CAS Removal Sulfamethoxazole 0.60 Gobel et al., 2007 
Primary + CAS Removal Sulfamethoxazole 0.83 
Kasprzyk-Hordern et al., 
2009  
Primary + CAS Removal Sulfamethoxazole 0.62 Nakada et al., 2006 
Primary + CAS Removal Sulfamethoxazole 0.00 
Spongberg and Witter, 
2008 
Primary + CAS Removal Sulfamethoxazole 0.00 
Spongberg and Witter, 
2008 
Primary + CAS Removal Sulfamethoxazole 0.00 
Spongberg and Witter, 
2008 
Primary + CAS Removal Sulfamethoxazole 0.61 Thomas et al., 2007 
Primary + CAS Removal Sulfamethoxazole 0.80 Watkinson et al., 2009  
Primary + CAS Removal Sulfamethoxazole 0.00 Xu et al., 2007 
Primary + CAS Removal Sulfamethoxazole 0.00 Xu et al., 2007 
Primary + CAS Removal Sulfamethoxazole 0.53 Zhou et al., 2009 
Primary + CAS Removal Sulfamethoxazole 0.66 Zhou et al., 2009 
Primary + CAS Removal Sulfamethoxazole 0.82 Zhou et al., 2009 
Ultrafiltration Removal Sulfamethoxazole 0.05 Snyder et al., 2007 
Ultrafiltration Removal Sulfamethoxazole 0.14 Snyder et al., 2006 
Influent Concentration 
(ng/L) Triclosan 
380.00 Bendz et al., 2005  
Influent Concentration 
(ng/L) Triclosan 4300.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Triclosan 9100.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Triclosan 89.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Triclosan 130.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Triclosan 610.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Triclosan 680.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Triclosan 
390.00 Gómez et al., 2007  
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Influent Concentration 
(ng/L) Triclosan 
4200.00 Gómez et al., 2007  
Influent Concentration 
(ng/L) Triclosan 1800.00 
Gómez et al., 2007  
Influent Concentration 
(ng/L) Triclosan 1930.00 
Lishman et al., 2006   
Influent Concentration 
(ng/L) Triclosan 
5210.00 McAvoy et al., 2002  
Influent Concentration 
(ng/L) Triclosan 3830.00 
McAvoy et al., 2002  
Influent Concentration 
(ng/L) Triclosan 16600.00 
McAvoy et al., 2002  
Influent Concentration 
(ng/L) Triclosan 15400.00 
McAvoy et al., 2002  
Influent Concentration 
(ng/L) Triclosan 10700.00 
McAvoy et al., 2002  
Influent Concentration 
(ng/L) Triclosan 618.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Triclosan 620.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Triclosan 978.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Triclosan 518.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Triclosan 803.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Triclosan 1020.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Triclosan 541.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Triclosan 352.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Triclosan 387.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Triclosan 404.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Triclosan 434.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Triclosan 219.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Triclosan 262.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Triclosan 346.00 
Nakada et al., 2006  
Influent Concentration 
(ng/L) Triclosan 
381.00 
Nakada et al., 2006 
Influent Concentration 
(ng/L) Triclosan 
296.00 
Nakada et al., 2006 
Influent Concentration 
(ng/L) Triclosan 
860.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Triclosan 
0.00 Rosal et al., 2010  
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Influent Concentration 
(ng/L) Triclosan 
2417.00 Rosal et al., 2010  
Influent Concentration 
(ng/L) Triclosan 
450.00 Ruel et al., 2010  
Influent Concentration 
(ng/L) Triclosan 
3000.00 Thomas and Foster, 2005  
Influent Concentration 
(ng/L) Triclosan 
3600.00 Thomas and Foster, 2005  
Influent Concentration 
(ng/L) Triclosan 3300.00 
Thomas and Foster, 2005  
Influent Concentration 
(ng/L) Triclosan 
800.00 Yu et al., 2006 
MBR Removal Triclosan 0.66 Kim et al., 2007 
MBR Removal Triclosan 0.73 Kim et al., 2007 
MBR Removal Triclosan 0.96 Snyder et al., 2007 
MBR Removal Triclosan 0.76 Snyder et al., 2007 
Microfiltration Removal Triclosan 0.00 Snyder et al., 2007 
Nanofiltration Removal Triclosan 0.99 Kim et al., 2007 
Primary + CAS Removal Triclosan 0.58 Bendz et al., 2005  
Primary + CAS Removal Triclosan 0.97 Blair et al., 2013 
Primary + CAS Removal Triclosan 0.99 Blair et al., 2013 
Primary + CAS Removal Triclosan 0.73 Blair et al., 2013 
Primary + CAS Removal Triclosan 0.75 Blair et al., 2013 
Primary + CAS Removal Triclosan 0.49 Blair et al., 2013 
Primary + CAS Removal Triclosan 0.89 Gómez et al., 2007   
Primary + CAS Removal Triclosan 0.60 Lee et al., 2003 
Primary + CAS Removal Triclosan 0.99 Lee et al., 2003 
Primary + CAS Removal Triclosan 0.73 Lee et al., 2003 
Primary + CAS Removal Triclosan 0.69 Lee et al., 2003 
Primary + CAS Removal Triclosan 0.84 Lee et al., 2003 
Primary + CAS Removal Triclosan 0.83 Lee et al., 2003 
Primary + CAS Removal Triclosan 0.84 Lee et al., 2003 
Primary + CAS Removal Triclosan 0.47 Lee et al., 2003 
Primary + CAS Removal Triclosan 0.94 Lee et al., 2003 
Primary + CAS Removal Triclosan 0.94 Lishman et al., 2006   
Primary + CAS Removal Triclosan 0.46 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.57 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.62 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.00 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.79 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.76 Nakada et al., 2006 
189 
 
 
 
Primary + CAS Removal Triclosan 0.52 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.70 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.93 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.98 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.86 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.77 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.66 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.59 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.91 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.75 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.50 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.70 Nakada et al., 2006 
Primary + CAS Removal Triclosan 0.72 Yu and Chu, 2009   
Primary + CAS Removal Triclosan 0.79 Yu and Chu, 2009   
Primary + CAS Removal Triclosan 0.69 Yu et al., 2006  
Ultrafiltration Removal Triclosan 0.88 Snyder et al., 2007 
Ultrafiltration Removal Triclosan 0.00 Snyder et al., 2006 
Influent Concentration 
(ng/L) Trimethoprim 
80.00 Bendz et al., 2005  
Influent Concentration 
(ng/L) Trimethoprim 
300.00 Benotti et al., 2007 
Influent Concentration 
(ng/L) Trimethoprim 220.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Trimethoprim 590.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Trimethoprim 36.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Trimethoprim 52.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Trimethoprim 18.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Trimethoprim 45.00 
Blair et al., 2013 
Influent Concentration 
(ng/L) Trimethoprim 
590.00 Brown et al., 2006  
Influent Concentration 
(ng/L) Trimethoprim 180.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Trimethoprim 1400.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Trimethoprim 0.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Trimethoprim 0.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Trimethoprim 0.00 
Brown et al., 2006  
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Influent Concentration 
(ng/L) Trimethoprim 0.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Trimethoprim 1000.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Trimethoprim 0.00 
Brown et al., 2006  
Influent Concentration 
(ng/L) Trimethoprim 
275.00 Choi et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 135.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 45.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 81.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 496.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 84.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 19.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 97.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 0.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 125.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 401.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 104.00 
Choi et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 
26.00 Ghosh et al., 2009  
Influent Concentration 
(ng/L) Trimethoprim 
106.00 Ghosh et al., 2009  
Influent Concentration 
(ng/L) Trimethoprim 89.00 
Ghosh et al., 2009  
Influent Concentration 
(ng/L) Trimethoprim 
210.00 Göbel et al., 2005 
Influent Concentration 
(ng/L) Trimethoprim 
440.00 
Gobel et al., 2005 
Influent Concentration 
(ng/L) Trimethoprim 290.00 
Gobel et al., 2005 
Influent Concentration 
(ng/L) Trimethoprim 
120.00 Gulkowska et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 
120.00 Gulkowska et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 320.00 
Gulkowska et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 210.00 
Gulkowska et al., 2008  
Influent Concentration 
(ng/L) Trimethoprim 200.00 
Gulkowska et al., 2008  
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Influent Concentration 
(ng/L) Trimethoprim 
1100.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Trimethoprim 
210.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Trimethoprim 580.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Trimethoprim 140.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Trimethoprim 1300.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Trimethoprim 300.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Trimethoprim 50.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Trimethoprim 700.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Trimethoprim 120.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Trimethoprim 350.00 
Karthikeyan and Meyer, 
2006  
Influent Concentration 
(ng/L) Trimethoprim 
1514.00 
Kasprzyk-Hordern et al., 
2009  
Influent Concentration 
(ng/L) Trimethoprim 
4673.00 
Kasprzyk-Hordern et al., 
2009  
Influent Concentration 
(ng/L) Trimethoprim 
140.00 Lindberg et al., 2005 
Influent Concentration 
(ng/L) Trimethoprim 
364.00 Lindberg et al., 2005 
Influent Concentration 
(ng/L) Trimethoprim 208.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Trimethoprim 172.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Trimethoprim 99.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Trimethoprim 651.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Trimethoprim 1300.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Trimethoprim 548.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Trimethoprim 946.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Trimethoprim 251.00 
Lindberg et al., 2005 
Influent Concentration 
(ng/L) Trimethoprim 
150.00 Radjenovic et al., 2009  
Influent Concentration 
(ng/L) Trimethoprim 
430.00 Radjenovic et al., 2009  
Influent Concentration 
(ng/L) Trimethoprim 204.00 
Radjenovic et al., 2009  
Influent Concentration 
(ng/L) Trimethoprim 
213.00 
Roberts and Thomas, 
2006  
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Influent Concentration 
(ng/L) Trimethoprim 
263.00 
Roberts and Thomas, 
2006  
Influent Concentration 
(ng/L) Trimethoprim 
213.00 
Roberts and Thomas, 
2006  
Influent Concentration 
(ng/L) Trimethoprim 
78.00 Rosal et al., 2006  
Influent Concentration 
(ng/L) Trimethoprim 
197.00 Rosal et al., 2006  
Influent Concentration 
(ng/L) Trimethoprim 104.00 
Rosal et al., 2006  
Influent Concentration 
(ng/L) Trimethoprim 835.00 Thomas et al., 2007 
Influent Concentration 
(ng/L) Trimethoprim 340.00 
Watkinson et al., 2007  
Influent Concentration 
(ng/L) Trimethoprim 
430.00 Watkinson et al., 2009 
MBR Removal Trimethoprim 0.00 Kim et al., 2007 
MBR Removal Trimethoprim 0.00 Kim et al., 2007 
MBR Removal Trimethoprim 0.67 Radjenovic et al., 2009 
MBR Removal Trimethoprim 0.48 Radjenovic et al., 2009 
MBR Removal Trimethoprim 0.76 Snyder et al., 2007 
MBR Removal Trimethoprim 0.90 Snyder et al., 2007 
Microfiltration Removal Trimethoprim 0.00 Snyder et al., 2007 
Nanofiltration Removal Trimethoprim 0.95 Kim et al., 2007 
Primary + CAS Removal Trimethoprim 0.68 Batt et al., 2007   
Primary + CAS Removal Trimethoprim 0.96 Batt et al., 2007   
Primary + CAS Removal Trimethoprim 0.75 Batt et al., 2007   
Primary + CAS Removal Trimethoprim 0.72 Batt et al., 2007   
Primary + CAS Removal Trimethoprim 0.49 Bendz et al., 2005   
Primary + CAS Removal Trimethoprim 0.60 Benotti et al., 2007 
Primary + CAS Removal Trimethoprim 0.00 Blair et al., 2013 
Primary + CAS Removal Trimethoprim 0.56 Blair et al., 2013 
Primary + CAS Removal Trimethoprim 0.42 Blair et al., 2013 
Primary + CAS Removal Trimethoprim 0.00 Blair et al., 2013 
Primary + CAS Removal Trimethoprim 0.24 Blair et al., 2013 
Primary + CAS Removal Trimethoprim 1.00 Choi et al., 2008  
Primary + CAS Removal Trimethoprim 0.36 Choi et al., 2008  
Primary + CAS Removal Trimethoprim 1.00 Choi et al., 2008  
Primary + CAS Removal Trimethoprim 0.84 Choi et al., 2008  
Primary + CAS Removal Trimethoprim 0.76 Choi et al., 2008  
Primary + CAS Removal Trimethoprim 1.00 Choi et al., 2008  
Primary + CAS Removal Trimethoprim 1.00 Choi et al., 2008  
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Primary + CAS Removal Trimethoprim 0.00 Choi et al., 2008  
Primary + CAS Removal Trimethoprim 0.75 Choi et al., 2008  
Primary + CAS Removal Trimethoprim 0.73 Choi et al., 2008  
Primary + CAS Removal Trimethoprim 0.00 Ghosh et al., 2009  
Primary + CAS Removal Trimethoprim 0.35 Ghosh et al., 2009  
Primary + CAS Removal Trimethoprim 0.03 Gobel et al., 2007 
Primary + CAS Removal Trimethoprim 0.00 Gobel et al., 2007 
Primary + CAS Removal Trimethoprim 0.14 Gobel et al., 2007 
Primary + CAS Removal Trimethoprim 0.20 Gobel et al., 2007 
Primary + CAS Removal Trimethoprim 0.00 Gobel et al., 2007 
Primary + CAS Removal Trimethoprim 0.70 
Kasprzyk-Hordern et al., 
2009  
Primary + CAS Removal Trimethoprim 0.70 Nakada et al., 2006 
Primary + CAS Removal Trimethoprim 0.26 Thomas et al., 2007 
Primary + CAS Removal Trimethoprim 0.98 Watkinson et al., 2009  
Ultrafiltration Removal Trimethoprim 0.18 Snyder et al., 2007 
Ultrafiltration Removal Trimethoprim 0.21 Snyder et al., 2006 
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Example Code for Ibuprofen 
 
 
PNEC=1650;%ng/L 
Secondaryinwo=[ 
3590 
2750 
34000 
984 
2700 
4113 
14600 
40 
8450 
1050 
694 
5700 
33764 
2687 
0 
12130 
3730 
31300 
10800 
9500 
6900 
3590 
8840 
2687 
0 
4113 
14700 
84000 
6328 
115000 
5700 
2640 
69700 
373110 
353000 
603000 
3000 
11000 
1300 
200 
 
 
 
840 
670 
4800 
168000 
0 
706 
746 
545 
806 
513 
479 
748 
1130 
756 
636 
381 
650 
407 
452 
27979 
7741 
1480 
2679 
2448 
2300 
1200 
0 
294000 
84400 
0 
105000 
319000 
0 
178 
 ]; 
  
  
CASRemovalwo=[ 
0.940746055 
0.92 
0.903238095 
0.93373913 
0.87 
0.895164018 
201 
 
 
 
0.88 
0.919313525 
0.992370464 
0.954556213 
0.91547619 
0.999292035 
0.990441176 
0.960294118 
0.64612326 
0.95821727 
0.93766347 
0.830985915 
0.883468835 
0.798913043 
0.989189189 
0.850404313 
0.983118971 
0.838709677 
0.935457006 
0.987173913 
0 
0.988343949 
0.960761905 
0.940634006 
0.991997319 
0.990963173 
0.923945409 
0.971929825 
0.991837161 
0.966788991 
0.843362832 
0.958068783 
0.928144654 
0.992473262 
0.896307692 
0.955036855 
0.996880531 
0.995223097 
0.97965412 
0 
0.918088737 
0.98 
0.986486486 
0.992534528 
202 
 
 
 
0.991830065 
0.669090909 
0.72 
0.76 
0.631578947 
0.632575758 
0.993945815 
0.998580889 
0.999 
0.999 
0.838461538 
0.999 
0.166666667 
0.82 
0.970769231 
0 
0.98 
];  
  
  
MBRmedianremvolwo=[ 
0.982896928 
0.946083418 
0.982197355 
0.968421053 
0.990225564 
0.983082707 
0 
0.999943141 
0.985135135 
0.991787981 
0.971813725 
0.992 
0.995 
    ]; 
 
Ultramedianremovalwo=[ 
0.076923077 
0.076923077 
    ]; 
Nanoremovalwo=[ 
0.99981203 
0.99981203 
    ]; 
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MicroMedianremovalwo=[ 
0.55 
0.55 
  ]; 
  
xaxisnumbers=[1,2,3,4,5]; 
Secondaryin=bootstrp(10000,@mean,Secondaryinwo); 
CASRemoval=bootstrp(10000,@mean,CASRemovalwo); 
MBRmedianremvol=bootstrp(10000,@mean,MBRmedianremvolwo); 
Ultramedianremoval=bootstrp(10000,@mean,Ultramedianremovalwo) 
Nanoremoval=bootstrp(10000,@mean,Nanoremovalwo); 
MicroMedianremoval=bootstrp(10000,@mean,MicroMedianremovalwo); 
  
figure('color',[1 1 1]); 
hold on; 
for i=1:10000; 
SecondaryEffluentmedian(i)=Secondaryin(i)*(1-CASRemoval(i)); 
MBReffmedian(i)=SecondaryEffluentmedian(i)*(1-MBRmedianremvol(i)); 
Ultraeffmedian(i)=SecondaryEffluentmedian(i)*(1-Ultramedianremoval(i)); 
Nanomedian(i)=SecondaryEffluentmedian(i)*(1-Nanoremoval(i)) 
Microeffmedian(i)=SecondaryEffluentmedian(i)*(1-MicroMedianremoval(i)); 
end; 
  
d=[SecondaryEffluentmedian;MBReffmedian;Ultraeffmedian;Nanomedian;Microeffmedi
an]; 
d2=d'; %tranpose matrix 
a=boxplot(d2,'Label',{'WWTP','MBR','UF','NF','MF'},'color','k'); 
  
set(a(7,:),'Visible','off'); %Turn outliers off 
ylabel('Effluent Concentration (ng/L)'); 
set(gca,'yScale','log'); 
dpi=600; 
set(gca,'box','off') 
% Turn offscientific notation 
%numericticks=get(gca,'yTick'); % get the values of the ticks 
%fullticks = num2str(numericticks','%7.0f'); % save as strings 
%set(gca,'yTickLabel',fullticks); % set the text labels to force 
%ylim([1 10000]) %Set y axis limits 
  
  
% 
% 
% 
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title('Ibuprofen (CAS WWTP)',  'FontWeight','bold'); 
SecondaryEffluentmax=max(SecondaryEffluentmedian); 
MBReffmax=max(MBReffmedian); 
Ultraeffmax=max(Ultraeffmedian); 
Nanoeffmax=max(Nanomedian); 
Microeffmax=max(Microeffmedian); 
  
  
maxconc=[SecondaryEffluentmax, MBReffmax, Ultraeffmax, Nanoeffmax, 
Microeffmax]; 
scatter (xaxisnumbers,maxconc,'+','k'); 
hold off; 
figure('color',[1 1 1]); 
hist(Secondaryin,50); 
%set(gca,'yScale','log'); 
ylabel('Count'); 
xlabel('Concentration (ng/L)'); 
title('Histogram - CAS Influent',  'FontWeight','bold'); 
  
%Start RQ Plot 
  
hold on; 
figure('color',[1 1 1]); 
x = [0 6]; 
y = [1 1]; 
plot(x,y,'--','color','k') 
  
hold on; 
h = [0 6]; 
t = [.1 .1]; 
plot(h,t,'--','color','k') 
hold on 
for i=1:10000; 
RQCAS(i)=SecondaryEffluentmedian(i)/PNEC; 
RQMBR(i)=MBReffmedian(i)/PNEC; 
RQUltra(i)=Ultraeffmedian(i)/PNEC; 
RQnano(i)=Nanomedian(i)/PNEC; 
RQMicro(i)=Microeffmedian(i)/PNEC; 
  
end 
hold on; 
b=[RQCAS;RQMBR;RQUltra;RQnano;RQMicro]; 
b2=b'; 
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z=boxplot(b2,'Label',{'WWTP','MBR','UF','NF','MF'},'color','k','whisker',1.5); 
  
set(z(7,:),'Visible','off'); 
ylabel('Effluent Risk Quotient'); 
set(gca,'yScale','log'); 
% 
% 
% 
title('Ibuprofen (CAS WWTP)',  'FontWeight','bold'); 
dpi=600; 
RQSecondaryEffluentmax=max(RQCAS); 
RQMBReffmax=max(RQMBR); 
RQUltraeffmax=max(RQUltra); 
RQNanoeffmax=max(RQnano); 
RQMicroeffmax=max(RQMicro); 
  
maxRQ=[RQSecondaryEffluentmax, RQMBReffmax, RQUltraeffmax, RQNanoeffmax, 
RQMicroeffmax]; 
scatter (xaxisnumbers,maxRQ,'+','k'); 
  
set(gca,'box','off') 
hold off; 
  
RQCAS1max=max(RQCAS); 
RQMBR1max=max(RQMBR); 
RQUltra1max=max(RQUltra); 
RQNano1max=max(RQnano); 
RQMicro1max=max(RQMicro); 
SecondaryEffluent1max=max(SecondaryEffluentmedian); 
MBReff1max=max(MBReffmedian); 
Ultraeff1max=max(Ultraeffmedian); 
Nanoeff1max=max(Nanomedian); 
Microeff1max=max(Microeffmedian); 
  
  
RQCAS1=median(RQCAS); 
RQMBR1=median(RQMBR); 
RQUltra1=median(RQUltra); 
RQNano1=median(RQnano); 
RQMicro1=median(RQMicro); 
SecondaryEffluent1=median(SecondaryEffluentmedian); 
MBReff1=median(MBReffmedian); 
Ultraeff1=median(Ultraeffmedian); 
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Nanoeff1=median(Nanomedian); 
Microeff1=median(Microeffmedian); 
  
display(RQCAS1max); 
display(RQCAS1); 
display(RQMBR1max); 
display(RQMBR1); 
display(RQUltra1max); 
display(RQUltra1); 
display(RQNano1max); 
display(RQNano1); 
display(RQMicro1max); 
display(RQMicro1); 
display(SecondaryEffluent1max); 
display(SecondaryEffluent1); 
display(MBReff1max); 
display(MBReff1); 
display(Ultraeff1max); 
display(Ultraeff1); 
display(Nanoeff1max); 
display(Nanoeff1); 
display(Microeff1max); 
display(Microeff1); 
  
output=[RQCAS1max; 
 RQUltra1max; 
 RQMBR1max; 
 RQMicro1max; 
 RQNano1max; 
RQCAS1; 
RQUltra1; 
RQMBR1; 
RQMicro1; 
RQNano1; 
SecondaryEffluent1max; 
Ultraeff1max; 
MBReff1max; 
Microeff1max; 
Nanoeff1max; 
SecondaryEffluent1; 
Ultraeff1; 
MBReff1; 
Microeff1; 
Nanoeff1] 
207 
 
 
 
CURRICULUM VITAE 
 
Benjamin D. Blair 
 
EDUCATION 
 
Master of Science in Business Education – Online Education Emphasis, University of 
Wisconsin at Whitewater, 2005 – 2006 
 
Bachelor of Business Administration in Finance, University of Wisconsin at Whitewater, 
2000-2004  
 
ARTICLES  
 
Blair, B., Crago, J., Hedman, C., Klaper, R., Pharmaceuticals and Personal Care Products 
Found in the Great Lakes above Concentrations of Environmental Concern, 
Chemosphere, 2013; 93:2116-2123 
 
Blair, B., Crago, J., Hedman, C., Treguer, R., Magruder, C., Royer, S., Klaper, R., 
Evaluation of a Model for the Removal of Pharmaceuticals, Personal Care 
Products, and Hormones from Wastewater, Science of the Total Environment, 
2013;444C:515-521 
 
Treguer, R., Blair, B., Klaper, R., Royer, S., Magruder, C., Evaluation of Actiflo
®
 Carb 
Process for the Combined Removal of Trace Organic Compounds and 
Phosphorous during Wastewater Tertiary Treatment, Proceedings of the Water 
Environment Federation’s Annual Technical Exhibition and Conference, 2012 
 
TEACHING EXPERIENCE 
 
Assistant Professor, Business Finance course (Online), Herzing University, Department 
of Management and Accounting, 2009 
 
Assistant Professor, Business Decision Making course (Online), Herzing University, 
Department of Accounting, 2009 
 
Lecturer, Business Finance course (Instructed both online and in-class), University of 
Wisconsin - Whitewater, College of Business and Economics – Department of 
Finance and Business Law, 2006 – 2007, 2009 
 
Lecturer, Personal Financial Planning course, University of Wisconsin - Whitewater, 
College of Business and Economics –Department of Finance and Business Law, 
2006 – 2007 
 
208 
 
 
 
Lecturer, Consumer Education course, University of Wisconsin - Whitewater, College 
of Business and Economics – Department of Information Technology and 
Business Education, 2006 – 2007 
 
PRESENTATIONS (PRESENTER UNDERLINED) 
 
Blair, B., Klaper, R., Kehl, J., Assessing the Change in Net Environmental Benefit from 
Water Quality Trading. Presented at the American Water Research Association 
Conference, March 25, 2013 
Treguer, R., Blair, B., Klaper, R., Royer, S., Magruder, C., Evaluation of Actiflo
®
 Carb 
Process for the Combined Removal of Trace Organic Compounds and 
Phosphorous during Wastewater Tertiary Treatment. Presented at the Water 
Environment Federation’s Annual Technical Exhibition and Conference October 
3, 2012 
Blair, B., Hedman, C., Crago, J., Magruder, C., Royer, S., Treguer, R., Klaper, R., 
Patterns of Removal of Pharmaceutical and Personal Care Products from 
Wastewater Treatment and their Fate in Lake Michigan: Choosing Model 
Chemicals for Monitoring. Presented at the National Society of Toxicology and 
Chemistry Conference, November 16, 2011 
Klaper, R., Blair, B., Hedman, C., Crago, J., Magruder, C., Royer, S., Treguer, R., 
Removal of   Pharmaceutical and Personal Care Products from a Milwaukee, WI, 
Wastewater Treatment Facility. Presented at the Midwest Society of Toxicology 
and Chemistry Conference, March 24, 2011 
 
POSTERS (PRESENTER UNDERLINED) 
 
Blair, B., Crago, J., Hedman, C., Klaper, R., Pharmaceuticals and Personal Care Products 
Found in Lake Michigan above Concentrations of Environmental Concern. Poster 
presented at the International Association for Great Lakes Research Conference, 
June 5, 2013 
Blair, B., Hedman, C., Crago, J., Magruder, C., Royer, S., Treguer, R., Klaper, R., Using 
Estimated Biodegradation Rates to Predict the Removal of Emerging 
Contaminants during Wastewater Treatment. Poster presented at the American 
Water Research Association Conference, June 26, 2012 
 
RESEARCH EXPERIENCE 
 
Visiting Scholar, University of Colorado – Denver, School of Public Affairs, 2013 – 
Present 
 Supervisors: Chris Weible, Ph.D., Tanya Heikkila, Ph.D. 
-Explore how the characteristics of coalitions and their interactions have 
influenced changes in hydraulic fracturing policy or regulations and what actions 
209 
 
 
 
might lead to common ground and policy change in the future across different 
venues and scales 
 
Research Assistant, University of Wisconsin – Milwaukee, 2010 – Present 
 Supervisor: Rebecca Klaper, Ph.D.  
-Oversaw data collection and analysis of pharmaceutical and personal care 
products in wastewater and the environment 
- Model policy implications of emerging contaminants and assess environmental 
impacts of nutrient reduction policies 
  
Research Assistant, University of Wisconsin - Whitewater, College of Business and 
Economics Online, 2005 - 2006 
 Supervisor: Robert Schramm, Ph.D. 
-Duties included oversight of technology used in the College of Business and 
Economics Online and assisting with the creation of online courses  
 
WORK EXPERIENCE 
 
Herzing University, Milwaukee, WI, March 2009 – September 2009 
Curriculum Manager in Online Education Division / Assistant Professor   
 Supervised the content development of  70 online courses using Blackboard 
 Instructed Business Finance and Business Decision Making 
University of Wisconsin – Whitewater, Whitewater, WI, August 2006 – May 2009 
Lecturer  
 Instructed and developed the online course for Business Finance 
 Instructed Personal Financial Planning, Consumer Education, and Business 
Finance  
HUSCO International, Waukesha, WI, May 2008 – September 2008 
 Engineer Intern – Summer  
 General design and testing of hydraulic valves and components 
 Created technical manuals and literature for customers and internal use 
University of Wisconsin – Whitewater, Whitewater, WI, August 2005 – January 2007 
Technology Coordinator / Associate Information Processing Consultant / 
Graduate Assistant 
 Assisted faculty with technology and educational training for online education 
using D2L 
 Created and managed content for online courses in the College of Business 
and Economics 
 
 
